Conclusions: Despite the relative low incidence of positive periprostatic lymph node, routine pathological work up of periprostatic fat pads should be performed to guarantee adequate lymph node staging.
Immunoexpression of Napsin A in Renal Neoplasms
B Zhu, SM Rohan, D DeFrias, X Lin. University of Illinois at Chicago, Chicago, IL; Northwestern University, Chicago, IL. Background: Immunohistochemistry (IHC) for Napsin A has been widely used to support a diagnosis of lung adenocarcinoma with high sensitivity (93.9%). Previous reports have stated that Napsin A is also highly specifi c for lung adenocarcinoma (up to 94.7%). However, a recent report demonstrated that Napsin A is expressed in papillary renal cell carcinoma (RCC). In this study, we evaluated the immunoexpression of Napsin A in renal neoplasms. Design: Duplicate tissue microarrays (TMA) of 159 surgically excised renal neoplasms of various types were constructed. IHC for Napsin A was performed on TMAs with appropriate positive and negative controls. Tumors with more than 10% cells staining positive for Napsin A were considered as immunoreactive.
Results: See Table 1 . 2.0(1.8-2.4) 2.8(2.5-3.03) p<0.0001 2.5(0-8) 2.6(0-13) NS Invasion Depth (Mean cm) 0.8(0.7-0.86) 1.6(1.3-1.6) p<0.0001 0.7(0-2.5) 0.5(0-2) NS
Conclusions:
Prior studies suggested poor outcomes for ADC when compared to SCC.However, this study reveals comparable RR and OS in early stages of ADC and SCC in two different geographic and ethnic cohorts.The paradigm of more aggressive therapy for early stage cervical ADC warrants further investigation to potentially reduce morbidity in these pts. ). The T-cells/macrophages ratio (CD3 + /CD163 + ) was signifi cantly lower in CCC (0.33) (p<0.05) compared to HGSC (0.55) and EC (0.54). However the variation of T-cells density was signifi cantly proportional to the variation of macrophages density in all ovarian cancer subtypes (p<0.05). Conversely there was no correlation between T-cells and PDCs density (p>0.05) and between macrophages and PDCs density (p>0.05).
The digital microscopy approach proposed here might improve the evaluation of the cancer "immune contexture" by analyzing large tumor areas. The variability in the density of T-cells and macrophages found in the different cancer subtypes might indicate heterogeneity in chemokine production and suggest different levels of immune editing taking place at the primary tumor site.
PAX-8 staining in mesothelial proliferations (n=112+)
Number of cases PAX-8+ WDPM (N=13) 9 Adenomatoid tumor (N=10) 0 Peritoneal inclusion cyst (N=5) 1 Reactive mesothelium (N=51) 2 Malignant mesothelioma (n=33) 0
Conclusions: All MM were negative for PAX-8, as were a majority of benign lesions. In WDPM, polyclonal PAX-8 showed more diffuse staining in a majority of cases compared to the monoclonal antibody. The four cases of WDPM that were PAX-8 negative were histologically similar small (1-3 mm), papilliform proliferations with a densely fi brotic core and bland mesothelial lining, while the positive WDPMs tended to be more complex, larger, and showed at least mild nuclear atypia. This raises the question whether these smaller lesions would be better classifi ed as papillary mesothelial hyperplasia. Overall, PAX-8 is a useful marker for distinguishing MM from gynecologic malignancies, but not is reliable for distinguishing benign and borderline mesothelial lesions from small/superfi cial epithelial proliferations of the gynecologic tract. Background: Immunohistochemical expression of GATA-3 is seen predominantly in non-neoplastic bladder and breast epithelium and their respective carcinomas; however, expression in normal and lesional trophoblastic tissues is unknown. Design: Immunohistochemical expression of GATA-3 was assessed in a range of normal/ lesional trophoblastic tissues (n=209), including non-molar products of conceptions and 2 nd and 3 rd trimester placentas, ectopic pregnancies, partial and complete hydatidiform moles, placental site nodules, normal and exaggerated implantation sites, epithelioid trophoblastic tumors, placental site trophoblastic tumors, and choriocarcinomas. Extent (0, <5% [+] cells; 1+, 5-24%; 2+, 25-49%; 3+, 50-74%; 4+, 75-100%) and degree of intensity of expression were recorded. Results: GATA-3 was expressed in 96% of cases, with the different cell types from normal and lesional tissues generally exhibiting a decreasing extent and/or intensity of expression in the following order: intermediate trophoblast (IT) [implantation and chorionic types] > villous trophoblastic columns > cytotrophoblast (CT) > syncytiotrophoblast (ST). Increasing gestational age was associated with a decrease in extent and intensity of expression in normal CT/ST while normal IT maintained diffuse and strong expression from early to late gestation. Expression was typically absent in decidua and myometrium. GATA Western blot and immunohistochemistry demonstrated that leiomyomas with complex MED12 mutations had signifi cant lower immunoreactivity for MED12 (p<0.01) than myometrial controls. Conversely, leiomyomas with point mutations of MED12 showed immunoreactivity for MED12 similar to those tumors without MED12 mutation. A total of 18 leiomyomas were strongly immunoreactive for HMGA2, accounting for 10.1% of cases. HMGA2 overexpression was exclusively found in those leiomyomas without MED12 mutations.
G ATA-3 E x p r e s s i o n i n Tr o p h o b l a s t i c T i s s u e s : A n

Conclusions:
Through this study, we demonstrated MED12 mutations are very common in leiomyomas with a wide range of simple to complex mutations identifi ed in intron 1 and exon 2. Although there is a reduction of MED12 protein in tumors with MED12 mutations, immunohistochemistry cannot separate leiomyomas with and without MED12 mutations. Most importantly, HMGA2 overexpression was exclusively found in tumors without MED12 mutations suggesting that MED12 mutations and HMGA2 overexpression represent independent molecular pathways for uterine leiomyomas.
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Development of a Response Scoring System to Quantify the Effect of Neoadjuvant Chemotherapy in Ovarian Cancer -Ovarian Cancer
Response Scoring (OCRS) Study S Boehm, I Said, A Faruqi, CB Gilks, N Singh. Barts Cancer Institute and St Bartholomew's Hospital, London, United Kingdom; Barts Health NHS Trust, London, United Kingdom; University of British Columbia, Vancouver, Canada. Background: Histopathological response scoring systems for solid tumours treated with chemotherapy are an objective measure of the response to therapy. To date, in ovarian cancer (OC) such scoring has not been established. Neoadjuvant chemotherapy (NACT) is given in advanced OC to reduce tumor burden in order to achieve complete cytoreduction at subsequent surgery (interval debulking surgery, IDS). With new therapies being developed and tested for different histotypes of ovarian cancer which may not be associated with raised serum CA125 or measurable lesions on imaging there is a need for standardization of tissue-based response criteria. Such a system has to be a) easily applicable in routine histopathological practice and b) reproducible among different centres. The primary endpoint of the present study was to develop a histopathological scoring system that standardizes response to neoadjuvant chemotherapy in ovarian cancer with good agreement between different pathologists. Design: An Ovarian Cancer Response Scoring System (OCRS) was developed based on the system proposed by Dworak et al. HE slides from IDS of 42 high-grade serous ovarian cancer (HGSC) patients treated at teaching hospital cancer centre were retrieved with informed consent and independently scored from 0-5 by three pathologists. Pathologists were blinded to each other as well as to clinical outcome and CA-125 response. A single section representing the area of lowest response at two sites (omentum and adnexa) was selected for the scoring. Fleiss' kappa statistics () and Kendall's coeffi cient of concordance (KCC) between pathologists were calculated separately for each site. Results: The fi ve score OCRS levels of inter-observer agreement in omental metastasis scoring were  = 0.36, (p<0.001) and KCC = 0.91 (p<0.001). Ovarian/pelvic tumor scoring resulted in  = 0.30 (p<0.001) and KCC = 0.85 (p<0.001). A condensed three item OCRS (combining scores 0-1, 2-3 and 4-5) increased agreement on omental scoring to  = 0.75, (p<0.001), KCC = 0.89 (p<0.001) and absolute agreement to 81%. Values for ovarian/pelvic three item OCRS were  = 0.55, (p<0.001), KCC = 0.79 (p<0.001) and absolute agreement was present in 68%. Conclusions: OCRS can be easily integrated in routine diagnostic practice and shows a good level of inter-observer agreement. Results of analysis of an independent validation set and correlation of OCRS with outcome data will be presented.
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HLA Ligandome Analysis Reveals HDAC1 as a TumorAssociated Antigen in High-Grade Serous Ovarian Carcinomas and Potential Candidate for a Multipeptide Vaccine H Boesmueller, J Peper, P Wagner, F Fend, H-G Rammensee, S Stevanovic, A Staebler. University of Tuebingen, Tuebingen, Germany. Background: Quantity and composition of intratumoral lymphocyte subsets in highgrade serous ovarian carcinomas (OvCa) are of signifi cant prognostic relevance. However, little is known about whether this is due to specifi c tumor antigens which are presented to intratumoral T-cells. The goal of our study was to use HLA ligandome analysis to identify tumor-associated antigens, and their correlation with T-cell subsets and prognosis in serous OvCa. Design: HLA presented peptides were obtained by immuno-affi nity-chromatography of HLA molecules using a special protocol developed for solid tissue analysis. Tumorassociated and overrepresented peptides were identifi ed by mass spectrometry and further tested in immunogenicity analysis. Finally, the combined prognostic effect of tumor infi ltrating lymphocytes (TILs) and the expression of specifi c antigens was evaluated with immunohistochemistry in a tissue microarray of 136 cases of serous OvCa. Results: One of the most commonly presented antigens identifi ed in OvCa tissues was histone deacetylase 1 (HDAC1) which is able to induce T-cell responses in healthy donors. When tested by immunohistochemistry, high HDAC1 expression impacted negatively on prognosis (median 26 vs. 42 months, p=0,011, log rank). However, high numbers of intratumoral T-cells were able to overcome the negative prognostic effect, potentially refl ecting the specifi c, antigen-triggered anti-tumoral immune response. Conclusions: Our study demonstrates the identifi cation of specifi c tumor-associated antigens from primary OvCa by HLA-ligandome analysis with mass spectrometry. The combined approach of proteomics and immunohistochemical analysis not only allows to analyze the interplay of immune cell infi ltrates and tumor antigens but is a valuable tool for the development of a multipeptide vaccine for ovarian cancer.
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Overexpression of Tubulin -3 in Endometrial Carcinomas AN Boto, P Hui, N Buza. Yale New Haven Hospital, New Haven, CT. Background: Paclitaxel is a widely used chemotherapeutic agent in gynecologic tumors to stabilize microtubules and inhibit microtubule depolymerization. Overexpression of tubulin -3 has been linked to paclitaxel resistance and has been previously described in a limited number of endometrial serous carcinomas. Design: We assessed tubulin -3 expression by immunohistochemistry in normal and hyperplastic endometrial samples and in endometrial carcinomas using a tissue microarray. Tubulin -3 expression was scored semiquantitatively as 0, 1, or 2, corresponding to absence of staining, weak/focal staining, and strong/diffuse staining, respectively. Results: A total of 63 serous and 185 endometrioid type endometrial adenocarcinomas, 40 normal and 26 hyperplastic endometrial samples were included in the study. Among endometrial carcinomas 41 of 63 serous (65%) and 104 of 185 endometrioid (56%) tumors showed tubulin -3 expression (score 1 or 2), compared to only 19% of endometrial hyperplasia and 13% of normal endometrium, respectively (Figure 1 ). Tubulin -3 expression showed statistically signifi cant correlation with lymph node metastases in serous carcinomas. However, no signifi cant correlation was observed between tumor stage and lymphovascular invasion and tubulin -3 expression. Conclusions: Tubulin -3 overexpression is present in a signifi cant proportion of endometrial carcinomas -both serous and endometrioid subtypes, as opposed to absence of staining in most endometrial hyperplasias and normal endometria, indicating that tubulin -3 may play a role in the pathogenesis and disease progression. Tubulin -3 expression is associated with increased chance of nodal metastases in serous carcinomas, thus it may be a marker of a more aggressive disease course. Background: The Cancer Genome Atlas (TCGA) identifi ed four major genomic groups of endometrial carcinomas (ECs), the POLE ultramutated class 1; C1), microsatellite instable hypermutated (class 2, C2), copy-number low (class 3, C3), and copy-number high (serous-like; class 4, C4) groups. The aims of the study were i) to determine the agreement between the reported diagnosis of FIGO grade 3 endometrioid carcinoma (Gr3-EMC) and independent review of these cases by two pathologists and ii) to study the TCGA genomic classes of discrepant cases. Design: Seventy-two Gr3-EMCs from the TCGA dataset were morphologically assessed by two gynecologic pathologists from two academic institutions. Virtual whole slide images publicly available at cBioPortal (http://www.cbioportal.org) were examined. The histologic type of a given case was recorded by each pathologist independently without knowing its TCGA genomic class, which was subsequently obtained from cBioPortal. Results: Among the 72 cases Gr3-EMCs reviewed, there were 49 agreements, 5 disagreements and 16 deferrals between the 2 pathologists. One case showed no tumor. The interobserver agreement results and correlation with the TCGA genomic classes are described in Table 1 .
TCGA class
Concordant DX (n=50) Discordant DX (n=5) Deferrals (n=16) C1 (n=16) 9 (56%); 8 EMC, 1 SC 2 (13%) 5 (31%) C2 (n=33) 25 (76%); 24 EMC, 1 SC 1 (3%) 7 (21%) C3 (n=9) 8 (89%) EMC 0 1(11%) C4 (n=13) 8 (62%); 4 EMC, 4 SC 2 (15%) 3 (23%)
Concordant results were observed in 9 C1 (56%), 25 C2 (76%), 8 C3 (89%) and 8 C4 (62%) Gr3-EMCs cases. Of the 13 Gr3-EMCs classifi ed as of C4 genomic subtype, 4 cases had a consensus morphological diagnosis of serous carcinoma (SC) upon re-review, and in additional 3 cases, 1 of the pathologists suggested a SC diagnosis.
Conclusions:
As many as half of C4 EMCs originally classifi ed as G3-EMCs may instead represent SC, whereas C3 tumors were never interpreted as SC. It remains a challenge to reproducibly distinguish SC from C1, C2, and C4 G3-EMCs. These data confi rm that C1 and C2 G3-EMCs are frequently morphologically ambiguous. If clinical studies can confi rm that C4 G3-EMCs are inseparable from SC, then accurate diagnosis of SC given a histologically ambiguous tumor should rely not only on p53 immunohistochemical stains, but also on the exclusion of C1 and C2 tumors by morphologic evaluation and ancillary testing. Background: Ovarian cancer (OC) is the leading cause of death from a gynecological malignancy.The standard taxol and carboplatin chemotherapy often fails and patients relapse with chemoresistant disease. ABC transporters including P-glycoprotein (P-gp), MRP2 and BCRP have been shown to be involved in chemoresistance in drug resistant cell lines. Patients with BRCA1 defi ciencies have an increased lifetime risk of approx. 39-46% for developing OC. BRCA1 has a role in many cellular functions including DNA damage repair. An inverse resistance relationship exists between platinum and taxane therapies in relation to BRCA1. Cells with non-functional BRCA1 are sensitive to platinums but resistant to taxanes. The opposite is true for cells with functional BRCA1. Design: OC cell-lines UPN251 (BRCA1 wildtype) and OVCAR8 (BRCA1 methylated) were used to develop novel taxane and platinum resistant cell lines. A selection strategy was set up to investigate the role of BRCA1 in resistance development in relation to, the inverse resistance relationship between platinums and taxanes and alternating doses of platinums and taxanes. Results: Doses of taxol and carboplatin were selected after examining clinical trial papers and pharmacokinetic studies to elucidate suitable doses with clinical relevance. OVCAR8 sublines did not produce signifi cant resistance and were not focused on post selection. Resultant UPN251 sublines displayed notable resistance for both drugs. R7-U-C was 3.4 fold resistant to carboplatin and R7-U-T was 8 fold resistant to taxol. UPN251 sublines developed using taxol were all signifi cantly resistant to taxol and vinblastine (known P-gp substrates). Resistance was reversed with the adition of elacridar (a known P-gp/BCRP inhibitor). Cross resistance in UPN251 carboplatin models were seen with cisplatin and CuSO 4 .
Conclusions: Overexpression of P-gp/BCRP are a possible resistance mechanism for our UPN251 models selected with taxol as elecridar reverses taxol and vinblastine reisitance. MRP2 may play a role in carboplatin resistant sublines due to cross resistance to cisplatin. CuSO 4 cross resistance indicates possible involvement of copper transporters. Western blotting is planned for P-gp, BCRP and MRP2 to confi rm involvement in our resistant models. BRCA1 wildtype cells (UPN251) developed resistant mechanisms easier than BRCA1 methylated cells (OVCAR8). UPN251 saw quicker development of possible MDR related mechanisms. UPN251 resistant sublines will be used to profi le miRNA markers for OC resistance.
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MicroRNA Profiling Reveals Increased MiR34 and C-Myc Downregulation in Obesity Associated Low Grade Endometrioid Adenocarcinomas L Casadei, S Costinean, V Balatti, L Cascione, CM Croce, A Suarez. The Ohio State University, Columbus, OH. Background: Epidemiologic evidence has revealed an association between adiposity and endometrial cancer risk. The most common endometrial cancer histologic type, low grade endometrioid adenocarcinoma (EC), is especially frequent amongst obese women. However, morphologically indistinguishable EC are also seen in some nonobese women. This highlights the currently incomplete understanding linking EC and its major risk factor. MicroRNAs (miRNA), a class of single-stranded non-coding RNA molecules, play critical roles in various biological regulation pathways including cell differentiation, proliferation and apoptosis. We investigate miRNA in FIGO 1 EC from obese vs non-obese women. Design: 11 FIGO 1 EC from obese women (BMI 30 kg/m 2 ) and 13 FIGO 1 EC from non-obese (BMI<30 kg/m 2 ) were randomly selected. RNA was analyzed with Nanostring. RT-PCR with Taqman probes was used to confi rm microRNA regulation. RT-PCR on target genes was also performed. Results: Nanostring miRNA profi ling of FIGO 1 EC from obese vs non-obese women identifi ed a single differentially-expressed miRNA: miR34c3p. This miRNA was found at 2.91 fold in tumors from obese women. Up-regulation of this miRNA was confi rmed by RT-PCR. In silico studies showed that miR34c3p targets c-myc proto-oncogene. Down regulation of c-myc in EC of obese women was also found by RT-PCR. Conclusions: Gaining a better understanding of the relationship between obesity and EC can provide new insights into pathogenetic mechanisms. Here we found a specifi c miRNA signature of obese vs non obese FIGO 1 EC and suggest a new possible role for miR34c3p as centerpiece involving c-myc.
1147
Specific MicroRNA Gene Signature Identifies Putative Role of BCL2 in the Tumorigenesis of Uterine Serous Carcinomas L Casadei, S Costinean, V Balatti, L Cascione, CM Croce, A Suarez. The Ohio State University, Columbus, OH. Background: Molecular mechanisms explaining the development and progression of uterine serous carcinoma (USC) are incompletely understood. MicroRNAs (miRs) function as sequence-specifi c regulators of gene expression through translational repression and/or transcript cleavage. MiRs play key roles in cellular processes of differentiation, proliferation, apoptosis and metabolic homeostasis. Design: 5 USC and 24 low grade endometrioid adenocarcinomas (EC) were randomly selected. RNA was analyzed with Nanostring. RT-PCR with Taqman probes was used to confi rm miR regulation. RT-PCR on target genes was also performed. Results: Only 7 miRs were differentially expressed: 6 downregulated in USC (miR521, miR522-3p, miR31-5p, miR18a-5p, miR660-5p, miR146b-5p) and 1 upregulated (miR375). The most signifi cantly regulated miR was miR375. Downregulation of: miR31-5p, miR 146b-5p and the upregulation of miR375 was confi rmed with RT-PCR. In silico studies showed that miR146b-5p targets RRM2B (repairing damaged DNA in a p53/TP53 dependent manner) and notably, miR375 targets BCL2. We ran RT-PCR on BCL2 and showed inverse correlation between miR375 and BCL2. Conclusions: MiRs expression distinguishes USC and EC. In particular we identifi ed miR375-BCL2 as a possible specifi c mechanistic pair in USC.
HPV Genotyping Does Not Predict Absence of CIN in the Conization Specimen in Women Treated for CIN2-3 P Castillo, M del Pino, A Rodriguez-Manfredi, R van Baars, J van der Marel, WGV
Quint, A Torne, J Ordi. Hospital Clinic-CRESIB, University of Barcelona, Barcelona, Spain; Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain; DDL Diagnostic Laboratory, Rijswijk, South Holland, Netherlands. Background: Conization is the mainstay technique for the treatment of cervical intraepithelial neoplasia grade 2 and 3 (CIN2-3). Even with the use of strict criteria approximately 10-20% of patients with histologically confi rmed CIN2-3 in the preconization biopsy have no residual CIN in the cone specimen. The role of high-risk human papillomavirus (hr-HPV) genotype in this outcome and its importance in the pre-treatment prediction of no residual CIN in the cone specimen remains to be evaluated. This study aims to evaluate whether certain genotypes or the presence of multiple hr-HPV co-infection are associated with absence of CIN in the conization specimen in women treated because of CIN2-3. Design: From 687 conizations performed between 2008 and 2011, 110 women showed absence of CIN in the surgical specimen. We selected all patients who fulfi lled the following criteria: 1) diagnosis of CIN2-3 in a pre-conization biopsy confi rmed by a positive p16 staining; 2) absence of lesion in the conization specimen with negative p16 result; and 3) available material for hr-HPV typing in both specimens (n=43). The control group consisted of one randomly selected age-matched control for each case with confi rmed diagnosis of CIN2-3 and positive p16 staining both in the pre-conization biopsy and in the conization specimen. HPV detection and genotyping in all histological specimens was performed using the highly sensitive SPF10 PCR technique. Results: All pre-conization biopsies from the study and the control group were positive for hr-HPV. In the conization specimens, hr-HPVs were identifi ed in 42/43 (97.7%) cases from the control group but only in 14/43 (32.5%) of the study group (p<0.001). Previous to conization, no differences in HPV genotypes or in multiple HPV co-infection were observed between the study and the control group (HPV16- 
Conclusions:
Neither specifi c hr-HPV genotype, nor multiple infection are associated with absence of CIN 2-3 in the conization specimen. hr-HPV genotyping does not add any additional information which could predict absence of CIN2-3 in the conization specimen before treatment. Within the identifi ed genes, SLC7A10 (solute carrier family 7, member 10) was overexpressed in ESS, and GEM (GTP binding protein overexpressed in skeletal muscle) and TAGLN (transgelin) were overexpressed in LMS. We hypothesized that examination of ESS and LMS by immunohistochemistry for expression of these markers may contribute to the differential diagnosis of ESS and LMS. Design: Cases were retrieved from the Pathology fi les and reviewed by two gynecologic pathologists. Only cases with a consensus diagnosis were included in the study. Paraffi n embedded tissue from 24 ESS and 24 LMS were examined by immunohistochemistry for expression of SLC7A10, GEM and TAGLN. Antibody expression was examined for nuclear versus cytoplasmic staining, strength of expression and semi-quantitatively scored as 0, 1+ to 3+. Appropriate negative and positive controls were used. Cases were considered positive with 2+ or 3+ expression. Background: PAX2 is a transcription factor necessary for the development of Wolffi an duct system. It is ubiquitously expressed in normal endocervical glandular epithelium. Recent studies have suggested that PAX2 expression is frequently lost in endocervical adenocarcinoma. To substantiate this fi nding and assess its usefulness as a diagnostic feature in our laboratory, we evaluated PAX2 expression in a group of endocervical adenocarcinomas in comparison with endometrial adenocarcinomas and ovarian serous carcinoma. Design: Immunohistochemical evaluation of PAX2 expression was performed on 229 cases of gynecological adenocarcinomas (ADCs) on tissue microarray sections including 60 endocervical ADCs (16 were adenocarcinoma in situ), 128 endometrial ADCs and 41 ovarian serous carcinomas (CAs). The presence or absence of nuclear staining in tumor cells was scored by three independent pathologists. The data was statistically analyzed using Fisher exact test. Results: A complete loss of PAX2 nuclear staining was observed in 16 of 16 (100%) endocervical adenocarcinoma in situ (AIS) and 42 of 44 (95%) invasive endocervical ADC. This is in sharp contrast with benign endocervical glands, all of which show strong PAX2 expression. In AIS cases, absence of PAX2 expression was often observed in the cytologically atypical portion of a gland only with retained expression in benign appearing glandular cells. PAX2 loss was found in 5 invasive adenocarcinomas that were negative for p16 immunostaining. It was also found in 6 of 8 unusual type endocervical adenocarcinomas (3 of 3 minimal deviation ADCs and 3 of 3 gastric type ADCs). The 2 tumors retained strong PAX2 expression were unusual type ADC with high grade clear cell carcinoma morphology. In comparison, PAX2 loss was a less frequent event in endometrial ADCs (45%, p<0.05) and ovarian serous CAs (42%, p<0.05). Among endometrial ADCs, PAX2 loss was found in 8 of 24 (33%), 37 of 58 (64%), and 13 of 38 (34%) tumors with FIGO grade 1, 2 and 3 morphology, respectively. Conclusions: Loss of PAX2 expression is a useful diagnostic feature discriminating malignant endocervical lesions including unusual type endocervical ADC from benign/ reactive process. It is also potentially useful in differentiating enodocervical ADC from endometrial ADC. Background: Loss of mismatch repair (MMR) proteins by immunohistochemistry (IHC) is a sensitive and specifi c way to identify defective DNA mismatch repair (dMMR). Germline mutation in MMR genes is characteristic of Lynch syndrome, which is associated with signifi cant increased risk of colorectal and endometrial cancer. Less commonly, malignancy has been reported in a variety of other organs, including breast, in patients with Lynch syndrome. Very little is known about the MMR status of these secondary tumors when they do occur. This study evaluates MMR protein expression in secondary tumors from a series of patients with known dMMR. Design: 1,476 tumors (index tumors) as well as all secondary malignancies associated with these index tumors were tested for MMR by IHC (MSH2, MSH6, PMS2, MLH1) between 2002 and 2013. Index tumors were predominantly non-selected endometrial (retrospective and prospective) and colon (prospective) carcinomas. All tumors with MLH1/PMS2 defi ciency were tested for hypermethylation or BRAF mutation, where appropriate. Results: Of the 1477 index tumors, 162 were dMMR, and of that subset 32 secondary tumors were identifi ed (19.7%). In contrast, 80 secondary tumors were identifi ed in the intact MMR group (6.0%). Though additional malignancies were more common in the dMMR group (p=0.0001), these patients were not more likely to have any specifi c subtype of tumor. In particular, breast cancer was not overly represented in the dMMR secondary tumors group and when it did occur, trended towards intact MMR. When secondary tumors had dMMR, they were more likely to have defi ciency in MSH2/ MSH6 than MLH1/PMS2 (p=0.01). No patients with tumors with sporadic MLH1 defi ciency had secondary tumors with dMMR. There was no signifi cant difference in age in patients with secondary tumors in the dMMR and intact MMR groups (mean, 61 vs 66 years). 32% of the secondary tumors in the intact MMR group occurred in men, compared to 3.7% in the dMMR group (p=0.0018).
Patients with tumors exhibiting mismatch repair defi ciency are more likely to have additional tumor(s) than those whose tumors have intact MMR (p=0.0001). This effect is more pronounced in women. Breast cancer does not appear to be overly represented in patients with MMR defi ciency. MSH2/MSH6 defi ciency is more commonly associated with a secondary tumor than MLH1/PMS2 defi ciency, even when methylation/BRAF status is taken into account. Background: HPV-associated squamous lesions of the lower anogenital tract present a diagnostic and terminological challenge. In 2012, a 2-tiered system, LSIL and HSIL, was proposed by the LAST Project. The biomarker p16 was also recommended for cervical biopsies: 1) to differentiate HSIL from benign mimics, 2) to establish a diagnosis of CIN-2, 3) professional disagreement, and 4) high-risk Paps where the biopsy is interpreted as  LSIL. We compared p16 use before and after implementation of the LAST guidelines and assessed HSIL detection attributable to the new protocol. Design: We reviewed all cervical biopsies diagnosed by two pathologists for 1 year prior to (Year A) and after adoption of (Year B) the p16 guidelines. All cases with p16 were categorized into 4 groups per the LAST guidelines. We calculated the percentages of and reason for p16 use across all biopsies, and the difference in HSIL detection by p16. Percentages were compared using chi-square analysis. Results: 1829 and 1728 biopsies were reviewed in Years A and B, respectively. p16 use signifi cantly increased from A to B, with signifi cant changes in reasons for p16 use (Table 1) . In Year A, p16 was used primarily for category 1 with fewer cases in category 2. In Year B, the frequency of category 1 decreased with concomitant increases in categories 2 and 4; approximately 1/3 of the cases in category 4 were p16 positive and diagnosed as HSIL. Finally, signifi cantly more cases of HSIL were detected by using p16 per the LAST guidelines ( Conclusions: Implementation of the p16 LAST guidelines in our practice resulted in a signifi cant increase in p16 use, nearly doubling the rate from 2.8% to 4.9%, albeit much lower than the 20% predicted in the LAST publication. This increase was largely due to increased p16 use in categories 2 and 4, and resulted in enhanced HSIL Background: Neuroendocrine carcinomas of the uterine cervix (NEC) are highly aggressive cancers. As in squamous cell carcinomas (SCC), in NEC p53 and Rb are down and p16 is up. MicroRNAs (miRs) are noncoding RNAs with roles in posttranscriptional regulation. Here, we identify a specifi c miR signature of NEC by comparing to SCC and adenocarcinoma of the uterine cervix (AC).We show that such signature reveals novel endocrine dependent tumorigenic pathways. Design: 4 NEC, 4 SCC and 2 AC were selected from tissue archives. RNA was analyzed by Nanostring. The deregulated miRs were confi rmed with RT-PCR. Targets were identifi ed by in silico studies and confi rmed by RT-PCR. MCF7 cell line (breast cancer) was transfected with miR31 and RET expression was assessed by Western Blot. Results: In the NEC vs AC analysis 6 miRs only were deregulated: 4 down (miR-215, miR-31-5p, miR-192-5p, miR-194-5p) and 2 up (miR-9-5p, miR-7-5p). 5 miRs were deregulated in NEC vs SCC, 3 down (miR-31-5p, miR-203, miR-205-5p) and 2 up (hsa-miR-375, hsa-miR-135a-5p). Mir31-5p, down in both analyses, by similar fold difference was validated by RT-PCR, as were miR203 and miR205-5p for NEC vs SCC. On the other hand, RT-PCR did not confi rm miR135a-5p deregulation. RET is target of miR31-5p (in silico). Noteworthily, estrogen receptor alfa 1 (ESR1) is target for all deregulated miRs identifi ed except miR205-5p. Transfection of miR31 in the MCF7 cell line was followed by downregulation of RET as seen on Western Blot. Conclusions: MiR profi ling generated a short list of deregulated genes in NEC vs both SCC and AC showing that NEC has a specifi c miR signature. One miR in particular, miR31-5p, was down by comparable amounts in NEC vs both SCC and AC. Interestingly, RET is a putative target for miR31-5p (in silico). Downregulation in similar amounts of miR31-5p was validated in both analyses, NEC vs AC and NEC vs SCC. Hence, NEC tumorigenesis might partially be RET driven, similar to other neuroendocrine tumors. Transfection of miR31-5p in MCF7 was followed by Western Blot confi rmed downregulation of RET, showing that this mechanism might play a role in many other cell types. Of note, in silico shows that all deregulated miRs (except miR205) target ESR1. Therefore, the miR signature of NEC reveals a dual nature: neuroendocrine and estrogen-sensitive. This is a fundamental progress in the understanding of this cancer and its potential treatment. A white, whorled and rubbery cut surface was noted in 43/52 (82%), 4 were polypoid (8%) and prominent cystic degeneration was seen in 5 (10%). Hemorrhage/ necrosis was seen in 9 tumors (17%). In 54 LM-BN the margin was well circumscribed and in the others could not be evaluated with certainty. Twenty-fi ve (37%), 25 (37%) and 18 (26%) LM-BN showed low, intermediate and high bizarre nuclei density respectively. Twenty-two (32%) tumors showed diffuse, 27 (40%) multifocal and 19 (25%) focal atypia respectively. Mitotic count ranged from 0 to 7/10 (average 1 to 2)/ 10 HPFs. Forty-three had <2/10 HPFs, 22 showed 2 to 5/10 HPFs and in 3 tumors mitotic count was 6, 7, and 7/10 HPFs respectively (two-focal and one-diffuse atypia). All but 3 LM-BN showed karyorrhectic nuclei that were striking in 12 mimicking atypical mitoses. Ischemic but not tumor cell necrosis was detected in 28 tumors (41%). Rhabdoid-like cells were noted in 23 tumors (striking in one). Follow up was available in 54 patients and they had no evidence of recurrence, 38 treated by hysterectomy and 16 by myomectomy, ranging from 1 to 13 years (overall average 5; in patients with myomectomy average 5.7 with range from 2.8 to 11).
Our results corroborate that LM-BN is associated with a favorable outcome even in those patients only treated by myomectomy and highlights that a conservative approach can be undertaken in these patients as many of them are of reproductive age. Because of the favorable outcome, the term LM-BN is preferable to alternative terminology including "atypical leiomyoma". Background: Primary ovarian mucinous neoplasms as well as metastatic mucinous carcinomas to the ovary, irrespective of their site of origin, often express enteric markers (CDX2 and CK20), making it diffi cult to distinguish a primary ovarian mucinous neoplasm from a metastatic mucinous carcinoma. SATB2 (special AT-rich sequence binding protein 2) is a nuclear matrix-associated transcription factor which is expressed in glandular cells of the lower gastrointestinal tract. The aim of this study was to evaluate the utility of SATB2 immunohistochemical (IHC) staining in distinguishing primary ovarian mucinous neoplasms (carcinomas and borderline tumors) from metastatic mucinous carcinomas to the ovary from the colon, appendix or pancreas. Design: IHC staining for SATB2, CDX2 and CK20 was performed on whole tissue sections from 84 resected mucinous neoplasms: 25 ovarian neoplasms (12 mucinous carcinomas and 13 borderline tumors, intestinal type), 19 metastatic carcinomas to ovary (10 appendiceal, 5 colonic, 4 pancreatic ) and 40 primary non-ovarian carcinomas (20 colonic, 10 appendiceal, 10 pancreatic). The extent of staining was graded as 0 (<5% nuclear staining), 1+ (5-25%), 2+ (26-50%) or 3+ (>50%), and intensity was graded as weak, moderate or strong. Results: IHC stains for CDX2 and CK20 were each positive in 92% of primary ovarian mucinous tumors and were positive in 90% and 85%, respectively, of all metastatic mucinous carcinomas to the ovary. SATB2 was expressed in 80% and 100% of mucinous colonic and appendiceal carcinomas metastatic to the ovary, respectively, with 3+ strong nuclear staining in all but 2 cases. Similar staining with SATB2 was seen in primary mucinous carcinomas of the colon (95%) and appendix (100%). In contrast, mucinous ovarian metastases from the pancreas were all SATB2 negative, as were all primary pancreatic carcinomas, 75% of primary ovarian mucinous carcinomas, and 85% of mucinous borderline tumors of the ovary. Conclusions: 1) CDX2 and CK20 are not helpful in distinguishing primary ovarian mucinous neoplasms from metastatic mucinous carcinomas from the colon, appendix, or pancreas, since they are commonly expressed by each of these tumors. 2) Although SATB2 cannot separate a primary ovarian mucinous tumor from a metastatic pancreatic carcinoma, it is extremely helpful in distinguishing primary mucinous ovarian neoplasms from metastatic mucinous carcinomas of colonic or appendiceal origin. Background: Zip1 is an zinc uptake transporter involved in the extraction of zinc from circulation and its accumulation intracellularly. We have previously demonstrated that ZIP1 is decreased in prostate cancer. However, the role of hZIP1 in carcinomas of the other organs has not been comprehensively examined. The goal of the current work is to study the expression of hZIP1 in mucinous carcinomas from a variety of organs as compared with non-neoplastic and conventional adenocarcinomas in these organs. Design: hZip1 protein expression in mucinous adenocarcinomas of the ovary, colon, stomach and lung in tissue microarrays (TMAs) were determined by IHC using an anti-hZip1 antibody. The TMAs were comprised of 35, 51, 31 and 21 mucinous adenocarcinoma of the ovary, colon, stomach and lung, respectively, 152 ovarian serous, 129 conventional colonic and 4 conventional gastric adenocarcinomas. Normal ovarian (n=17), colonic (n=12) and gastric (n=5) tissue were also present in the TMAs. hZip1 immunoreactivity in the epithelial cells were scored as follows: negative, 0; 1+, < 10%; 2+, 10-50% and 3+, > 50% positive cells. Results: hZip1 showed consistently low expression in mucinous adenocarcinoma of the ovary, colon, stomach and lung with an average score of 1.3, 1.7, 2.2 and 2.4, respectively. The expression of hZip 1 was signifi cantly lower in mucinous adenocarcinomas as compared to 1) ovarian serous carcinoma (P<0.001) and normal ovarian tissue (P=0.015), 2) colonic adenocarcinoma and normal colonic mucosa (P<0.001), and 3) conventional gastric adenocarcinoma (P<0.05) and normal gastric epithelium (P=0.027). The mean score of hZip1 was signifi cantly lower in low and intermediate grade mucinous carcinomas of the stomach, as compared to high grade counterparts (2.7 versus 1.9, p<0.01). There was no association between stage and hZip1 scores in any of the mucinous tumors. 152 ovarian serous carcinomas revealed hZIP1 scores of (0), 1+, 2+ and 3+ in 1 (0.7%), 13 (9%), 32 (22%) and 106 (70%) cases, respectively. There was a statistically signifi cant lower expression of hZip1 in low compared to high grade serous carcinomas (P<0.05). Conclusions: hZIP1 expression appears to be consistently decreased in mucinous adenocarcinomas from a variety of organs. However hZIP1 is also decreased as a function of increasing grade in both mucinous and non-mucinous tumors. These fi ndings suggest that hZIP1 plays a fundamental role in the carcinogenesis of some organs that is particularly accentuated in mucinous tumors. Tissue Types  ER  ER  PR  AR  NcOA3  CCC  6  100  2  4  49  ESC  50  100  56  57  50  EEC grade 1  94  100  88  50  0  EEC grade 2  84  100  88  42  10.53  EEC grade 3  67  100  67  50  33  Proliferative Endometrium  100  100  100  0  11  Secretory Endometrium  78  100  90  0  50  Atrophic Endometrium  100  100  100  40  0 Conclusions: A signifi cant subset of CCC express hormone receptors, but generally at low levels and in a small proportion of tumor cells. However, a signifi cantly larger subset of CCC (62%) express NcOA3, and typically in a diffuse pattern. These fi ndings raise the possibility of a novel role for hormone receptor coactivators such as NcOA3 in CCC, whereby the upregulation of NcOA3 may allow the pathogenesis of this cancer to be driven at least partially by hormones, even if demonstrable hormone receptor expression is low.
SATB2 Immunohistochemical Staining Is Useful in Distinguishing Primary from Metastatic Mucinous Tumors in the Ovary
The Prognostic Effect of MLH1 Loss in Endometrial Endometrioid
Intraoperative Diagnosis of Hysterectomies for Endometrial
Carcinoma; How Reliable in Identifying Patients at Risk? F Eren, F Gerin. Marmara University School of Medicine, Istanbul, Turkey. Background: Hysterectomies for endometrial carcinoma are submitted for intraoperative consultation to identify patients who are at risk for extrauterine spread and require further staging. High risk parameters include high tumor grade or serous/ clear cell types;deep myometrial invasion and cervical extension.Among these tumor grade and histological subtyping were found to be less reliable for intraoperative diagnosis. The aim of this study is to evaluate the accuracy of intraoperative diagnosis at identifying the high risk parameters that will lead to surgical staging in patients with endometrial adenocarcinoma. Design: Frozen section and permanent diagnosis of 50 hysterectomies performed for endometrial adenocarcinoma at Marmara University Hospital between 2011-2013 were evaluated. As a routine practice depth of myometrial invasion,presence of cervical extension and tumor histological subtype were reported intraoperatively in all cases. Intraoperative reporting of tumor grade was present in only 27 of the cases.This was either because the clinicians did not demand it or due to the lack of pathologists experience. In all cases frozen section and fi nal pathology reports are compared for high risk parameters.
Results:
The agreement between intraoperative diagnosis and fi nal pathology for depth of myometrial invasion and histological type were 86% (n:43) and 88% (n: 44) respectively. In 6 (12%) cases the depth of myometrial invasion changed in fi nal report but in only 2 (4%) the error would affect patient management. In 5 cases diagnosis changed from endometrioid to serous/clear cell or malignant mixed mullerian types in the fi nal report. In 4 of these cases deep myometrial invasion was also reported intraoperatively so the error in tumor type did not affect patient management. The agreement between intraoperative and fi nal pathology for tumor grade was 77% (n:21). All errors related to grade were between grade 1 and 2 which would not affect operative procedure. Overall when all high risk parameters are evaluated together in only 3 (6%) cases the errors in intraoperative diagnosis leads to suboptimal operative management. All the error cases but one were evaluated by pathologists not experienced in gynecological pathology. All subgroup 1 cases showed a high degree of concordance in immunoprofi le between appendiceal and ovarian tumors, with identical expression of appendiceal pattern in >90% of markers. In subgroup 2 tumors, however, the concordance was poor, with only one case showing concordance in all markers. Two cases showed CDX2+/PAX8-LAMNs and CDX2-/PAX8+ ovarian mucinous cystadenomas, and another case showed contrasting appendiceal/ovarian patterns for CK7 (-/+), CK20 (+/-), CDX2 (+/-), MUC2 (+/-), MUC5AC (-/+), and p16 (-/+).
Conclusions
Conclusions:
When there is peritoneal and/or ovarian surface involvement, even only microscopic, the synchronous tumors were all of appendiceal primary. Of those without peritoneal lesion, however, they were heterogeneous with some most in keeping with truly independent primary tumors. Further molecular characterization is needed to confi rm these interpretations. Conclusions: Although Napsin A, AMACR, and HNF1 are all viable markers of CCC, Napsin A most optimally combines high sensitivity and high specifi city. HNF1 is highly sensitive but is limited by its suboptimal specifi city; AMACR is highly specifi c but is relatively insensitive. Using CCC as a diagnostic end-point relative to all other tumors, the best performing immunoprofi les are Napsin A positivity (OR 857) and the co-expression of all three markers (OR 707). The latter, however, has a suboptimal sensitivity of only 0.65. Therefore, Napsin A (sensitivity 0.82; specifi city 0.99) is the single best marker for CCC. Background: Clear cell carcinomas of the endometrium (E-CCC) are extraordinarily rare, which is a limitation on investigative efforts into their molecular basis and the development of molecularly-directed therapies. Clear cell carcinomas of the ovary (O-CCC), in contrast, are signifi cantly more common, and accordingly have been studied more extensively. Although these tumors are recognized to display broad phenotypic overlap, it is unclear how readily fi ndings in O-CCC can be extrapolated to E-CCC. In the present study, the authors utilized a proteomic technology, matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS), to assess and quantify the differences between O-CCC and E-CCC. MALDI IMS supplements gene expression approaches in that it accounts for postranslational modifi cations to proteins, and also supplements immunohistochemical approaches by screening for large numbers of proteins without a specifi c target. Design: Slides from TMAs containing 54 O-CCC and 47 E-CCC were analyzed by MALDI IMS and unique spectral peaks were identifi ed for every 0.05 mm 2 of tissue. Non-viable tissues and tumor-associated stroma were excluded prior to subsequent analyses. A linear mixed effect model with random intercept was fi t for each spectral peak, and effect size (mean peak area difference between the two groups, or ratio of mean peak area of E-CCC to O-CCC) for each peak were determined. p values were obtained from each model, and were subsequently adjusted using the false discovery rate. Results: From 730 normalized peaks in samples from both groups, 93 (12.7%) showed a≥1.5 fold difference (and at an adjusted p value cutoff of 1e -10 ) between E-CCC and O-CCC. Figure 1 shows results from a cluster analysis of these peaks (red, left side of panel is E-CCC; green is O-CCC). The underlying heat map is based on the median peak area of each patient.
Our fi ndings suggest that there are demonstrable proteomic differences between O-CCC and E-CCC, quantifi ed here at 12.7%. Although this fi gure may be modulated by a variety of analytic factors, it may also be explained by the different microenvironments in which these tumors originate, with a signifi cant subset of O-CCC arising from the highly oxidative environment of endometriotic cysts.
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Increased Expression of Monocarboxylate Transporters 1 and 4 Correlates with Histologic Type of Uterine Cervical Cancer J Ferreira, F Silva, L Silva, J Serpa, A Felix. Instituto Português de Oncologia, Lisboa, Portugal; CEDOC-FCM, Lisboa, Portugal. Background: Cancer cells are dependent on anaerobic glycolysis for their high energy needs. This leads to production of large quantities of lactate, which is transferred in/ out the cells by Monocarboxylate Transporters (MCTs). MCTs have been shown to be upregulated in various tumors. In cervical cancer, a lactate-rich microenvironment has been associated with poor prognosis. Furthermore, MCT immunoexpression has been described to increase from preinvasive to invasive carcinomas. Our aim was to study the role of MCTs in cervical cancer by evaluating the immunohistochemical expression of MCT1 and MCT4 in a large series of cervical lesions (preneoplastic and neoplastic) and assessing its clinical-pathological value. Design: Tissue microarrays with 11 CIN3, 70 invasive squamous cell carcinomas(SCC), 4 adenocarcinomas in situ and 37 invasive adenocarcinomas(ADC) were immunohistochemically stained for MCT1 and MCT4. Immunoreactions were evaluated quantitatively. Clinical data and follow-up were recorded. Results: Tissue from 122 patients (median age: 46 years old; mean of follow-up: 54 months; FIGO stages I(55%), II(21%), III(6%) and IV(6%)) was included. We excluded ten cases from the analysis because they were either lost to follow-up or tissue was lost. MCT1 was present in 72% and 32% of SCC and ADC cases, respectively. MCT4 expression was found in 37% and 68% of the cases in SCC and ADC. We found a signifi cant association of the expression of MCT1 with SCC (p<0.001) and of MCT4 with ADC (p<0.001). There was evidence of increasing expression of MCT4 from CIN3 lesions to SCC (0% vs. 59%, p<0.05) but not of MCT1 or from adenocarcinoma in situ to ADC. Increased MCT1 expression was correlated with metastasis in ADC (p<0.05). No correlations were found between the association of MCT1 or MCT4 expression and stage, local recurrence or death from disease.
Conclusions:
The association between MCT1 and MCT4 expression and the histological type might underline a different metabolic profi le in these two histological types. MCT4 expression was found to increase from preinvasive squamous lesions to invasive squamous cell carcinomas. MCT1 expression is associated with lymph node or distant metastasis in adenocarcinoma. These fi ndings suggest that MCT1 and MCT4 may have an important role in cervical cancer progression. Background: Melanoma does not respond to traditional chemotherapy/radiation, so targeted therapies are very important. Advances in molecular diagnostics have identifi ed mutations in BRAF, NRAS  ckit genes. The rates of mutations vary by anatomic site  sun-exposure status. NRAS mutations tend to occur with chronic sun exposure, BRAF in non-sun exposed skin and ckit in mucosal sites  chronically sun-exposed skin. Targeted therapies exist for BRAF  ckit mutated tumors. To our knowledge, no study to date has systematically characterized the incidence of molecular mutations in these genes in melanomas originating from gynecologic sites (MOGS): vulva, vagina and cervix. Vulvar melanomas often originate in skin, while vaginal, cervical (and some vulvar) melanomas arise in squamous mucosa. This study examines whether MOGS have similar mutations as a group  whether mutational status matches those previously reported for skin  mucosal melanomas. Design: 60 patients with MOGS were identifi ed  HE stained sections were reviewed for the accuracy of diagnosis, histopathologic features,  presence of adequate tumor for molecular analysis. 32 cases had adequate FFPE tissue for analysis. Utilizing the Pinpoint Slide DNA Isolation System™ followed by PCR suitable amplifi ed DNA was extracted from 27 cases. Sanger sequencing was performed for the 3 genes in question  analysis of known mutations sites was undertaken. We compared rates of mutation for skin vs mucosal lesions  reviewed histopathologic features of tumors with a mutation looking for similarities. Results: We found 5 of 27 MOGS (18.5%) harbored a mutation in the ckit gene: 3 insertion/deletions (two in exon 14, one in exon 15)  2 point mutations (exon 14). None of the cases had mutations in the BRAF or NRAS genes. Two cases had been previously tested for BRAF  ckit mutations, one had a ckit mutation in exon 14. The 6 tumors with ckit mutations included 1 arising in the vagina (mucocsa)  5 arising in the vulva (2 involving skin  mucosa and 3 skin only). Of note, 4 cases had co-existing atypical nevi present. Conclusions: Though MOGS can arise from either skin or squamous mucosa, they are molecularly more similar to each other  follow the mutation pattern previously described in mucosal melanomas (ckit mutations). While 65% of all melanomas from the skin harbor a mutation in BRAF, not a single case in our study was mutated. These fi ndings my help guide clinicians when choosing molecular testings for patients with MOGS. The patients with confi rmed ckit mutations may be benefi t from tyrosine kinase inhibitors such as imatinib mesylate (Gleevec).
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Malignant Mesonephric Tumors of the Female Genital Tract: A Clinicopathologic Study of 14 Cases M Fukunaga. Jikei University Daisan Hospital, Tokyo, Japan. Background: Malignant mesonephric tumors (MMTs) are rare neoplasms of the female genital tract, arising primarily in the cervix, and they are considered to be derived from remnants of the mesonephric duct. Because of their rarity, the biologic behavior of MMTs is not well known. Extrauterine tumors have been rarely reported. Design: Fourteen cases of MMT were clinicopathologically studied to further understand the histologic diversity, histogenesis, and biologic behavior. Results: The patients ranged in age from 46 to 73 years (mean, 58 years). There were 10 adenocarcinomas (ACs) and 4 malignant mixed mesonephric tumors (biphasic tumors with a sarcomatoid component) (MMMTs). The ACs were found in the cervix (6), meso-ovary or ovary (3), and uterine body(1). The MMMTs involved the mesoovary or ovary (2), uterine cervix (1), anduterine body (1). ACs showed variable proliferative patterns, including glandular, tubular, papillary, retiform, and solid. One of the ACs exhibited cartilaginous differentiation in the lung metastasis. Among the MMMT subgroup,3 were homologous and 1 was heterologous (cartilage). One each of AC and MMMT had mixed epithelial elements, including serous and endometrioid adenocarcinomas. Mesonephric remnants or hyperplasia was observed in 2 cervical ACs and 1 meso-ovarian MMMT. One ovarian AC was associated with endometriosis. Immunohistochemically, all tumors were positivefor CAM5.2, CD10, and calretinin and negative for ER, PgR, and CEA. Of the 11 patients with follow-up information available (mean, 60 months), 3 patients with MMMT (2 in meso-ovary or ovary, 1 in uterine body) died of spread disease at 25, 51, and 100 months, respectively, after surgery. No patients with AC and follow-up information died of disease. One patient was alive with lung metastases and the remaining 7 had no evidence of disease 6 to 76 months postoperatively.
Conclusions:
The diversity of histologic patterns was characteristically observed. Seven cases arose outside of the uterine cervix, and mesonephric remnants or hyperplasia was found in only 3 cases. Since two cases exhibited mixed epithelial elements and one was associated with endometriosis, some MMTs without mesonephric remnants may be considered adenocarcinoma with mesonephric differentiation. The possibility of a mesonephric tumor should be considered when encountering an unusually appearing carcinoma, malignant mixed tumor, or even an endometrioid adenocarcinoma. All of the patients with AC and follow-up information survived. In contrast, 3 of 4 patients with MMMT died of disease. MMMTs may be more aggressive than ACs.
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Early Stag e Placental Mesenchymal Dysplasia: A Clinicopathologic Study of 10 Cases with Gestational Age Less Than 20 Weeks M Fukunaga. Jikei University Daisan Hospital, Tokyo, Japan. Background: Placental mesenchymal dysplasia (PMD) is characterized by placentomegaly and may be mistaken for partial hydatidiform mole (PM) or complete mole (CM) with co-twin both clinically and macroscopically because of the presence of "grape-like vesicles". It may be associated with a normal fetus, a fetus with intrauterine growth restriction, or a fetus with features of Beckwith-Wiedemann syndrome (BWS). However, PMD is both underdiagnosed and underreported. PMD with gestational age less than 20 weeks is rarely reported. Design: In order to elucidate the clinical presentation, complications, microscopic features, and differential diagnoses, 10 cases of PMD with gestational age less than 20 weeks were clinicopathologically analyzed. Immunohistochemical study of p57 (Kip2) (p57) and TSSC3, both are products of a paternally imprinted, maternally expressed gene, was also done. Results: Maternal ages ranged from 23 to 40 years (mean age, 32 years). Five patients were initially diagnosed as PM and one was as CM with twin on ultrasound examination. The gestational periods ranged from 12 to 19 weeks. One case was associated with BWS. Histologically, early stage PMD was characterized by moderate swelling of stem villi with cistern formation, myxoid change, dilated veins, mild stromal cell proliferations, and the absence of trophoblastic hyperplasia. Dilated subchorionic vascular vessels with or without luminal thrombosis, or chorangiosis, which were observed in the third trimester PMD, were not found. Cytotrophoblasts were positive for p57 and TSSC3 in all cases. Regarding p57, villous stromal cells were diffusely positive in 3 cases, focally positive in 5, and uniformly negative in 2. TSSC3 was negative in stromal cells in all cases. Conclusions: PMD presents with a wide spectrum of clinicopathologic fi ndings. It is important to identify PMD cases prenatally to reduce fetal morbidity and mortality. Early stage PMD can be clinically or pathologically misdiagnosed as abortion, PM, or CM with a twin. Histologic features in early stage PMD are less distinctive compared with those of PMD in the third trimester. The diagnostic clues are moderate swelling of stem villi with cistern formation, myxoid change, dilated veins, and mild stromal cell proliferations, and the absence of trophoblastic hyperplasia. The p57 and TSSC3 immunohistochemical study is useful for differential diagnoses in equivocal cases. It is important to identify PMD cases in early stage to reduce fetal morbidity and mortality.
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Twin Placenta with Complete Hydatidiform Mole and Its Mimics: Histologic Diagnosis and Immunohistochemistry for the Imprint Gene Products P57 (Kip2) and TSSC3 M Fukunaga. Jikei University Daisan Hospital, Tokyo, Japan. Background: Twin pregnancies with a normal placenta and complete mole (CM) are very rare, and they may pose a diagnostic challenge. Microscopically, they resemble partial mole. The differential diagnosis is very important for patient management. p57 (Kip2) (p57) and TSSC3 are products of paternally imprinted, maternally expressed genes. Design: Twelve cases of morphologically putative twin pregnancies with CM, all of which were in the fi rst trimester, were retrieved from a fi le of 526 CMs, and they were analyzed by the immunostaining of p57 and TSSC3. DNA ploidy in six of the 12 cases was also analyzed by fl ow cytometry, and all of them were diploid. Results: The admixture of large hydropic villi with circumscribed trophoblastic hyperplasia and smaller, normally appearing villi without trophoblastic hyperplasia was observed in fi ve cases. The cytotrophoblasts and stromal cells in larger villi were negative for p57 (androgenic) and TSCC3, whereas these cells were positive in the smaller villi (biparental). The fi ve cases were diagnosed as CM with twin (twin pregnancy with a coexisting normal placenta and CM). In the remaining seven cases, some villi had histologically typical CM features and some showed edema, stromal cell hyperplasia, and the absence of trophoblastic hyperplasia. Some villi exhibited hydropic stroma and focal trophoblastic hyperplasia. The villi with CM features showed typical immunohistochemical profi les of p57 and TSCC3. In villi with edema, stromal cell hyperplasia, and the absence of trophoblastic hyperplasia, cytotrophoblasts were positive for p57 and TSSC3 (biparental) and stromal cells were negative for them (androgenic). In villi with hydropic stroma and focal trophoblastic hyperplasia, TSSC3 was focally expressed. The seven cases had been erroneously diagnosed as CM with twin. The fi ndings suggested that the seven cases were CMs due to androgenic/biparental chimera or a mosaic, although molecular cytogenetic analysis was not done.
Conclusions:
The fi ndings support the hypothesis that misexpression of p57 and TSSC3 is involved in the abnormal development of androgenic CMs. The immunohistochemical analysis is a useful tool for the differential diagnosis of twin placenta with CM and morphologically challenging CM cases. CMs probably due to androgenic/biparental chimera or a mosaic histologically mimic twin with CM. Immunohistochemistry for the imprint gene products p57 and TSSC3 can be a useful screening tool for cytogenetic analyses.
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Ovarian Background: Ovarian carcinoma is the third most common tumor type in patients with Lynch Syndrome (LS), after colorectal and endometrial carcinomas, and patients with LS have a 10-12% lifetime risk of developing ovarian carcinoma. Few cases series describing the histotype of the ovarian tumors in patients with LS have been reported and these typically lacked either central pathological review or application of current diagnostic criteria for determination of ovarian carcinoma histotype. This study was undertaken to determine the spectrum of ovarian carcinoma histotypes seen in patients with LS. Design: We collected 20 cases of ovarian carcinoma in patients known to have LS. All slides from these cases were reviewed and ovarian carcinoma histotype assigned, without knowledge of the previous diagnosis. Results: In 19 of 20 patients information regarding the exact LS mutation was available: MSH2 mutations were most common, being present in 11 patients, while 3 patients had MLH1 mutations and 2 had MSH6 mutations. The ovarian carcinomas, based on review, were of the following histotypes: 10 endometrioid carcinomas, 4 clear cell carcinomas and 5 mixed carcinomas (3 mixed endometrioid/clear cell, 1 mixed endometrioid/ malignant Brenner, 1 mixed endometrioid/seromucinous borderline tumor). The fi nal tumor was a de-differentiated carcinoma. There were no serous carcinomas or serous borderline tumors. Although mucinous differentiation was common in the endometrioid carcinomas, there were no mucinous tumors of intestinal type. In 2 cases the histotype diagnosis changed based on review (from mucinous to endometrioid and from highgrade serous to endometrioid, respectively). Conclusions: All ovarian carcinomas associated with LS in this series were of nonserous histotypes, and thus completely non-overlapping with the histotype of ovarian carcinomas associated with the other common autosomal dominant hereditary cancer susceptibility syndrome, Hereditary Breast and Ovarian Cancer syndrome. The carcinomas were of histotypes associated with endometriosis. These fi ndings have implications for screening of ovarian carcinomas for mismatch repair enzyme expression by immunohistochemistry, as well as genetic counseling and mutation testing for LS.
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Application of p16 Immunostain in Classification of Adenoid Basal Tumors of the Cervix A Goyal, CG Przybycin, B Yang. Cleveland Clinic, Cleveland, OH. Background: Our understanding of adenoid basal tumors of the cervix has evolved over time. Most of the proliferations referred to as "adenoid basal carcinomas" have a clinically benign course -leading some to suggest the term "adenoid basal epitheliomas". However, it has been acknowledged that rarely, these may be associated with invasive carcinomas. Here we investigate the role of p16 in the classifi cation of these tumors. Design: A database search was conducted from January 1990 to June 2013 for adenoid basal lesions of the cervix. The hematoxylin and eosin stained slides were reviewed.
Immunohistochemical stain for p16 was performed on representative sections with adequate controls. The histologic features, staining patterns and the clinicopathologic data were recorded. Results: Ten cases of adenoid basal tumors of the cervix were retrieved. The patient age ranged from 53 to 77 years and the average age was 67.7 years. The specimens included 4 hysterectomies, 3 loop electrosurgical excisions, 2 biopsies and 1 polypectomy. Seven cases revealed bland histology consistent with adenoid basal epithelioma. Other three cases showed an invasive cytologically malignant component (2 adenoid basal/ squamous carcinomas, 1 papillary squamous cell carcinoma) intermixed with a bland epithelioma component. All non-invasive adenoid basal epithelioma cases showed either negative or patchy cytoplasmic p16 immunostaining pattern. In contrast, all invasive carcinomas showed strong and diffuse nuclear p16 immunostaining pattern. Followup was available in seven patients and showed no evidence of disease (duration: 3-60 months, average: 13 months). Conclusions: Distinct p16 immunostaining patterns exist between non-invasive adenoid basal epitheliomas and invasive adenoid basal carcinomas. Diffuse and strong nuclear p16 staining associates with invasion. Our study indicates that p16 immunostaining can be a useful tool in differentiating between non-invasive and invasive adenoid basal tumors along with careful histopathologic evaluation.
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Immunohistochemical Expression of GATA3 in Primary Extramammary Paget Disease of the Vulva A Goyal, G Zhang, B Yang. Cleveland Clinic, Cleveland, OH. Background: GATA binding protein 3 (GATA3) plays a critical role in breast development by promoting luminal cell differentiation and has proven to be a useful immunohistochemical marker for breast carcinomas. Breast tissue has a close resemblance to apocrine/eccrine glands due to similar embryologic derivation. Further, it is speculated that extramammary vulvar Paget disease has an apocrine/eccrine origin. Given these considerations, in this study, we investigated the expression of GATA3 protein in primary vulvar Paget disease. Design: A database search was conducted from January 2000 to September 2013 for biopsies/excisions of vulvar Paget disease. Clinical history of any other internal malignancy was recorded and cases of secondary Paget disease were excluded. The majority of cases that were included for further study had undergone immunohistochemical workup for confirming primary nature of the disease. Immunohistochemical stain for GATA3 was performed on representative sections and the staining patterns and clinicopathologic data were recorded. Staining was recorded as positive (nuclear staining) or negative with the intensity as weak, moderate or strong and the distribution as focal (< 50% tumor cells) or diffuse ( 50% tumor cells). Results: Thirty-three cases of vulvar Paget disease from 20 patients were retrieved: 30 cases with intraepithelial Paget disease and 3 cases with invasive carcinoma. Patient age ranged from 57 to 85 years with a mean of 72 years. Eleven patients had multiple recurrences of Paget disease. No history of urothelial carcinoma or colorectal adenocarcinoma was present in any of the patients. GATA3 immunostain exhibited diffuse nuclear staining in Paget cells in all the 33 cases -with strong intensity in 31 cases and with moderate intensity in 2 cases. The Paget cells were easily distinguishable from the surrounding keratinocytes due to their abnormal nuclear morphology and more intense staining pattern. There was no difference in staining patterns between the intraepithelial and the invasive components. Conclusions: Our study demonstrates that GATA3 protein is overexpressed in vulvar Paget cells. Given its expression in both the intraepithelial and the invasive components, it may be involved in the early pathogenesis of vulvar Paget disease. GATA3 is a highly sensitive immunohistochemical marker for primary extramammary vulvar Paget disease and can be employed as a useful ancillary tool in its diagnosis.
Clinico-Pathologic Characteristics of Female Anal Pap Smears in an Urban County Hospital
T Guillory, M Mosunjac, A Winkler, S Ehdaivand. Emory University, Atlanta, GA. Background: It is projected that over 4000 women will be diagnosed with anal cancer in 2013. There are no national screening guidelines or consensus criteria for anal cytology (AC); however, cervical cancer screening guidelines are often used. In this study, we aimed to delineate the characteristics of women who have AC screening at an urban hospital. Design: A retrospective chart review for all female AC smears was performed between July 2004 to July 2013. Demographic information, cervical pap, genital histology, and information related to HPV and HIV status were also obtained. Results: A total of 139 AC smears from 88 patients were identifi ed, including fi ve transgender patients. The mean age was 42 . The mean time between AC was 14.6 months. The vast majority were African American (85.1%) with smaller numbers of Caucasian (10.4%), Hispanic (3.4%), and American Indian/Alaskan (1.1%). The data on AC diagnoses are located in Table 1 . 22% of AC had a corresponding anal histology, of these, 32% had AIN2 or 3. 88.6% of patients were HIV positive and 44.3% had AIDS. Table 2 contains data concerning AC diagnosis and HIV/AIDS status. There was no statistical signifi cance between AC diagnosis and HIV/AIDS status. The HPV status was known for 56 patients, with 79% being positive. Of the patients with cervical cytology, 70% with an abnormal AC also had an abnormal cervical pap. Clinically visible lesions were associated with 20% of AC.
Conclusions:
Our study shows a predominantly African American population with a large burden of HIV. Our population had a high pre-test probability of abnormal AC due to the prevalence of HIV or the presence of clinical lesions. More than 60% of patients had an abnormal AC, but no patients had an AC diagnosis of HSIL. All of the HSIL diagnosed on subsequent histology were missed by AC. This may indicate that less conservative diagnostic criteria than the Bethesda system should be applied to AC . We found that there was no statistical signifi cance between a positive HIV/AIDS status and severity of AC diagnosis. Historically patients who are immunosuppressed have a higher burden of SIL. Further study may be needed to defi ne diagnostic criteria specifi c for AC.
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Gastrointestinal-and Müllerian-Type Epithelium in Ovarian Mucinous Cystadenoma: Immunohistochemical Analysis of 139 Cases SA Halimi, D Maeda, M Fukayama. Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Background: Ovarian mucinous tumors show stepwise malignant transformation from mucinous cystadenoma (MA) to mucinous borderline tumor (MBT) and to mucinous adenocarcinoma (MCa). Two subsets of MBT have been established: gastrointestinal (GI) and Müllerian (M) types. However, no such distinction is made for MAs. An association between Müllerian derivatives and M-type mucinous tumors has been reported, while the origin of GI-type mucinous epithelium is unclear. This study analyzed a series of MAs immunohistochemically using gastric, intestinal, and Müllerian markers to elucidate the direction of the differentiation of mucinous epithelium that arises in the ovary and to seek a link between GI-and M-type epithelium. Design: We retrieved 139 cases of MA. The tumors were initially evaluated morphologically for presence or absence of GI-and M-type epithelium. Representative slides of morphologically pure GI-and M-type MAs were chosen. If a transition from M-type epithelium to GI-type epithelium was observed, slides containing such areas were sent for immunohistochemistry. The expression of the gastric marker claudin-18 (CLDN18) and intestinal (CDX2) and Müllerian (ER) markers was evaluated immunohistochemically. The epithelium that was positive for CLDN18 or CDX2 was designated as "GI type", and the epithelium showing the CLDN18-/CDX2-/ER+ phenotype as "M type". Results: GI-type epithelium characterized by CLDN18 or CDX2 positivity was present in 93% (129/139) of the MAs. Of these, 14 were associated with teratomas and one with a Brenner tumor. A transition from M-type (CLDN18-/CDX2-/ER+) epithelium to GI-type epithelium was seen in 12 cases (9%). Although most GI-type epithelium was ER-negative, scattered ER positivity was observed in 18 cases (14%). A rare subset of MAs (eight cases) was purely Müllerian type, consisting of epithelium with Müllerian morphology and diffuse ER expression. Conclusions: Ovarian MAs can be subclassifi ed into GI and M types. In GI-type tumors, the gastric phenotype is predominant. Since the transition from M-type epithelium to GI-type epithelium is seen in some cases, we conclude that GI-type epithelium can arise not only from teratomatous lesions or Brenner tumors but also from Müllerian duct derivatives or ovarian surface epithelium via metaplastic/neoplastic processes. Background: Undifferentiated uterine sarcomas (UUS) are rare primary uterine sarcomas. They appear to have a heterologeneous biology and a poor prognosis. The goal of this study was to examine the role of various clinical and pathological variables in the prognosis of these tumors. Design: Twenty-six cases of UUS were identifi ed in the archives of the Karolinska University Hospital. All original slides were re-reviewed and a variety of clinical and pathologic parameters were recorded, including age at diagnosis, mitotic rate, presence of tumor necrosis, tumor size, presence of lymphovascular invasion, and grade of nuclear atypia. Follow up data in the form of overall survival was available on all patients. Results: Analysis of mitotic rate demonstrated that these tumors could be clearly divided into two groups. One group (n=10 cases) had an extremely high mitotic rate (mean 36.8 ± 8.6) while the other (n=16 cases) had a lower rate (mean 8.7 ± 5.8). No cases had a mitotic rate between 18 and 30. Grouping the cases according to mitotic rate high vs. low demonstrated a statistically signifi cant difference in overall survival by Kaplan-Meier analysis (p=0.00391). None of the other parameters evaluated showed a correlation with overall survival, including grade of atypia, presence of tumor necrosis, stage, and age at diagnosis. Conclusions: These results indicate that UUS can be divided into two prognostically relevant groups using mitotic rate. Although this study involved only twenty-six cases, a statistically signifi cant difference could be demonstrated. Although UUS has previously been considered to have a uniformly poor prognosis, these results indicate that clinically relevant subgroups exist within this tumor type.
Undifferentiated Uterine Sarcomas Can Be Divided into Two Prognostically Distinct Groups Using Mitotic Index
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Unique ( Background: Extra-uterine high-grade serous carcinoma (HGSC) has been linked to the distal fallopian tube via an early preinvasive intraepithelial neoplasm (TIC). TIC is found in approximately 5% of prophylactic salpingo-oophorectomies of women with BRCA1 or BRCA2 mutations (BRCA+) and 40% of unselected HGSCs. We have recently discovered that TICs are paradoxically less commonly found with high stage HGSC, raising questions about the origin of many HGSCs in this population. We sought to validate this discovery in more than one context by correlating specifi c tumor patterns with TIC frequency. Design: A series of documented BRCA+ and BRCA-HGSCs that were analyzed by the SEE-FIM protocol were scored for 1) associated TIC and 2) pattern of serous carcinoma differentiation, including SET features (Solid, pseudo-Endometrioid and Transitional; Soslow 2012) and "classic "serous differentiation. Ovaries from a separate subset of tumors lacking TIC were analyzed by calretinin staining to confi rm or exclude neoplastic transformation of the ovarian surface epithelium (OSE). Results: 24 and 30 BRCA+ and BRCA-cases were studied; 5/24 (21%) and 16/30 (53%) were TIC+ (p = .02). Of 20 and 28 informative for optimal histologic classifi cation, 9 (45%) and 2(7%) were SET+ (p=.004). One of 4 BRCA+ TIC+ cases were SET+ and 0 of 14 TIC+ BRCA-cases were SET+. Overall 17 of 18 (94%) TIC+ cases showed classic serous differentiation versus 20 of 30 (67%) TIC-cases (p = .035). Analysis of 100 ovarian histologic sections from 25 additional TIC-cases did not reveal evidence of transformed OSE in proximity to the neoplasm. Conclusions: SET features correlate both with BRCA+ (as previously reported by Soslow et al) and the absence of TIC, the latter fi nding paradoxically linked to high stage HGSCs in BRCA+ women. The origin (tube vs ovary) of this signifi cant subset of HGSCs remains unclear but resolution of this question is particularly relevant to the BRCA+ population if prophylactic salpingectomy alone is contemplated as a cancer prevention measure. There is no immunohistochemical evidence from this analysis to implicate a direct transformation of the ovarian surface epithelium. Background: KRAS mutations are frequently seen in malignancies with mucinous morphology. Endometrial carcinomas (EC) of the mucinous type (MCs) are defi ned by the WHO (1994) as a variant of endometrial carcinoma with abundant intracytoplasmic mucin. In our previous study, MCs were associated with a signifi cantly higher frequency of KRAS mutations as compared to matched conventional endometrioid carcinomas. Some workers use predominate mucinous component, viz, >50% to defi ne endometrial MC. We designated those 'mixed' type ECs that show from >10% to <50% mucinous differentiation as ECs with signifi cant mucinous differentiation (ECMD). This study expands our previous report by contrasting the KRAS mutational status of the mucinous components of MCs and ECMDs vs. their associated 'usual' endometrioid components. Design: The 17 KRAS+ cases from our previous report were studied, including 6 MCs and 11 EMMDs. The specimens were microdissected to isolate only a morphologically pure endometrioid component. In addition, morphologically benign endometrium associated with its MC and/or EC SMD was microdissected from 5 cases (3 from MCs and 2 from ECMDs). Direct DNA sequencing for KRAS mutations at codons 12 and 13 using capillary electrophoresis were done. PNA test was used to verify equivocal cases. Results: KRAS mutations were detected in the endometrioid components of 5/6 (83%) MCs, 3/11 (27%) ECMDs, and 0/5 (0%) of benign endometrium. A statistically signifi cant difference in the frequency of KRAS mutations was found in the ECMD group when the components of mucinous and endometrioid tumor were compared (11/11, 100% and 3/11, 27%), respectively. (p<0.001). Conclusions: Our current study shows a strong association of KRAS mutations in the endometrioid component of our prior KRAS mutation-positive MCs (83%). When the mucinous component predominates, qualifying for an MC, KRAS mutations appear to be widespread, irrespective of the mucinous or non-mucinous differentiation of the tumor cells. In comparison to the MCs the endometrioid component of ECMD were less frequently associated with KRAS mutations (27%), even when the mucinous component of the same tumor contained a mutation (100%); the difference is statistically signifi cant (p<0.001).
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The Diagnostic Accuracy of FIGO Grade 3 Uterine Endometrioid Adenocarcinoma Correlates with Specialty Gynecologic Pathology Practice O Hassan, QF Ahmed, Y Hussein, Z Al-Wahab, B Alosh, R Soslow, R Ali-Fehmi. WSU, Detroit, MI; MSKCC, NY, NY. Background: Low rates of interobserver diagnostic agreement are seen in high-grade endometrial carcinomas (EC), including FIGO 3 endometrioid carcinoma (EMC). The aim of our study was to assess the degree of accuracy in diagnosing FIGO 3 EMC between two institutions. Design: 70 and 65 cases diagnosed as FIGO 3 EMC were identifi ed from pathology archives of institution A (general sign out) and institution B (subspecialty sign out) respectively. An average of 4 slides from each case was reviewed together by 2 GYN pathologists from each institution. The cases were then re-classifi ed according to tumor type and grade. Clinicopathologic f/u was obtained for all cases. Results: Of 70 cases from institution A, 25 (35.7%) were re-classifi ed. These included FIGO 2 with focal marked nuclear atypia EMC (n=8), serous carcinoma (ca) (n=3), mixed with serous ca (n=12) and undifferentiated ca (n=2). From institution B, 11 (16.9%) of the 65 cases were re-classifi ed. These included serous ca (n=1), mixed with serous ca (n=4), undifferentiated (n=5) and mixed with clear cell ca (n=1) (table 1). The diagnostic accuracy of FIGO 3 EMC, defi ned by consensus, was better at institution B (p=0.002). The recurrence rate for consensus FIGO 3 EMC (21.2%) and re-classifi ed cases (19.4%) were comparable (p=0.81). More patients (25%) in the re-classifi ed group died of disease (14.5%) p=0.04. Median f/u was 172 mths for consensus FIGO 3 and 137 mths for re-classifi ed cases. Overall survival between the two cohorts was not signifi cant p= .110. 
Conclusions:
Our results suggest that subspecialty sign out may be preferable to general practice in evaluating and grading endometrial ca. Diagnostic reproducibility and accuracy should be optimized for the diagnosis of high-grade endometrial ca since treatment paradigms are becoming increasingly subtype-specifi c. Background: Napsin A is a recently introduced immunohistochemical marker that is useful in the diagnosis of pulmonary adenocarcinoma and some renal cell carcinoma subtypes. However, its expression in carcinomas of the gynecologic tract has not been extensively studied. The diagnostic reproducibility of uterine clear cell carcinoma (CCC) is suboptimal due to morphologic overlap with other endometrial carcinoma subtypes (clear squamous and secretory change in endometrioid carcinomas and hobnail cells in serous carcinomas) and benign mimics. The immunoprofi le of CCC with commonly used markers is non-specifi c; thus, additional diagnostic markers are needed. This study evaluated napsin A expression in uterine carcinomas and gestational endometrium. Design: Sixty-two endometrial carcinomas including 23 clear cell carcinomas, 15 serous carcinomas, and 24 endometrioid carcinomas (14 -FIGO grade 1, 6 -FIGO grade 2, and 4 -FIGO grade 3) were assessed for napsin A expression using monoclonal anti-napsin A antibody (Novacastra). The percentage of tumor cells with cytoplasmic staining was quantifi ed to the nearest 10%. Twelve cases of gestational endometrium with or without Arias-Stella reaction were also studied. Results: Results are summarized in Table 1 . Among uterine carcinomas, napsin A demonstrated a sensitivity of 91% and a specifi city of 95% for identifying CCC. All cases of gestational endometrium/Arias-Stella reaction also expressed napsin A. Conclusions: Napsin A serves as a sensitive and specifi c marker for distinguishing CCC from other endometrial carcinoma subtypes and could improve the diagnostic reproducibility of CCC. However, it does not distinguish CCC from benign mimics such as gestational endometrium/Arias-Stella reaction. Thus, it cannot be used in peri-and postmenopausal women to differentiate CCC from atypical secretory change/AriasStella-like reaction in the setting of hormonal therapy. Background: GATA3 is a transcription factor critical for embryogenesis, development, and cell differentiation, and has recently been shown to be immunoreactive in urothelial and breast carcinomas, and negative in endometrial carcinomas. We have observed GATA3 expression in the epididymis of the testis (Wolffi an), and therefore questioned its expression in mesonephric/Wolffi an remnants and neoplasias in the Mullerian tract. Design: GATA3 immunohistochemistry (IHC) was performed on 27 formalin-fi xed paraffi n embedded cervical samples containing mesonephric epithelia (11 mesonephric remnants, MR; 14 mesonephric hyperplasias, MH; and 2 mesonephric carcinomas, MCA), 30 endocervical adenocarcinomas (ENCA), 155 endometrial adenocarcinomas (EMCA) on a TMA (152 endometrioid and 3 serous type), 2 EMCA in which the possibility of mesonephric differentiation was mentioned in the fi nal report but based on IHC (Inhibin/CD10 negative and Inhibin/Calretinin negative) was classifi ed as EMCA, 6 fallopian tube (FT) MRs, and 3 female adnexal tumors of probable Wolffi an origin (FATWO). Cases were evaluated for nuclear intensity (weak, moderate, or strong), and extent (negative=0-5%, focal=5-50%, patchy=50-75%, or diffuse=>75%). Results: Benign endocervical and endometrial epithelia were negative for GATA3, while squamous epithelium of the cervix was weakly positive in scattered cells. All cervical mesonephric lesions were GATA3 positive, including 11/11 (100%) MRs and 14/14 (100%) MHs (all moderate-strong and diffuse). One MCA, which was associated with MH, showed strong diffuse GATA3 staining, while the other MCA demonstrated moderate and patchy staining. Five of 6 FT MRs were positive for GATA3; however, the staining pattern was variable (4 patchy, 1 focal; 2 weak, 2 moderate, 1 strong). Only 1/3 FATWOs demonstrated moderate and patchy staining for GATA3. 1/30 (3%) ENCAs exhibited weak-moderate, patchy GATA3 immunoreactivity, while the remaining 29/30 (97%) were completely negative. All EMCAs in the TMA were negative for GATA3, while the 2 EMCA where mesonephric differentiation was entertained showed moderate patchy GATA3 staining. Conclusions: GATA3 is a highly sensitive and specifi c marker for cervical mesonephric differentiation, and it can be useful when the differential diagnosis includes endocervical and endometrial adenocarcinomas, as the latter are negative for GATA3. GATA3 appears to be less reliable in mesonephric/Wolffi an lesions in adnexa; however, a larger cohort should be evaluated to confi rm these fi ndings. Background: MA is a rare mixed mesenchymal tumor of the female genital tract, composed of malignant but often low grade stroma and benign-appearing epithelium. Sarcomatous overgrowth (SO), the only established prognostic histological variable, associates with higher stage and shorter survival. To date, molecular or immunohistochemistry (IHC) tools for the diagnosis of MA have not been elucidated. Our goal is to study genomic mutations and copy number variations (CNVs) in MA to understand better their pathobiology and develop specifi c diagnostic tools. Design: DNA was extracted from 17 FFPE tissue samples of MA representing 15 subjects, including two cases in which areas of typical histology and SO were tested separately. Samples were analyzed using OncoPanel, an assay interrogating the exonic sequences of 275 cancer genes for mutations and CNVs as well as 91 introns across 30 genes for cancer-associated rearrangements. Massively parallel sequencing was performed using target enrichment by hybrid capture (Agilent SureSelect) and an Illumina HiSeq 2500 sequencer. MuTect and GATK (Broad Institute) were used to detect single nucleotide variants and indels; VISCAPCancer and CCOPY were used to detect CNVs. Results: Overall, 2 nonsense, 63 missense, 2 frameshift, and 1 small deletion mutations were identifi ed. The most frequent amplifi cation, involving CDK4 and MDM2 on 12q14-15, was seen in 5/15 (33%). Activating alterations in PIK3CA/AKT/MTOR pathway members were seen in 6/15 (4 missense mutations and 2 copy number gains). STAT6 gain was found in 3/15, with 1 carrying a novel missense mutation. FGFR1 amplifi cation was identifi ed in 1 case. Notably, TP53 mutations were not identifi ed in any cases. Predicted chromosomal abnormalities showed increased aneuploidy in SO vs typical MA samples, and included loss of 9q and monosomy of 3, 16, and X. BAP1 loss was seen in 3/15, including 2 with SO. BCL6 loss also was noted in both cases of SO. KIT and PDGFRA co-amplifi cation was present in 1 SO. Single gene amplifi cations were seen predominantly in cases associated with SO (identifi ed in both matched typical MA and SO samples), while TERT gain and BCL2L12 loss were found only in samples of SO. No rearrangements were identifi ed.
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GATA3 Is a Sensitive and Specific Marker of Mesonephric Differentiation and Neoplasia in the Lower
Conclusions:
We have identifi ed a number of recurrent genomic alterations in MA, including potential markers associated with, and possibly driving, SO. Although further investigation of these fi ndings is needed, confi rmation of one or more may lead to new mechanistic insights and novel IHC markers for this often diffi cult-to-diagnose tumor. Background: Uterine leiomyosarcoma (LMS) is a rare uterine malignancy that arises from the smooth muscle of the uterine wall. Compared to other types of uterine cancers, LMS is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage at presentation. We hypothesized that comprehensive genomic profi ling of clinical LMS samples could identify genomic-derived drug targets of therapy for patients with this lethal cancer. Design: Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to≥ 50ng of DNA extracted from 25 LMS FFPE tumor specimens and sequenced to high, uniform coverage. Genomic alterations (base substitutions, small indels, rearrangements, copy number alterations) were determined and then reported for these patient samples. Actionable GA were defi ned as those identifying anti-cancer drugs on the market or in registered clinical trials. Results: There were 25 female LMS patients with a median age 57 years (range 42-70 years). There were 1(4%) Grade 1, 3(12%) grade II and 21 (84%) grade III tumors. Three (12%) LMS were Stage I, 5 (20%) were stage II, 3 (12%) were Stage III and 14(56%) were Stage IV. All patients had sequencing performed on their primary tumors. 23 (92%) of LMS had GA on NGS with A total of 85 GA were identifi ed, with 23/25 cases (92%) harboring at least one genomic alteration with an average of 3.4 GA per tumor. The most common non-actionable GA were alterations in RB1 (64%), TP53 (60%), ATRX (32%)and MYC (16%). Nine (36%) LMS had at least 1 actionable GA with an average of 0.9 actionable GA per patient including: mutation, amplifi cation or homozygous deletion of: PTEN (16%), RICTOR (12%), TSC1 (8%), ATK2 (8%) and CCNE1 (4%) and CDKN2A (4%) In a single case, a STK32B-ALK fusion that fused the intact kinase domains of ALK to STK32B was identifi ed. Conclusions: More than one third of the LMS patients in this study harbored at least one actionable GA with the potential to infl uence and personalize therapy selection. Given the limited treatment options and poor prognosis of patients with leiomyosarcoma in general, comprehensive NGS-based genomic profi ling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease. Background: The Cancer Genome Atlas (TCGA) identifi ed four major genomic groups of endometrial carcinomas (EC), including a POLE ultramutated subtype comprising 10% of endometrioid EC. This subtype is characterized by POLE hotspot mutations, ultrahigh somatic mutation rates, and very favorable clinical outcomes. The aim of this study was to examine the morphologic and clinicopathologic features of ECs harboring a POLE hotspot mutation. Design: The HE slides and pathology reports for 8/17 POLE mutant EC cases (EC-POLE) described in the TCGA study were retrieved from 3 contributing institutions; for the remaining cases, virtual whole slide images publicly available at cBioPortal (www.cbioportal.org) were examined. Morphological features, including nuclear grade, tumor heterogeneity, metaplastic changes, and tumor infi ltrating lymphocytes (TILs) were assessed. Clinical follow-up information and molecular data were obtained from cBioPortal. Results: Median age of the 17 EC-POLE cases was 54 yrs (range 33-87). Twelve cases presented as stage I, 1 stage II and 4 stage III. All cases were of endometrioid type. Five cases were FIGO grade I, 4 grade II, and 8 (47%) grade III. Eight cases (47%) showed marked nuclear atypia; some in the form of giant bizarre nuclei. Nine cases (53%) exhibited abundant eosinophilic/squamoid cytoplasm. TILs (>40 lymphocytes/10HPFs) were seen in 13 cases (76%). One case showed a focal undifferentiated component. Four cases showed ambiguous features exhibiting an architecture that suggests endometrioid differentiation, associated with marked increase in TILs commonly seen in microsatellite instable (MSI) tumors, but with nuclear features that suggest serous carcinoma. In fact, the majority of EC-POLEs were microsatellite stable (65%) but 6 cases (35%) showed MSI (3 MSI-high, 3 MSI-low). TP53 mutations were present in 6 of 17 EC-POLE cases (35%), of which 4 and 2 cases had non-sense/frameshift and missense mutations, respectively. The majority of EC-POLEs also harbored mutations in PTEN (94%), FBXW7 (82%), ARID1A (76%), and PIK3CA (71%). All patients were alive without disease and none of the patients developed recurrence at time of follow-up (median 33 months; range 2-102 months).
Evaluation of Uterine Leiomyosarcoma by Next Generation Sequencing Reveals Actionable Genomic Abnormalities and New Routes to Targeted Therapies
A Huho, CE Sheehan, GA Otto, K Wang, G Palmer, R Yelensky, D Lipson, SM Ali, D Morosini,
Conclusions:
The recognition of EC-POLE cases is important given their favorable outcome. Our histopathological review revealed that EC-POLEs commonly show high grade and ambiguous morphology. As these cases also frequently harbor TP53 mutations, it is important not to misclassify EC-POLEs as serous carcinoma. of increased sensitivity to chemotherapy, and possibly due to the tendency to spread in the form of circumscribed rounded metastases amenable to optimal debulking. The aim of this study is to evaluate the signifi cance of invasion patterns in metastatic BRCA-HGSC cases. Design: Thirty-one cases of advanced stage HGSC with known BRCA1 or BRCA2 germline mutation were retrieved from our institutional fi les. Nineteen patients had germline mutation of BRCA1 vs 12 with BRCA2 mutation. Pattern of invasion at metastatic sites was recorded and classifi ed as pushing pattern (PP), micropapillary infiltrative pattern (MIP), and infiltrative pattern (IP). Histologic evaluation of metastatses was performed without knowledge of genotype or clinical outcome. Clinical data was abstracted from medical records. Appropriate statistical tests were performed. Results: Median age was 56 yrs (range 31-73 yrs). All cases presented at stage IIIC/ IV and underwent complete surgical staging followed by chemotherapy. All 31 BRCA-HGSC cases showed either PP metastases (25; 81%) or MIP (6; 19%). No cases exhibited IP metastases. Among the 6 MIP cases, 5 had BRCA1 germline mutation vs 1 BRCA2. Median time of follow-up was 26 months (range, 13-49 months). All MIP cases recurred or died of disease (4 recurrences and 2 deaths), compared to 12 of 25 (48%) of PP cases (10 recurrences and 2 deaths) (p value=0.03).
The recognition of invasion patterns of metastatic extrauterine BRCA-HGSC is important and has prognostic and probably therapeutic implications. MIP of invasion is associated with worse outcome and is more frequently seen in BRCA1 associated HGSC. Further studies with a larger cohort are warranted to validate this fi nding. Background: Since our fi rst description of the microcystic stromal tumor (MST) of the ovary, a distinctive neoplasm with a predominant microcystic pattern and a CD10+/ vimentin+ immunophenotype, 2 MST with -catenin nuclear localization and CTNNB1 mutation have been reported. We undertook a detailed immunohistochemical study and CTNNB1 genetic analysis to further characterize this rare neoplasm. Design: 12 ovarian MST were stained with ß-catenin,FOXL2, SF-1, WT-1, cyclin D1, e-cadherin, estrogen/progesterone receptors, synaptophysin, chromogranin, CD56, and CD99, and scored as diffuse (50% tumor cells) positive, focal (<50%) positive, and negative (0%). Genomic DNA was extracted from formalin-fi xed paraffi n-embedded tumor samples and CTNNB1 hotspot mutation analysis performed using primers and PCR that amplify exon 3 of CTNNB1, followed by Sanger sequencing. Results: Immunohistochemical results (positive cases/total cases) are shown in Table 1 and as follows: Synaptophysin, 6/12; chromogranin, 0/12; CD56, 1/12, and CD99, 0/12. Heterozygous missense point mutations in exon 3 of CTNNB1 were detected in 8 of 12 cases, resulting in amino acid changes at codons 32, 34, 35 and 37. There was no apparent correlation between CTNNB1 exon 3 mutation status and tumor immunophenotype. Conclusions: 1. MST of the ovary exhibits a characteristic nuclear -catenin+/FOXL2+/ SF-1+/WT-1+/Cyclin D1+/E-cadherin-immunoprofi le. 2. The fi nding of diffuse nuclear FOXL2 and WT-1 immunostaining in all cases and SF-1 in most supports the classifi cation of MST within the sex-cord stromal category. 3. All MSTs of the ovary show aberrant nuclear -catenin expression, which appears to be the result of stabilizing CTNNB1 mutations in two-thirds. The cause for nuclear -catenin accumulation in the remainder is unknown.
4. Activation of -catenin with upregulation of cyclin D1 may play a role in the tumorigenesis of MST.
Napsin A Is Frequently Expressed in Clear Cell Carcinoma of the Ovary and Endometrium
Chiba University School of Medicine, Chiba, Japan. Background: Napsin A has been considered as a reliable marker for primary pulmonary adenocarcinoma. Napsin A expression has also been shown in extrapulmonary carcinoma including those of renal and thyroid origin. Furthermore, a few recent studies have identifi ed napsin A expression in a subset of ovarian clear cell carcinoma (O-CCC) as well as in a small number of ovarian and endometrial endometrioid carcinomas. Napsin A expression in endometrial clear cell carcinoma (EM-CCC) remains unknown. This study was carried out to investigate the extent of napsin A expression in O-CCC and in EM-CCC, and to compare the former with other carcinomas of ovary, including endometrioid carcinoma (O-EC) and high-grade serous carcinoma (HGSC). Design: Eighty-nine cases of resected ovarian and uterine carcinomas (22 O-CCCs, 15 EM-CCCs, 13 O-ECs, 39 HGSCs) were examined using immunohistochemistry with a monoclonal antibody to napsin A (TMU-Ad02), comparing results with antibodies to another lung-restricted marker TTF-1 (8G7G3/1), and gynecologic tract-restricted marker PAX8 (polyclonal) and CA125 (Ov185:1). The immunohistochemical expression was scored using: 0 = negative, <10% = rare, 10-60% = focal, and > 60% = diffuse. Results: Napsin A was positive in 21/22 (95%) of O-CCCs, and 10/15 (67%) of EMCCCs, with focal or diffuse positive cells in 19 cases in the former, and 6 in the latter.
In contrast, napsin A was expressed in 1/13 (8%) of O-EC with rare positive cells, and 0/39 (0%) HGSC. TTF-1 was positive in 0/22 (0%) of O-CCC, 1/15 (7%) EM-CCC, 3/13 (23%) O-ECs, and 2/39 (5%) HGSCs, usually with rare or focal positive cells. PAX8 was positive in all 89 cases examined, while CA125 was positive in 22/22 (100%) of O-CCCs, 12/15 (80%) EM-CCCs, 13/13 (100%) O-ECs, and 39/39 (100%) HGSCs, usually with diffuse positive cells. There were no Napsin A-positive/TTF-1-positive cases except one EM-CCC, in which positive cells were focal for both markers. In all napsin A-postive and/or TTF-1-positive cases, both PAX-8 and CA 125 were positive. Conclusions: Napsin A is frequently expressed in O-CCC and in EM-CCC, rarely in O-EC, and not in HGSC. Although TTF-1 is not expressed in O-CCC, it is rarely expressed in EM-CCC, O-EM, and HGSC. These fi ndings confi rm the importance of using a panel of antibodies including Napsin A, TTF-1, PAX8 and/or CA125 in the evaluation of metastatic carcinomas of unknown primaries, especially in which gynecologic and pulmonary adenocarcinomas are in the differential diagnosis.
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Histologic Predictors of Clinical Outcome in Vulvar Squamous Cell Carcinoma: A Study of 145 Cases SK Jeffus, A Gehlot, E Holthoff, R Stone, S Post, CM Quick. UAMS, Little Rock, AR. Background: There is only limited literature regarding the prognostic signifi cance of patterns of invasion and stromal tumor response in vulvar squamous cell carcinoma (vSCC), although it has been suggested that a fi bromyxoid tumor response (FMXTR) is associated with more aggressive tumor behavior. The aim of this study was to identify histologic patterns of invasive vSCC and associated stromal tumor response, and correlate these features with clinical outcome. Design: One hundred and forty-fi ve consecutive cases of invasive vSCC were reviewed by two gynecologic pathologists. Patterns of invasion were classifi ed as infi ltrative or nested/pushing. Stromal tumor response was documented if a prominent FMXTR (defi ned as myxoid stroma surrounding the tumor) or a prominent band-like lymphoid tumor response (LTR) was easily identifi ed at low power magnifi cation (4x). Age, depth of invasion (DOI), lymph node involvement (LNI), clinical stage and recurrence were obtained by chart review. Statistical analysis was performed using unpaired t-test and 2-tailed chi square test. Results: Sixty-three (43%) cases had an infi ltrative pattern of invasion; the remainder had a nested/pushing pattern. FMXTR or LTR was seen in 67 (46%) and 55 (38%) of cases, respectively (neither in 23,16%). When both FMX and LTR were present in the same tumor (n=27/19%), they were mutually exclusive for any given area. The presence of the infi ltrative pattern (compared to nested/pushing) correlated with the presence of fi bromyxoid stroma (85%, p<0.0001), greater DOI (1.13 vs 0.65 cm, p=0.0048) and recurrence (41% vs 25%, p=0.0458). Increased LNI was associated with an infi ltrative pattern but this was not signifi cant (27% vs 14%, p=0.06). Likewise, the presence of fi bromyxoid stroma (in comparison to a prominent LTR) correlated with infi ltrative growth pattern (p=<0.0001), greater DOI (p=0.0375) and LNI (p=0.0028), but not recurrence (p=0.2446). Age and clinical stage showed no statistical signifi cance. Conclusions: This is the fi rst study to demonstrate that infi ltrative tumor histology is signifi cantly associated with recurrence, deeper invasion and a fi bromyxoid stromal response. Likewise, nested/pushing tumors are associated with an infl ammatory stromal response and demonstrate overall a more favorable outcome when compared to tumors with a fi bromyxoid tumor response. Recognition and reporting of these features can help to plan more effi cient therapeutic protocols for women affected with this devastating disease.
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Black Raspberry Extract Induces Caspase-14 in a Vulvar Cancer Cell Line: A Potential Natural Agent to Treat Neoplastic and Preneoplastic Vulvar Squamous Lesions AS Joehlin-Price, J Stephens, TJ Knobloch, CM Weghorst, AA Suarez. The Ohio State University Wexner Medical Center, Columbus, OH; The Ohio State University, Columbus, OH. Background: Natural compounds have been shown to induce caspase-14, a key protein in maturation of squamous epithelia. We examine the in-vitro effect of black raspberry extract (BRE) on a vulvar squamous cell carcinoma (VSCC) cell line and document altered caspase-14 expression in archival malignant and premalignant vulvar squamous lesions. Design: VSCC cell cultures (SW954; ATCC, Manassas, VA) were grown and exposed in triplicate vials to varying doses of BRE for 32 hours. Cells were fi xed and used to create cell blocks. Immunohistochemistry for caspase-14 (PA1-46317, Thermo, IL) was performed on sections of the cell blocks, archival whole tissue sections, and a tissue microarray (TMA). The whole sections and TMA contained normal vulva, lichen sclerosus (LS), differentiated vulvar intraepithelial neoplasia (dVIN), classic VIN (cVIN), and VSCC. Cell block sections were photographed and manually scored. Results: Normal squamous epithelium confi rmed that caspase-14 expression increases with maturation. 5/11 (46%) LS cases demonstrated abnormal full thickness caspase-14 staining, while one LS case had absent caspase-14 expression. 4/7 (57%) dVIN showed markedly reduced expression, and 6/22 (27%) cVIN had either absent or reduced caspase-14. The majority (26/28, 93%) of VSCC had absent or markedly reduced (limited to isolated neoplastic cells) caspase-14. SW954 treated with varying doses of BRE demonstrated a signifi cant increase in caspase-14 (p=0.013) with predominant paranuclear staining. Specifi cally, 7.3% (±2.0%) of untreated SW954 cells stained positive for caspase-14, while 21.3% (±8.9%), 21.7% (±4.8%), and 22.6% (±5.3%) of SW954 cells were positive for caspase-14 after treatment with 200, 400, and 800 μg/ mL BRE, respectively. Pair-wise comparisons between the treatment groups and the control demonstrated signifi cant differences between no treatment with BRE and each of these treatment concentrations (p-values of 0.024, 0.021, and 0.014, respectively).
Conclusions: Caspase-14 expression is abnormally decreased in many premalignant vulvar lesions and in most VSCC. BRE was shown to increase caspase-14 expression in a VSCC cell line. Further investigation is warranted to elucidate the potential use of BRE to treat preneoplastic and neoplastic vulvar squamous lesions.
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The Background: Disruption of the equilibrium between pro-apoptotic and anti-apoptotic signaling may eventuate in carcinogenesis through a net reduction in apoptosis, and there are now numerous chemotherapeutic strategies that directly or indirectly target apoptotic pathways. However, a large scale assessment of apoptosis-related proteins has not previously been performed in endometrial clear cell carcinoma (CCC). This study aims to determine the signifi cance of 8 apoptosis-related proteins in the pathogenesis of CCC. Design: The expression of 5 anti-apoptotic proteins (Bcl-2, Bcl-xL, FLIP L , survivin, NF-kappaB_p65 [NFK]) and 3 pro-apoptotic proteins (Bax, caspase 3, caspase 8) were assessed by immunohistochemistry (IHC) on 49 CCC, 17 endometrial serous carcinoma (ESC), 49 endometrioid carcinomas (EEC); 18,19,12 grades 1,2,3) and 25 non-neoplastic endometrial samples (NNE) in a TMA. Objective IHC scores were assigned by an automated image capture system. Scores were then correlated with clinicopathologic parameters. Results: Only Bcl-2 showed signifi cantly increased expression in CCC as compared to NNE (p=0.011). FLIP L and Caspase 3, in contrast, showed signifi cantly decreased expression in CCC relative to NNE (p <0.0001 and 0.002). There were no signifi cant differences between NNE and CCC regarding their expression of the other markers. Among the most noteworthy histotype comparisons, FLIP L and caspase 3 showed signifi cantly lower expression in CCC as compared with EEC and ESC (p <0.0001 and 0.029). Most markers, including Bax, BCl-xL, FLIP L , and NFK, showed higher levels in EEC than CCC. Bcl-2 and survivin were signifi cantly more expressed in CCC as compared with EEC, but not ESC. Our correlation analysis in the CCC cohort showed that FLIP L was negatively correlated with caspase 8 and NFK (p=0.0001-0.0005), nearly negatively correlated with caspase 3 (p=0.06), and positively correlated with survivin (p=0.0092). None of the markers showed a signifi cant association with patient outcomes. Conclusions: Our analysis of the expression and correlation patterns of a large panel of apoptosis-related proteins suggests that the downregulation of caspase 3 and FLIP L are signifi cant, since these were seen in CCC relative to all other tissues, including EEC, ESC and NNE. FLIP L is an important regulator of death receptor signaling, which is an integral component of the extrinsic pathway of apoptosis. The relative downregulation of FLIP L expression in CCC may be an important component of its pathogenesis.
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PAX2 Expression in Endometrial Biopsies Simultaneously Diagnosed Using the World Health Organization (WHO) and Endometrial Intraepithelial Neoplasia (EIN) Classification Systems
AK Joiner, SK Jeffus, CM Quick. UAMS, Little Rock, AR. Background: Currently, two classifi cation schemes for precancerous endometrial lesions exist: WHO and EIN. Alteration (predominately loss) of PAX2 staining is useful in diagnosing EIN, while its utility in the WHO system is questionable. The purpose of this study was to evaluate PAX2 staining patterns in a series of endometrial biopsies that were classifi ed using both systems. Design: Diagnosis text search for all precancerous endometrial lesions (simple and complex hyperplasia with and without atypia, EIN, benign hyperplasia and small focus of atypical glands) from 2005-2013 was performed. 108 cases were identifi ed, stained with PAX2, and reviewed by two gynecologic pathologists each of whom trained in one of the classifi cation systems. Thirty cases were deemed benign by both pathologists (anovulatory, polyp, secretory, etc) and 11 cases lost the tissue of interest on deeper sections. PAX2 staining was scored in lesional tissue as normal or altered (lost, markedly increased or markedly decreased, compared to background). Results: Forty-four of 67 (66%) cases demonstrated altered PAX 2 staining. Twenty-seven of those 44 patients had subsequent hysterectomies, and 8 cases contained adenocarcinoma (30%). EIN plus PAX2 loss was seen in 37 of 44 cases (84%) compared to 23 of 44 cases (52%) with complex atypical hyperplasia (CAH) and PAX2 loss. Complex hyperplasia (CH), with or without atypia, showed PAX-2 alteration in 39 cases (89%). Of the 30 cases deemed benign, only 1 (3%) showed PAX2 alteration (complete loss); 21 of the benign cases had follow-up samples, and none contained precancerous lesions. Conclusions: PAX2 alterations correlate well with EIN (84%), but not with CAH (52%). Regardless, in cases of complex hyperplasia with equivocal cytologic atypia, PAX-2 may be helpful in identifying lesions that may have a higher risk of progression. One third of patients with a PAX2 altered lesion, regardless of type or classifi cation scheme, were found to have adenocarcinoma on subsequent sampling. Normal PAX2 staining is helpful in worrisome biopsies, as 100% of cases with normal PAX2 staining showed no signs of malignancy upon further sampling.
Morphologic Features and 2SC Immunohistochemical Staining in Uterine Leiomyomas from Young Women
UCSF, SF, CA; USC, LA, CA; MSKCC, NY, NY. Background: Hereditary Leiomyomatosis and Renal Cell Carcinoma syndrome (HLRCC) occurs due to germline fumarate hydratase (FH) mutations and predisposes patients to skin and uterine smooth muscle tumors (USMTs) and renal cell carcinoma. The USMTs in HLRCC often present in young patients and display characteristic morphologic features (prominent eosinophilic nucleoli, perinucleolar halos, and cytoplasmic inclusions) that have been recently described. Expression of 2-succinylcysteine (2SC) has been shown to be both sensitive and specifi c for HLRCC-associated tumors. We examined the morphologic features and 2SC expression of USMTs in patients less than 40 years of age to determine the frequency of 2SC positive cases in this patient population and to assess the sensitivity and specifi city of morphologic features for detection of HLRCC. Design: USMTs from 120 patients under age 40 were examined. All HE slides were independently reviewed by 2 pathologists who were blinded to the results of the 2SC antibody staining. The combined presence of prominent eosinophilic nucleoli, perinucleolar halos, and cytoplasmic inclusions was considered highly suspicious for HLRCC. Tissue microarrays (TMAs) were constructed and stained with 2SC antibody. Results: All the USMTs were classifi ed as leiomyomas. 2SC was diffusely positive in 3 cases (2.5%) and negative in 117 cases. The morphologic features are summarized in table 1. On blinded review, both pathologists classifi ed all 3 2SC positive tumors as highly suspicious for HLRCC. Of the 2SC negative USMTs, the 2 pathologists classifi ed 1 and 4 cases respectively as highly suspicious for HLRCC. Conclusions: Universal testing for MMR proteins in endometrial cancers predominantly identifi es MLH1 protein loss. MLH1 gene promotor hypermethylation studies were positive in all tested cases with MLH1 protein loss. Therefore, the true incidence of Lynch syndrome in patients presenting with endometrial cancer is low (6%), but consistent with literature (3-5%). Refl ex testing for MMR protein in endometrial cancers could possibly be limited to patients younger than 65 years, with tumors of non-serous morphology. Our data also questions the clinical utility of promotor hypermethylation studies for MLH1 gene in endometrial cancer as they are almost always positive. We tried to see the relationship among histologic patterns with recurrence  staging. Also, we sought to explore the role of IMP3  marker of EMT molecule, E-cadherin in predicting recurrence. Design: 9 cases of stage I  31 cases of stage III HGOSC were included. Three predominant histologic patterns, infi ltrating micropapillary (MP), non-papillary (NP)  intracystic (IC)) were assesed in the ovary  peritoneum (stage III). Primary  metastatic tumors were stained with IMP3  E-cadherin. The immunohistochemistry (IHC) slides were evaluated semiquantitatively (0-4). Logistic regression analysis was performed to compare patterns  IHC results with recurrence status. Results: All stage I cases were predominantly IC. Only one recurred in 59 months. In stage III cases, 17 recurred within 18 months  14 cases did not recur after 49 months. The main histologic features separating recurrence from non-recurrence cases were seen in the metastases. In recurrence group, 11/17 cases had predominantly MP pattern in the peritoneum, while only 4/14 tumors in the non-recurrence category showed MP pattern in the peritoneum (p=0.02). 6/17 tumors in the recurrence group had predominantly NP or IC pattern in the peritoneum, whereas 10/14 tumors in the non-recurrence group had predominantly NP or IC pattern in the peritoneum. IMP3 positivity in the ovary was observed 15/17 cases in the recurrence group, while 6/14 cases in the non-recurrence group expressed IMP3 (p=0.01). E-cadherin staining was signifi cantly low in the peritoneum of the recurrent cases compared to that in the primary tumor, while no difference was observed in the non-recurrence group. Conclusions: 1. All stage I cases were IC tumors without MP areas. 2. In stage III carcinomas the histologic pattern of the HGOSC is important as 73% of the tumors with MP pattern recurred, whereas only 27% of non-recurrent tumors showed this pattern. In contrast, NP  IC patterns were seen in 71% of the non-recurrent and 35% of recurrent tumors.
3. E-cadherin showed signifi cant decrease in expression in the invasive component, mainly in the metastases of the recurrent cases. The signaling pathway protein IMP3 is expressed in 88% of recurrent cases, especially in the MP areas, hence it can be used as a predictive biomarker in HGOSC.
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Expression of DNA Repair Proteins in Endometrial Cancer Predicts Disease Outcome GN Kim, PM Fauceglia, M Sharifi an. LAC+USC Medical Center, University of Southern California, Los Angeles, CA. Background: DNA repair and apoptosis are two essential systems for maintaining the integrity of the human genome. Recently, alterations of DNA repair proteins have shown to be involved in endometrial carcinogenesis. The aim of this study is to determine the expression and value of DNA repair proteins in endometrial cancer (EC). Design: This is a retrospective study conducted during a 10 year period (1999-2009). PARP1, H2AX, ATM, FANCD2, PTEN, BRCA1, and p53 were evaluated using immunohistochemistry on paraffi n-embedded tissue from 357 EC patients. The expression of these biomarkers were correlated with clinico-pathologic parameters (age, tumor size, histologic subtypes, depth of myometrial invasion, lymphovascular invasion, FIGO grade, lymph node positivity, recurrence, disease status, recurrence time and survival time). Results: PARP1, H2AX, ATM, FANCD2, PTEN, BRCA1, and p53 were positive in 77%, 66.5%, 59%, 36%, 38%, 31% and 45% of cases respectively. The expression of several of the DNA repair proteins were found to be associated with one another. 
Conclusions:
This study demonstrates substantial accuracy (as determined by concordance with central review diagnosis) and interoberver agreement in typing of ovarian carcinoma, based on routine histology, among the study pathologists. Immunohistochemistry was used frequently, being requested in 54% of cases, and use of the immunostaining results signifi cantly improved both diagnostic accuracy and interoberver agreement. These results indicate that ovarian carcinoma type can be reliably diagnosed by pathologists from different centers and different countries, and further demonstrates that immunohistochemistry has an important role in improving diagnostic accuracy and agreement between pathologists. This indicates the importance of further studies to standardize and improve interpretation of immunohistochemical staining. Over the last two decades new insights into molecular features, treatment response and patient demographics led the scientifi c community to conclude, that the histological types of ovarian carcinomas are best considered to be different disease entities. Today fi ve types of ovarian carcinoma are proposed in the literature, leading to a change in diagnoses. To monitor the evolution of ovarian carcinoma diagnosis a clinical trial cohort, which underwent expert gynecopathology case review a decade ago, has now been re-reviewed applying current criteria of ovarian carcinoma histopathology. Design: In the year 2002 a patient cohort, which was derived from the AGO OVAR 3 trial (recruitment 1995-97), was reviewed by two experienced gynaecopathologists for translational research purposes. All cases were typed according to the then up-to-date criteria and were classifi ed as either serous, mucinous (MUCI), endometrioid (ENDO), clear cell (CCC), transitional cell (TCC) or undifferentiated (UNDIF) carcinoma. Tumor grade was assessed according to the FIGO grading system. The same cohort was now re-assessed by two gynecopathologists of which one of them was responsible for the original case review. Cases were now diagnosed as either high grade serous carcinoma (HGSC), low grade serous carcinoma (LGSC), MUCI, ENDO or CCC. Results: 334 cases of advanced-stage ovarian carcinomas were available with central review diagnoses from the year 2000. 60% of the original diagnoses were confi rmed after applying current ovarian carcinoma histopathology knowledge. In contrast to the original diagnoses where 44,7% cases were assigned to the serous type (MUCI: 7,9%, ENDO: 19,2%; CCC: 12,3%; TCC: 5,3%; UNDIF: 10,6%) now 85,6% were diagnosed as serous carcinoma, of which 92% were classifi ed as HGSC (HGSC: 79,3%; LGSC: 6,5%; MUCI: 3%; ENDO: 5,5%; CCC 4,8%). Conclusions: Our study demonstrates the diagnostic shift in ovarian carcinoma pathology with signifi cantly more cases being called "serous" nowadays. With respect to the upcoming era of ovarian carcinoma type-specifi c trials and fi nally patient treatment, accurate histotyping will become a key point. To accordingly address this important issue in translational research projects it might be desirable to obtain up-to-date diagnoses rather than accepting what has been provided in the past.
Evolution of Ovarian Carcinoma Diagnosis: Insights from a Clinical Trial Case Series
1199
Making Background: Based on the current literature one may assume that a considerable number of patients in clinical trials of ovarian carcinoma have histopathological diagnoses in confl ict with inclusion criteria possibly causing unintended patient morbidity and study bias. It has been suggested that specialized pathology review prior to randomization should become standard procedure in study protocols. We hypothesized that our new, internet-based high throughput infrastructure would be capable of providing specialized second opinion pathology within 10 days. Design: Patients scheduled for the AGO OVAR17 ovarian carcinoma chemotherapy trial were registered for expert pathologic case review using a new internet-based central pathology review platform prior to randomization. All original slides were requested from local pathologists. Slides were scanned and uploaded to a secured internet server. A network of internationally recognized gynecological pathologists was connected to the server through a custom-designed software platform. If deemed necessary by expert pathologists, immunohistochemistry was available through a collaborating pathology lab. Results: 880 patients with an original diagnosis of ovarian epithelial carcinoma were registered through our internet platform for expert pathology review from 10/2011 -07/2013. In 2.5% (n=22) of cases, a major diagnostic discrepancy of potential clinical relevance was found leading to exclusion from the chemotherapy trial. In 10.7% (n=94) of cases the diagnosis of ovarian carcinoma was confi rmed but patients were excluded for other reasons. For second opinion pathology fi ve gynecopathologists from Austria, Switzerland and Germany were available online. The average time from patient registration until completion of pathology review was 5.2 days. Conclusions: Our results show that the use of a new internet-based infrastructure makes specialized case review prior to patient randomization feasible within less than 10 working days. Our new approach might not only help to avoid disregarding of clinicopathologic inclusion criteria but also to further improve quality of patient care through minimization of overtreatment with chemotherapy of patients with ovarian borderline tumors and inadequate treatment of patients with ovarian metastases.
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The Background: Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) is a rapidly emerging tool for the analysis of proteins on formalinfi xed tissue sections while preserving the spatial orientation of the tissue. One of the main advantages of MALDI IMS is the ability to screen for large numbers of proteins simultaneously on a single section, thereby expediting the discovery of proteins that may be characteristic of a particular tumor type or disease, and to accurately type them by IMS. In this pilot study, we assessed the applicability of MALDI IMS to the histotyping of endometrial carcinoma, using a test model of 2 histotypes [endometrioid (EEC) and clear cell (CCC) carcinoma]. Design: 57 CCC and 72 EEC (of all grades) were randomly assigned to 2 equally-sized tissue microarrays (TMA), each containing single 1-mm cores from 27 or 28 CCC and 36 EEC. The TMAs were then analyzed by MALDI IMS. After the exclusion of stromal areas and non-viable tumor areas in each TMA, peptide signatures were identifi ed that differentiated CCC from EEC. The signatures were then cross validated. Results: 47 CCC and 72 EEC had suffi cient tissue for analysis. A total of 598 spectral peaks (m/z) were identifi ed in both arrays, of which 261 (44%) had Wilcoxon p-values <0.05, indicative of signifi cant differences between EEC and CCC. 11 peaks had areas under receiver operator characteristic curves of greater than 0.85, identifying peaks displaying the greatest differences between CCC and EEC. A genetic algorithmic classifi cation model was generated from a mixed dataset derived from approximately half of both TMAs, which classifi ed the dataset with a 96.57% accuracy (95.83% for CCC; 97.3% for EEC). The prediction accuracy of the model was estimated using a cross-validation algorithm in which 20% of the data were randomly left out in each of 10 iterations. After this leave-20%-out cross-validation algorithm was applied, the new model classifi ed the dataset with 87.11% accuracy (82.22% for CCC; 92% for EEC). When the cross-validated signature was applied to the other half of both TMAs, it correctly classifi ed 70.1% of the CCC spectra and 76.4% of the EEC spectra. Conclusions: Since peptide signatures can be further analyzed to identify their associated proteins, this pilot study shows that MALDI IMS is a promising approach for the study and quantifi cation of the differences and similarities between histotypes of endometrial carcinoma, and potentially, for the rapid discovery of discriminatory biomarkers.
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Ovarian Design: IHC using FXDY2, HNF1, and STAT3 was done on tissue-microarrays of material from 52 OCCC and 51 OSC patients. This was scored from 0-3 based on nuclear staining intensity of the tumor cells with 0-1 interpreted as negative/weak and 2-3 as positive. Samples from the same patient were averaged and rounded to the nearest integer. Clinical history was available for 32 of the 52 OCCC patients to correlate with STAT3 expression; patients not receiving chemotherapy were excluded. Results: HNF1, FXYD2, and STAT3 were positive in 90%, 86%, and 50% of OCCC and 10%, 77%, and 8% of OSC, respectively. Conclusions: Staining for HNF1 confi rms its use as a sensitive (90%) and specifi c (90%) immunomarker for OCCC in the differential diagnosis with OSC, while FXDY2 is not. STAT3 may serve as a potential immunomarker in diagnostically challenging cases of OCCC (specifi city 92%, sensitivity 50%). Though STAT3 expression appears to positively correlate with responsiveness to chemotherapy, prior studies showed in vitro inhibition of IL-6 reduced the phosphorylation and activation of STAT3 (p-STAT3), enhancing tumor cell sensitivity towards cisplatin. Further analysis of p-STAT3 rather than STAT3 overexpression may serve as a more accurate predictor of chemoresistance.
HNF1
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Ovarian Germ Cell Tumors Arise from Pre-Meiotic Stem Cells HA Kwak, P Reddy, L Joseph, AG Montag. University of Chicago, Chicago, IL. Background: In female gonadal development, primordial germ cells reach their peak number in the second trimester and then cease to proliferate after entering the fi rst meiotic division. Oogonia remain arrested in meiosis I until puberty, after which ovulating cells complete meiosis. In mammals, there is no convincing evidence of a stem cell pool to produce additional oogonia in post-natal life. Ovarian germ cell tumors (OGCT) constitute a broad range of tumors, benign and malignant, which are canonically believed to derive from primordial germ cells. Previous reports have suggested that OGCTs can arise from either pre-meiotic primordial germ cells (or stem cells) or post-meiotic germ cells. The present study uses genetic fi ngerprinting applied to several histologic types of OGCTs to determine whether they refl ect the pre-meiotic genome of the patient or derive from a post-meitotic cell. Design: After receiving IRB approval, we selected 5 dysgerminomas, 5 mature teratomas, and 5 endodermal sinus tumors (EST) available in 1990-2013 from the pathology archives of the University of Chicago Hospitals. Corresponding nonneoplastic tissue from the same patient was also selected. DNA was isolated from malignant and benign cells that were macrodissected from formalin fi xed paraffi n embedded (FFPE) tissues. Short tandem repeat (STR) analysis was performed using AmpFlSTR profi ler plus kit from Applied Biosystems on all samples with comparison of normal and neoplastic cell DNA profi les for each patient. Results: STR analysis of 8 ovarian germ cell tumors in parallel with normal tissue from the corresponding patient demonstrated identical DNA profi les in 88% (7/8) of the cases, with one non-identical case suggesting origin from a post-meiotic cell. The remaining 7 cases were excluded for failure of DNA amplifi cation due to the poor quality of the DNA from FFPE tissues. Conclusions: In spite of the general consensus in the literature that there is no reserve pool of primordial oogonia in the human ovary, STR analysis shows that the majority of germ cell tumors in this study arise from a pre-meiotic cell: either a primordial oogonia or another pleuripotent stem cell. One case, a mature teratoma, was consistent with origin from a post-meiotic cell. Background: Ovarian cancer is the fi fth most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. The vast majority present in advanced stages and this is due to lack of a reliable screening test and the absence of symptoms. Currently, no standardized reliable screening test exists. Pelvic examination is practiced widely, but it is not sensitive enough to be used as a reliable screening tool. There is a need for reliable diagnostic and prognostic markers for this disease. MicroRNA profi ling has allowed the identifi cation of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. Design: RNA extraction from serum was extracted using Qiagen miRNeasy® Mini Kit. A training set of 5 serous papillary ovarian adenocarcinomas (stage 3
OGCT
, grade 3) and 5 benign serous cystadenomas were selected for the initial training. A validation set included 20 serous papillary ovarian adenocarcinomas (stage 3, grade 3) and 20 benign serous cystadenomas. The serum/Plasma focus microRNA Exiqon panel was used for the training set. For the validation set a mix and pick Exiqon panel, which focuses on microRNAs of interest was used.
Results:
The panel profi ling was successfully completed. The raw data all show good data quality. 5 microRNAs were found to be differentially expressed using a cutoff of p-value < 0.05. Based on the results of the pilot study the top 23 deregulated microRNAs were validated. All samples passed the quality control tests. A panel of 4 microRNAs was signifi cantly down regulated in cancer patients. These microRNAs target WNT signaling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemo resistance. Conclusions: MicroRNAs could act as diagnostic biomarkers in ovarian cancer.
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Increasing the Sensitivity of Endocervical Curettings by Performing ThinPrep® Pap on Transport Container Fluid: Is Diagnostic Material Going down the Drain? RR Lastra, SE Meykler, ZW Baloch, JE Barroeta. Hospital of the University of Pennsylvania, Philadelphia, PA; Pennsylvania Hospital, Philadelphia, PA. Background: Endocervical currettings (ECC) performed at the time of loop electrocautery excision procedure (LEEP) have a high risk of harboring residual dysplasia and micro-invasive carcinomas. The false-negative rate reported for ECC in patients with cervical intraepithelial neoplasia (CIN) involving the endocervical canal is 45%. ECC samples are transported to pathology in either formalin or saline-fi lled containers and this fl uid is discarded after the specimen is submitted. We evaluated the utility of performing liquid-based pap smears from the left-over ECC transport container fl uid as a way to retrieve cells, increasing the diagnostic sensitivity of ECC. Design: Consecutive ECC specimens received at one of the participating institutions (5/2013-9/2013) were prospectively selected. The surgical pathology mesh bag was placed over a ThinPrep® CytoLyt® Solution container (Hologic, Inc. Marlborough, MA), and the specimen was fi ltered through the bag, collecting the transport fl uid in the container. The specimen in the mesh bag was processed routinely. The CytoLyt® was processed to obtain a ThinPrep® liquid-based pap slide. The pap smears were blindly reviewed by two pathologists and the fi ndings were compared to those from the ECC and follow-up specimens. Results: The case cohort included 19 patients, mean age of 40.5 years (range 23-70 years). Pre-ECC pap smear diagnoses were: 7 ASCUS, 7 LSIL, 2 HSIL, 2 AGC, and 1 high grade vulvar intraepithelial neoplasia (VIN III). Discrepancies between the ThinPrep® (TP) slide and the ECC were seen in 7/19 (37%); the TP impression was confi rmed by biopsy or molecular testing in 4 cases. Discrepancies are summarized in table 1. 
Conclusions:
Combining the pathologic evaluation of ECC specimens with liquidbased cytology performed on the transport container fl uid can increase the diagnostic sensitivity of the ECC procedure for detecting cervical lesions. 
Design: 80 SIL Q cases were randomly selected from a group of 332 with SIL Q as the worst initial visit colposcopy diagnosis and were stained by standard immunohistochemistry (IHC) with p16 and Ki67. 149 controls slides of 44 NILM, 15 LSIL, 75 HSIL and 15 AIS were also stained to validate the IHC. Staining was scored together by 2 observers using 2 separate systems for each biomarker. Scoring was based on the location and number of stained SIL Q cells and categorized as positive or negative. System 1 required a basal layer and 2 did not. Outcome was based on the worst histology in 24 months of colposcopy and/or surgical follow up. Biomarker and outcome status were correlated and sensitivity, specifi city PPV and NPV were determined. Results: Performance in the detection of outcome which was positive in 38 (48.1%) cases and 100 (67.1%) controls with system 1, and system 2 was: Amongst the cases, the sensitivity and NPV were high, specifi city was low, and the PPV was modest regardless of scoring system, biomarker type and whether the markers were measured singly or in combination. Combined markers scored with System 1 achieved the highest NPV. All performance metrics were high amongst the controls.
In terms of SIL Q management, p16 and/or Ki67 IHC staining of SIL Q is of little value in the detection of a positive outcome, but may be of some value in the detection of a negative outcome. Results: TP53/CK7 was an independent negative prognostic factor for progressionfree survival of serous adenocarcinoma after resection and chemotherapy (P<0.001). TP53/DAPI/CK7 was an independent negative prognostic factor for overall survival (P=0.040). Additionally, pERK is positively associated with response to platinum chemotherapy (P=0.006) and lack of tumor recurrence (P=0.020). VEGF is positively associated with response to platinum chemotherapy (P=0.028) and tumor recurrence (P=0.004). SAM analysis was used to evaluate gene expression in primary tumors vs normal tissue identifi ed upregulation of empirically-selected biomarkers: p53, VEGF, 
Morphologic Correlates of Human Papilloma Virus (HPV) Infection in Low-Grade Squamous Lesions of the Female External Genital Tract G Liles, K Scharre, B Balzer, D Barbuto, E Silva. Cedars-Sinai Medical Center, Los
Angeles, CA. Background: The histologic features of low-grade HPV-associated lesions in the female external genital tract, namely condyloma, are varied and can be subtle. Histologic identifi cation of condyloma in hair-bearing skin can be problematic because the classic cytopathologic effect of HPV, koilocytosis, may be absent. We retrospectively examined a series of HPV positive lesions from this region for nine specifi c morphologic features, which may be associated with HPV infection. Design: Twenty-fi ve cases of HPV in situ hybridization (ISH)-positive condylomas involving genital skin were collaboratively reviewed by four gynecologic pathologists. Each case was evaluated for the presence or absence of nine morphologic features (Figure 1 ). Ki-67 immunostain was performed on each case and suprabasal keratinocytes with nuclear positivity were counted and categorized as 0-5, 5-20, or >20 positive cells.
Results:
In all cases, the most frequent features were rounded papillae with papillary dermal vascular ectasia (PDVE) (88%), atypical parakeratosis (76%), koilocytosis (60%), and hypergranulosis accentuated in the dells (52%). In cases lacking koilocytosis, the most frequent fi ndings were rounded papillae with PDVE (100%), hypergranulosis accentuated in the dells (70%), dense hyperkeratosis (60%), and atypical parakeratosis (60%) (Figure 1 ). Ki-67 positivity in suprabasal keratinocytes was found in the following frequencies: >20 (56%), 6-20 (12%), and <5 (32%). The Ki-67 count was >5 in 78% of all cases but only 50% of cases lacking koilocytosis had >5 Ki-67 positive cells.
Conclusions:
The most specifi c histologic feature of low-grade HPV-associated lesions of the female external genital tract is koilocytosis; however, in our series, 40% of cases lacked koilocytosis. In such cases, identifi cation of rounded papillae with PDVE, hypergranulosis accentuated in the dells, atypical parakeratosis, and dense hyperkeratosis can aid in the recognition of HPV lesions. In addition, Ki-67 expression in suprabasilar keratinocytes can act as an adjunct supportive test when used in combination with the evaluation of specifi c histologic features. Background: Immunohistochemistry (IHC) with p16 evaluation of potential cervical dysplasia has aided signifi cantly with distinguishing normal from dysplastic tissue, and in determining the degrees of dysplasia. Sensitivity for the detection of dysplasia is much higher with p16 staining than histologic interpretation alone; however, there are rare cases where p16 can lead to false positive and negative results. To explore this issue, we conducted an evaluation of cervical biopsies with p16 and Ki-67staining and compared these results to the HE histologic features. Design: We reviewed 171 cases of cervical biopsies, all with p16 and Ki-67 stains. These cases were classifi ed as classical dysplasias, classical metaplasias, questionable dysplasias, and probable metaplasias positive for p16. Ten of the 171 cases fell into the latter two categories based on incongruent results between HE and p16. In these incongruent cases, HPV low and high risk in-situ hybridization (ISH) and specifi c nucleic acid sequence detection for high risk subtypes using signal amplifi cation methods were performed. In positive cases for high risk HPV, whenever enough DNA was available, refl ex tests were performed for subtypes 16/18 and non 16/18. A total of 26 high risk HPV subtypes were investigated. Results: In 161 cases (94.2%) the HE fi ndings were congruent with the p16 and Ki-67. In 10 cases (5.8%) the results of the HE and p16 and Ki-67 were incongruent. Six of the 10 cases were possible dysplasias by HE but p16 in these cases was positive in only isolated cells. All 6 cases were positive for high risk HPV types. In 4 of these cases, we had enough DNA for refl ex which confi rmed the presence of non-16/18 high risk subtypes. The remaining four of the 10 cases stained diffusely for p16; however, HE were not atypical enough for classical dysplasias. There were residual mucinous cells in the upper part of the squamous metaplastic epithelium, and Ki-67 was positive in very few parabasal cells. All 4 cases were negative for HPV by ISH and signal amplifi cation. Conclusions: 1-Diffuse p16 staining is an excellent marker to confi rm cervical high grade dysplasia in 94.2% of the cases. 2-Diffuse p16 can rarely be seen in squamous metaplasia, mainly in cases where residual mucinous cell are present. K-i67 stains positively in very few cells, predominantly at the base of the epithelium. 3-Focal/patchy p16 staining, frequently considered negative, can be associated with high-grade dysplasia due to high risk HPV but not 16-18 types.
An Immunohistochemical Comparison of Ovarian and Uterine
Pseudorosette-Like Proliferations in Endometrium MM Lomme, L-W Lin, CJ Sung, WD Lawrence, MR Quddus. Brown University Women
 Infants Hospital, Providence, RI; National Taiwan University Yun-Lin Campus, Yun-Lin, Taiwan. Background: The capricious nature of endometrium results in a wide spectrum of appearances in both neoplastic and non-neoplastic tissue. Unusual stromal proliferations may be encountered leading to misinterpretation. In this study we investigated pseudorosette-like proliferations (PLPs) in the stroma of proliferative endometrium which have not been previously reported. Design: Fifteen cases of PLPs were identifi ed for this study. Patient age, reason for biopsy, and exogenous hormone use were collected. Characteristics of the endometrium including phase, breakdown, hyperplasia, or endometritis were recorded. The cases were then immunostained for cytokeratin AE1/AE3, CD10, smooth muscle actin (SMA), S-100 and caldesmon to evaluate the nature of these proliferations.
Results:
The mean age of patients was 48.3 years (range 37-56). All biopsies were performed for abnormal bleeding. In all 15 cases the endometrium was in the proliferative phase with no evidence of hyperplasia or endometritis. Only one case showed signifi cant breakdown and epithelial metaplasia. Each endometrial sample contained one or more PLPs ranging from 0.4 -1.5 mm.
In 9 cases, a pseudorosette-like focus was available for immunostaining. Eight of the 9 cases showed strong (3+) staining of the PLP for SMA and one case showed moderate (2+) staining. Six cases showed negative or weak (1+) staining for CD10 in the PLP. The remaining 3 cases showed 2+ staining for CD10. In all cases, staining for SMA was stronger than for CD10. In all cases, PLPs were negative for cytokeratin, S-100, and caldesmon. Conclusions: Pseudorosette-like proliferations may occur in the stroma of proliferative endometrium. Such proliferations appear unrelated to use of exogenous hormone, breakdown, endometritis or hyperplasia. While PLP may weakly or moderately express CD10, they invariably strongly express SMA, suggesting smooth muscle differentiation. Recent work has shown that human endometrial stem cells will successfully differentiate into smooth muscle cells when supplemented with myogenic growth factors in vitro. Further studies are needed to elucidate the factors contributing to smooth muscle differentiation of endometrial stromal proliferations in vivo. 
Utility of Claudin-18 Immunohistochemistry for Detecting Benign Endocervical Glandular Lesions Exhibiting Gastric Differentiation (SoCalled Lobular Endocervical Glandular Hyperplasia) D Maeda, Y Mikami, M Fukayama.
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Kyoto University Hospital, Kyoto, Japan. Background: Lobular endocervical glandular hyperplasia (LEGH) was initially proposed to be a benign hyperplastic/metaplastic lesion consisting of bland mucinous glands with lobulated architecture. Subsequently, the gastric phenotype of LEGH was identifi ed. Now, the term LEGH is frequently used to refer to the proliferation of gastrictype mucinous glands that express gastric markers such as MUC6. Furthermore, LEGH is recognized as a possible precursor of gastric-type adenocarcinoma of the endocervix. Therefore, the need for accurate diagnosis of the lesion is increasing. However, the extent of the lobular architecture is variable across cases, and it is often diffi cult to diagnose LEGH from small specimens that contain only non-lobulated glands. In this study, we examined the utility of a new pan-gastric immunohistochemical marker, claudin-18 (CLDN18), in the diagnosis of LEGH. Design: Seven cases with benign endocervical glandular lesions exhibiting gastric differentiation were retrieved. The diagnosis of LEGH was made when the proliferation of glands with gastric-type morphology, either foveolar or pyloric type, was present, and when at least focal lobular architecture was seen. Immunohistochemistry for CLDN18, MUC5AC, MUC6, and ER was performed. The immunophenotypes of the glands of LEGH and background endocervical glands were compared. Results: The diagnosis of LEGH was made in all cases, although a signifi cant number of non-lobulated glands were present in many of them. All LEGHs were immunoreactive for the gastric markers CLDN18, MUC5AC, and MUC6. CLDN18 was usually negative in the background endocervical glands, whereas the focal expression of MUC5AC and MUC6 was observed frequently. ER expression was lost in most LEGHs. Conclusions: CLDN18 is a sensitive, specifi c gastric marker for LEGH. Positive CLDN18 immunoreactivity and negative ER immunoreactivity suggest the possibility of LEGH, even when the lobular architecture is inconspicuous morphologically.
MED12 Mutations in Adnexal (Ovarian and Paraovarian)
Leiomyomas D Maeda, M Fukayama. Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Background: Adnexal (ovarian and paraovarian) leiomyomas are rare and their histogenesis is uncertain. No study has evaluated the genetic alterations of a series of ovarian/paraovarian leiomyomas in detail. Recent reports have shown that the MED12 (mediator complex subunit 12) gene is frequently mutated in uterine leiomyomas, but not in leiomyomas at other sites, such as the gastrointestinal tract and soft tissues. This study elucidated the frequency of MED12 mutations in adnexal leiomyomas, and examined a possible link in the pathogenesis of adnexal and uterine leiomyomas. Design: Five cases of adnexal (three ovarian, two paraovarian) leiomyomas were retrieved from the archives of the Department of Pathology of the University of Tokyo Hospital. All of the tumors presented as unilateral adnexal masses. None of the tumors were attached to the uterus. Immunohistochemistry for desmin, smooth muscle actin (SMA), WT-1, ER, PgR, vimentin, calretinin, -inhibin, and CD10 was performed to confi rm the diagnosis of leiomyoma. We analyzed all of the tumors for MED12 mutations. Four-μm-thick sections were cut from paraffi n-embedded blocks containing leiomyomas and blocks containing background non-neoplastic tissues. Representative areas of the sections were dissected. Genomic DNA was extracted from the sections. The samples were subjected to polymerase chain reaction (PCR) using a pair of primers encompassing the frequently mutated region of MED12 (5'-ACTCTCCCACCCCTTCCCCC-3' and 5'-GGCAGGATTGAAGCTGACGTTC-3'). Then, the PCR products were sequenced. Results: Immunohistochemically, all of the tumors were positive for desmin, smooth muscle actin (SMA), WT-1, ER, PgR, and vimentin and negative for calretinin, -inhibin, and CD10. Somatic MED12 mutations were detected in all fi ve leiomyomas.
Four of the tumors harbored missense mutations. In one of the cases, the tumor harbored an in-frame deletion mutation.
MED12 mutations in adnexal leiomyomas
Age Conclusions: MED12 exon 2 mutations are frequent in adnexal leiomyomas. Our data suggest that the pathogenesis of adnexal leiomyomas is similar to that of uterine leiomyomas. Based on our study and reports on MED12 mutations in smooth muscle tumors from various sites, we speculated that pelvic and extra-pelvic smooth muscle tumors are distinct in terms of their background genetic alterations. Results: FISH analysis showed 2 PTEN copies in 17 cases, 3 copies in 9, hemizygous PTEN deletion in 2, and more than one cell population with different PTEN copy number in 3 cases. A good correlation was seen between FISH and aSNP, particularly in cases with 3 PTEN copies. FISH identifi ed 2 cases with deletion of whole chromosome 10, but did not identify a focal deletion of PTEN. Five cases with PTEN deletion and duplication of the second allele by aSNP were interpreted as normal by FISH. Concordance between FISH and MLPA was seen in 15 cases with 2 PTEN copies, while two cases were discordant. Concordant pattern of PTEN deletion by FISH and MLPA was seen in 2 cases, while results were discordant in 2. Six cases were interpreted as amplifi ed by MLPA, but showed polyploidy by FISH. One case with complex MLPA pattern (amplifi cation and deletion) was interpreted as normal by FISH. FISH was superior to aSNP and MLPA in assessing the 3 tumors with more than one cell population with different PTEN copies. IHC correlated quite well in cases with 1 and 2 PTEN copies. However, tumors with 3 PTEN copies did not show increased PTEN protein levels.
FISH Analysis of PTEN in Endometrial Carcinoma. Comparison with SNP Arrays and MLPA O Maiques, D Cuevas, DA Garcia Dios, L Coenegrachts, M Santacana, J Valls, A Velasco, M Romero, S Gatius, D Lambrechts, S Muller, HC Pedersen, X Dolcet, F
Conclusions:
In general, results show good concordance between FISH, aSNP and MLPA, particularly regarding tumors with 2 or 3 PTEN copies. aSNP was superior in tumors with deletion of one copy and duplication of the second allele. FISH was superior to aSNP and MLPA in interpreting molecular results in correlation with morphological features, and assessing tumor heterogeneity. 
Results:
The pts' age ranged from 3 to 85 years (median, 49). Most cases presented with either abdominal/pelvic pain or mass, ascites or abdominal distension. Rare symptoms included: back/neck pain, leg swelling, weight loss, vomiting and changes of bowel habits. 12 cases were incidentally found. A vague history of asbestos exposure was noted in 3 cases. A positive family history of cancer was obtained in 30/42 cases. An elevated CA125 was noted in 24/38 cases. The involvement of multiple sites was common while the involvement of a single site was noted in 8 cases. Most tumors had a combination of architectural patterns including: papillary, tubular, cystic, solid, single cells, clusters of cells or trabeculae; four tumors showed a single architectural patttern (solid, 3; cystic,1). 79 cases were composed of epithelioid cells and 16 cases had also spindle cells. 44 cases had marked variation in the nuclear grade (0 to 3), 31 cases had a nuclear grade 0-1, and 18 had a nuclear grade 2-3. The MI ranged from 0 to 27 per 10 HPFs (median, 1). Psammoma bodies were seen in 23 cases. Invasion was documented in 83 cases. TX included surgery with or without chemotherapy or intraperitoneal chemotherapy including the hypethermic modality. Outcome: 24, DOD (2-168mos); 18, AWD (4-108mos); 19, ANED (4-99mos) and 3, alive, status unknown (7,18 and 41mos). Conclusions: MMFP is an uncommon disease seen in pts of a wide age range. MMFP can be incidentally found. The indolent behavior of some cases of MMFP could be related to focal rather than extensive involvement and the use of new treatment modalitites such as hypethermic intraperitoneal chemotherapy.
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Female Adnexal Tumor of Probable Wolffian Origin and Mimics: An Immunohistochemical Study with Mesonephric and Mullerian Markers R Masand, A Goyal, AA Roma. Baylor College of Medicine, Houston, TX; Cleveland Clinic, Cleveland, OH. Background: Female adnexal tumor of probable wolffian origin (FATWO) is a rare tumor, believed to be of wolffi an (mesonephric) origin. It lacks a specifi c immunohistochemical profi le with variable expression of cytokeratins, calretinin, androgen receptors and CD10, and usual lack of EMA. Considering the important roles of PAX2, PAX8 and GATA3 in the development of the mesonephros, recent studies describing expression of PAX2 and PAX8 in mesonephric lesions, as well as GATA3 in cervicovaginal mesonephric lesions, we studied its expression in FATWOs and FATWO-like tumors. In addition, we explored the expression of these markers in rete ovarii, another proposed site of origin of FATWO tumors.
Design: A database search (1990-2013) was conducted for cases of FATWO and tumors with FATWO-like areas. In addition, 11 recent cases of ovary with rete ovarii were included. PAX8 immunostain was performed in all cases, while PAX2 and GATA3 immunostains were performed in cases with available blocks or unstained slides. For all the stains, only nuclear staining was considered positive. Stains were interpreted as negative (<5%), focal (5-20%), patchy (20-50%), diffuse (>50%); weak or strong intensity. Results: Thirteen cases were identified: 9 FATWOs and 4 ovarian/paraovarian endometrioid adenocarcinomas with FATWO-like areas. PAX8 was negative in all 9 cases of FATWO. PAX2 and GATA3, studied in 6 and 5 FATWO tumors, respectively, were also negative. PAX8 was positive in all 4 endometrioid adenocarcinomas: 2 strong and diffuse, 1 strong and diffuse in the glandular areas but weak and focal in spindled areas, and 1 weak and focal. PAX2 and GATA3 were studied in 3 endometrioid adenocarcinomas. PAX2 was positive in two, one strong and diffuse and one weak and focal. GATA-3 was negative in two and showed rare positive cells in one case. All rete ovarii showed strong and diffuse positivity for PAX8, while negative for PAX2 and GATA3. Conclusions: 1. Our study reveals that PAX8 and PAX2 are not expressed in FATWOs and can be employed as useful tools in differentiating these tumors from Mullerian tumors such as endometrioid adenocarcinomas with FATWO-like areas. 2. The difference in PAX-8 staining suggests that FATWOs do not arise from rete ovarii. 3. It is curious, however, that FATWOs do not express mesonephric markers, including GATA3 that stains cervicovaginal mesonephric lesion, which questions their probable mesonephric origin -it is possibly related to an origin from a distinctive portion of the Wolffi an duct. Design: 18 cases of UCA with available slides and blocks were retreived from our fi les (1988-present). HE slides were reviewed. The following IHC stains were performed: Keratin cocktail (KC), CK5/6, CK8/18, PAX8, ER, PR, HER2/neu, EGFR, c-KIT, MLH1, MSH2, MSH6, PMS2, with appropriate controls. Genetic testing results were obtained from patients' charts when lack of MMRP staining was detected. Staining was graded as negative (<5%), focal (5-25%), patchy (26-75%), diffuse (>75%). Results: PAX8 was negative in 78% of UCA with moderate diffuse staining in 3 and patchy in 1 case. KC was diffusely positive in 55%, CK8/18 in 61% and CK5/6 was negative in 78% of cases. ER and PR were negative in 83% and 94% of cases respectively. EGFR was negative in 66%, and HER2/neu and c-KIT were negative in all cases. Concurrent loss of MLH1 and PMS2 staining was identifi ed in 11/18 (61%) cases. MSH2 and MSH6 staining was retained in all cases. Genetic testing was performed only in 4/11 patients with MLH1/PMS2 loss, and all 4 showed MSI-high tumors. Conclusions: PAX8 appears to a reliable marker in distinguishing UCA from other high grade carcinomas, as it is negative in majority of cases. Although UCA is reportedly negative/focally positive for KC, we found it to be diffusely positive in over half the cases, limiting its utility in this differential. Despite the morphologic resemblance to BLC, UCA does not have a similar IHC profi le. Given that 2/3rd of patients in our study had MLH1/PMS2 loss, genetic testing in all patients with UCA should be considered. Background: Uterine carcinosarcoma is a biphasic tumor characterized by the presence of carcinoma and sarcoma components. In this study, we performed a comprehensive mutation analysis of 25 genes previously implicated in the oncogenesis of uterine cancer/sarcoma. Design: We studied 15 uterine carcinosarcomas with matched frozen tumor, formalinfi xed paraffi n-embedded tumor and normal tissue. The carcinoma and sarcoma areas were separately evaluated in 9 cases and peritoneal tumor metastasis was analyzed in
Mutation Profiling of Uterine Carcinosarcoma -Insights into Tumor
7. An Illumina Custom TruSeq amplicon panel was used, which covered all exons of 25 genes (ABCC9, AKT1, AKT2, AKT3, ARID1A, CCND1, CHD4, CSMD3, CTCF,  CTNNB1, EP300, FBXW7, FGFR2, MAP3K4, MED12, PIK3CA, PIK3R1, PIK3R2 , POLE, PPP2R1A, PTEN, SPOP, TP53, TSPYL2 and ZFHX3). Libraries were constructed with genomic DNA extracted from matched tumor and normal tissue, pooled and run on the MiSeq (Illumina). All somatic non-synonymous mutations were manually checked in bam fi les using Integrated Genome Viewer. Results: Mutations were detected in all 15 primary tumors (1 to 14 genes, median of 4 genes mutated per tumor). In the 9 cases where the carcinoma and sarcoma components were analyzed separately, 8 shared identical mutation(s) in at least one gene (1 to 11 genes, median of 2 genes); the remaining tumor showed a single mutation in the sarcoma component only. These ancestral mutations were also identifi ed in their respective metastatic tumors. There were a greater number of genes mutated in the sarcoma component (average 5.1 genes) compared to the carcinoma component (average 4) (paired t-test, p = 0.04). Mutations involving PI3K pathway genes were identifi ed in 9 of the 15 primary tumors, most commonly involving PIK3CA (7), followed by PTEN (4) and PIK3R1 (4). The carcinoma and sarcoma components, as well as the metastatic tumors all shared the same PI3K-pathway mutation(s). TP53 mutations were observed in 7 primary tumors. One tumor harbored a POLE mutation and displayed a hypermutation phenotype (mutations in 14 of 25 genes).
Conclusions:
Our results suggest that uterine carcinosarcomas arise occur through transdifferentiation of carcinoma into sarcoma. We observed frequent PI3K pathway mutations in uterine carcinosarcoma which are acquired prior to tumor transdifferentiation and metastasis. These fi ndings provide further support for the use of therapy that target PI3K signaling and downstream pathway in uterine carcinosarcoma. Immunohistochemistry was performed using a mouse monoclonal antibody against human FH protein (Clone J-13, Santa Cruz Biotechnology).
HER2 Immunohistochemistry Significantly
Results: IHC was interpreted as positive or negative when cytoplasmic staining was identifi ed. Histologically, tumors were classifi ed as atypical leimyoma, and one SMT of unknown malignant potential. All patients had multiple uterine SMT with maximum diameters ranging from 1.8 to 8.9 cm (m 5.84 cm). 
Conclusions:
The study suggests, for the fi rst time 1) that TIC is signifi cantly less likely to be identifi ed in advanced HGSCs of women with BRCA mutations and 2) the subset of BRCA+ advanced HGSCs without TIC develops at a younger average age relative to both BRCA+ (3 yrs) and BRCA-women (7 yrs) with TIC. This lends support to the novel hypothesis that despite the high frequency of TIC in early or asymptomatic BRCA+ malignancies, BRCA+ tumors discovered in an advanced stage are younger, less likely to be associated with TIC, and more likely to evolve rapidly. Further study of potential precursors in the fi mbrial-ovarian region is warranted to explain this paradox and more accurately estimate the effectiveness of salpingectomy alone in preventing HGSC in BRCA+ women. 21.28, p<0.05).
Conclusions: Vascular lesions seen in FVT were relatively uncommon in our random sample. Diffuse VSK or AVV in combination with SVT and/or CPT, particularly if recent, were associated with poor neonatal outcome. As the extent of SVT and CPT increased, so did the likelihood of morbidity/mortality. Background: GATA3 is a zinc-fi nger transcription factor which has been shown to induce trophoblast differentiation in trophoblast stem cells. In tumors, GATA3 is known to be sensitive and specifi c for urothelial and breast carcinomas, and recent studies have also demonstrated GATA3 in paragangliomas and lesions with mesonephric differentiation. Despite the known association of GATA3 with trophoblast-specifi c gene expression and placental function, its expression in trophoblast-related neoplasia has not been evaluated. Design: GATA3 immunohistochemistry was performed on 22 normal placentas (11 immature and 22 mature), 1 atypical placental site nodule, 11 partial hydatidiform moles, 14 complete hydatidiform moles, and 11 gestational trophoblastic tumors including 5 choriocarcinomas, 3 placental site trophoblastic tumors, and 3 epithelioid trophoblastic tumors. 160 endometrial adenocarcinomas (153 endometrioid, 3 serous, 4 clear cell) on a TMA were also stained for comparison. Strong nuclear immunoreactivity was considered a positive result. Results: Immature placentas are characterized by strong and diffuse nuclear GATA3 staining of the implantation site (intermediate trophoblasts) and cytotrophoblast layer, with variable staining in the syncytiotrophoblast layer. Mature placentas demonstrate less expression of GATA3 with only scattered positive cells in villous cytotrophoblasts, and little to no expression in syncytial knots. Complete and partial hydatidiform moles show diffuse expression in the cytotrophoblasts and implantation site, and heterogeneous expression in extravillous trophoblastic hyperplasia. All choriocarcinomas, placental site trophoblastic tumors, and epithelioid trophoblastic tumors, as well as the atypical placental nodule, were positive for GATA3. All endometrial adenocarcinomas were negative for GATA3. Conclusions: All trophoblast lineages (cytotrophoblasts, intermediate trophoblasts, and syncytiotrophoblasts) were positive for GATA3. Extent of GATA3 expression varied signifi cantly in immature and mature placentas, suggesting a role in trophoblast maturation. GATA3 does not help distinguish molar gestations from normal immature placental tissue, nor does it distinguish the different gestational trophoblastic tumors. Nevertheless, GATA3 can help distinguish trophoblasts (neoplastic or non-neoplastic) from epithelial malignancies, and this could be especially useful in biopsy specimens. Lastly, GATA3 may be helpful in subtyping metastatic tumors when a trophblastic neoplasm is in the differential; however, distinction from breast and urothelial carcinomas with additional markers would be required.
IMP3 Oncofetal Protein Expression Can Detect Precursor Lesions in Fallopian Tubes of Patients with BRCA Gene Mutation M Mirzabeigi, Y Liu, S Goodman, A Khan, D Kandil. UMass Memorial Medical
Center, Worcester, MA. Background: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein almost exclusively expressed in fetal tissue and malignant tumors. IMP3 expression has been shown to be a marker of aggressive behavior and correlated with reduced overall survival in many tumors. In the gynecologic tract, IMP3 expression was reported in high-grade serous carcinoma of the ovary, while negative in borderline and serous cystadenomas. Patients with BRCA gene mutation are at an increased risk for developing high-grade serous carcinomas (HGSC) of the ovary, many of which may represent a fallopian tube (FT) origin. Studies of prophylactic salpingo-oopherectomies have identifi ed precursor lesions in the FT such as serous tubal intraepithelial carcinoma (STIC). Overexpression and mutation of TP53 were also identifi ed in these cases. Design: Herein, we studied the expression of IMP3 immunohistochemistry in FT specimens of forty-four patients with BRCA gene mutation, and compared it to that of TP53. These included four patients (4/44) with an associated HGSC. The remaining 40 patients had prophylactic salpingectomies. STIC was identifi ed in 2 patients, 1 of whom had high-grade ovarian carcinoma (bilateral STIC), while the other patient had an incidental fi nding. Results: Among the four patients with high-grade ovarian carcinomas, 3 (75%) were positive for IMP3, while all cases were negative for TP53. Both patients (100%) with STIC expressed IMP3, one of which, co-expressed TP53 (50%). Among the prophylactic group, 46% (19/41) showed focal expression of IMP3, compared to 15% (6/41) with focal TP53 over-expression. Conclusions: Our data suggests that alteration in IMP3 protein may represent an early stage in the pathogenesis of HGSC, and may serve as a potential marker for detection of precancerous lesions in this subset of patients. Nevertheless, an exhaustive genomic study of this specifi c type of tumors has opened new avenues in the identifi cation of molecular markers involved in tumor progression. Using this approach, our group has been focused on the new potential markers identifi cation not only related to ovarian carcinogenesis but also to metastasis and recurrence in HGS-OVCa. Design: We performed a preliminary study based on exome sequencing (SOLID technology) of paired samples from the same patient including: primary tumor, distant metastasis and main relapse tumors as well as normal tissue used as control.
Impact of Mutation in MYBBP1A Gene Related to Ovarian Cancer Recurrence
Results:
In the mutational analysis we discovered 46 mutations with pathogenic effect using Bioinformatic prediction, affecting genes directly or indirectly related to transcription. A relevant fi nding is the presence of mutations in MYBBP1A (MYB Binding Protein -P160-1a) which has been involved in tumor recurrence in head-neck tumors (BMC Cancer 2012, 12:72). In order to understand the molecular role of this gene in ovarian tumor progression, we evaluated MYBBP1A expression in a cohort of HGS-OVCa including 50 primary and 45 recurrence samples. Conclusions: Our results point out for the fi rst time at the potential role of MYBBP1A in tumor recurrence in HGS-OVCa.
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Morphologic Features of Endometrial Clear Cell Carcinomas with p53 Overexpression J Munkberg, A Ziober, C Reyes. Hospital of the University of Pennsylvania, Philadelphia, PA. Background: Endometrial clear cell carcinomas (E-CCC) are known to have a poor prognosis. Recent studies have shown that E-CCC with p53 positivity (p53+) may behave more aggressively. There are few studies however, that correlated p53+ E-CCC with its morphologic features. Our aim was to compare clinicopathologic and morphologic features of p53+ and p53 wild type (p53-wt) E-CCC. Design: Hysterectomy specimens with diagnosis of E-CCC were retrieved from two institutions between 1994-2013, yielding 33 cases. Cases were reviewed (1-8 slides/ case) and 20 cases met diagnostic features of E-CCC. Immunohistochemical staining of formalin fi xed paraffi n embedded tissue for p53 was performed, and each case was considered p53+ (>75% tumor cells) or p53-wt (<75% tumor cells). Clinicopathologic variables analyzed included: age at diagnosis, stage, lymph node (LN) status, predominant architectural pattern (>50% of tumor), nucleoli, lymphovascular invasion (LVI), depth of myometrial invasion (MI), cytoplasm type, nuclear grade (1-3), stromal infl ammation, necrosis, and mitoses. Results: Six of the 20 cases (30%) were p53+. Average age at diagnosis was 73y (range 57-82) in the p53+ group vs. 63y in the p53-wt group (range 43-83). Three of the 6 p53+ cases (50%) presented at a high stage (T3 or T4) as opposed to only one of 14 p53-wt cases (7%). Only one p53+ case had LN metastasis (20%), while 3 of 12 p53-wt cases (25%) had LN metastases. Predominant architectural pattern in the p53+ cases was glandular (4/6, 67%); remaining 2 were papillary (2/6, 33%). P53-wt group showed predominantly solid (7/14, 50%) and glandular (6/14, 43%) patterns with one case being papillary. Conclusions: Few studies have investigated the frequency of negative LEEPs following a CIN2+ colposcopic biopsy diagnosis, but published data suggest it occurs in 10-20% of cases. We observed a signifi cant reduction in the frequency of negative LEEPs in the period from 2006-2012, which is also when our practice began using p16 to assist with CIN2+ classifi cation. The potential impact of p16 to reduce the number of unnecessary LEEPs has been anticipated and now supported by our retrospective study. Clearly, fewer unnecessary LEEPs improves patient care and the cost-effectiveness of this surgical treatment.
Ovarian Teratomas Associated with Anti-NMDAR Encephalitis Are Distinguished by Neural Teratomatous Elements Containing Lymphoid Aggregates with Germinal Centers
A Nolan, C Zaloudek, JT Rabban. University of California San Francisco, San Francisco, CA. Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare severe paraneoplastic limbic encephalitis in young women that is often associated with ovarian teratoma. Limited data suggests such teratomas can be distinguished from teratomas in women without encephalitis by the presence of lymphoid infi ltrates and reactive lymphoid aggregates involving the teratomatous neural elements. The aim of this study was to topographically map and quantitatively compare these morphologic features in ovarian teratomas from women with versus without anti-NMDAR encephalitis. Design: Lymphoid populations were evaluated in 5 mature ovarian teratomas in women with anti-NMDAR encephalitis (average patient age 23) and in 21 mature ovarian teratomas in women without encephalitis (average age 28). The topographic distribution (neural versus non-neural elements), cellularity, and quantity of lymphoid infi ltrates and aggregates (with versus without germinal centers) was compared in teratomas from women with versus without encephalitis. Results: Average tumor size was smaller (2.36 cm) in women with encephalitis than without (6.9 cm). Neural elements were present in all teratomas. Average # of low power fi elds of neural elements was 1 in women with encephalitis and 3.8 in those without encephalitis. Table 1 Conclusions: Lymphoid aggregates with germinal centers involving neural elements in an ovarian teratoma are associated with anti-NMDAR encephalitis. However, lymphoid infi ltrates and aggregates without germinal centers are commonly present in conventional mature teratomas of the ovary and are not specifi cally associated with anti-NDMAR encephalitis. Background: Uterine tumors resembling ovarian sex cord tumor are rare tumors composed of epithelial-like cells with architectural patterns resembling those described in sex cord stromal tumors of the ovary. Since their initial description in 1976, it has been unclear whether UTROSCT represents complete overgrowth of sex cord-like elements within the family of endometrial stromal tumors (EST), as the latter can exhibit varying amounts of sex cord-like differentiation, or a distinct and unrelated uterine neoplasm as by electron microscopy they do not show features of stromal neoplasia and they lack t(7;17) by FISH. Recently, a study revealed that all endometrial stromal tumors with sex cord -like differentiation (n=7) showed rearrangement involving PHF1; therefore, the purpose of this study was to address the possibility that if UTROSCT are in fact EST with extensive sex cord-like differentiation, they would show evidence of PHF1 rearrangement. Design: Cases of UTROSCT were identifi ed from our multi-institutional archive and included both in-house and consultation specimens. Fluorescence in situ hybridization (FISH) was performed on interphase nuclei obtained from formalin-fi xed paraffi nembedded sections utilizing a laboratory developed break apart probe for PHF1 (at 6p21.3). Performance and interpretation of interphase FISH was done according to a clinically validated protocol. Results: Seven UTROSCT were identifi ed from our fi les. They were from patients who underwent hysterectomy and whose age ranged from 31 to 53 (mean 43) years. All seven tumors were negative for rearrangements involving PHF1 by FISH. Conclusions: If UTROSCT represented a subset of EST, then one would predict that these tumors would share a similar histologic appearance as well as a similar genetic pathway. While UTROSCT has previously been shown to lack JAZF1-JJAZ1 translocation seen in most EST with classic morphology, it was possible that they could have represented a variant of EST that arose from a different genetic pathway, namely one involving rearrangements of PHF1, which has been shown in all EST with variant sex cord like differentiation examined to date. Our results, combined with published data, therefore support the theory that UTROSCT represents a distinct tumor category separate from EST. Background: Cervical adenosquamous carcinomas are a relatively uncommon histological subtype of cervical cancer. However, these tumors, like adenocarcinomas, have worse prognosis than squamous cell carcinomas. The identifi cation of somatic mutations may augment patient diagnosis and treatment in this disease. This project is nested within a larger whole exome sequencing (WES) analysis of 100 cervical tumors in Norwegian women. Design: Seven of the 100 cervical tumors were identifi ed as adenosquamous carcinomas by combining hematoxylin-eosin based diagnostics with hierarchical clustering of tumor gene expression data. Tumor and blood DNA were subjected to Illumina-based WES. Single nucleotide variants and small insertion/deletions were identifi ed by the MuTect and Indelocator algorithms respectively. Somatic copy number (CN) data were derived from WES data using the CapSeg algorithm, and signifi cantly recurrent CN alterations were identifi ed by GISTIC2.0 analysis (q<0.25). Results: Three of the 7 cervical adenosquamous tumors harbored somatic point mutations (E95K, I525L and R529T) in the USP15 gene. We also observed recurrent R323T mutations in the DSN1 gene in 2 tumors, while a third tumor had focal deletion peak that included DSN1. The USP15 and DSN1 mutations occurred only in the adenosquamous tumors within this cohort. Furthermore, we found PIK3CA mutations (E545K, L267V) and/or amplifi cation in 4 of the 7 tumors. Six of the 7 adenosquamous
increases the stability of the oncogenic HPV16 E6 protein. Therefore, our data suggest that USP15 may be an oncogene, at least in the context of HPV-related cancers. The putative loss-offunction mutations observed in the DSN1 gene are in keeping with the role of the DSN1 protein as an essential kinetochore protein required for proper chromosome segregation. Our fi ndings also support the notion that cervical adenosquamous carcinomas may be included in clinical trials of PI3-kinase inhibitors, alongside other cervical tumors. Finally, our data suggest that chromosome 19q gain should be further investigated as a potential diagnostic marker in cervical adenosquamous carcinomas. . We aimed to analyze with highly sensitive PCR techniques the tumors testing negative for HPV by HC2 and to determine the clinico-pathological characteristics and yhe prognosis of the patients with tumors with confi rmed HPVnegativity. Design: WWe included 136 women with CC (32 adenocarcinomas, 104 squamous cell carcinomas) and a HC2 testing performed either simultaneously or within 6 months before the histological diagnosis. Formalin-fi xed paraffi n-embedded tumor samples from all HC2-negative cases were reanalyzed and genotyped for HPV using three different PCR assays (SPF10, GP5+/6+ and E7 specifi c assay). p16 expression was evaluated by immunohistochemistry in all cases. Clinico-pathological features, as well as disease free and overall survival (DFS and OS) were analyzed for women with HPV-negative and -positive tumors. Results: Fourteen out of 136 (10.2%) women were negative for HPV by HC2. After reanalysis by PCR-based techniques only 8/136 (5.8%) tumors were confi rmed to be HPV-negative, whereas in six cases different HPVs were identifi ed; fi ve of them were HPV types included in the probes of HC2 test (HPV 16, 18, 45 and 68). Adenocarcinomas were more frequently in the HPV-negative confi rmed group than squamous cell carcinomas (5/32, 15.6% vs. 3/104, 2.9%, respectively; p=0.017). Background: Polyclonal PAX-8 has been shown in multiple studies to be a good marker for gynecological, renal, thyroid and thymic tumors. In most studies, polyclonal PAX-8 has been negative in peritoneal mesothelial lesions, and thus believed to help discriminate ovarian carcinomas from peritoneal mesotheliomas. However, some recent studies have reported positivity in neoplastic and non-neoplastic peritoneal mesothelial lesions. The aim of this study was to test a new PAX-8 monoclonal antibody in a variety of peritoneal mesothelial lesions and compare its specifi city and sensitivity to PAX-8 polyclonal antibodies previously used in most studies. Design: Immunohistochemistry using monoclonal antibody for PAX-8 (BC12 API 438, AA Biocare medical) was performed in 39 mesothelial lesions including 14 malignant mesotheliomas, 9 well differentiated papillary mesotheliomas, and 16 multicystic mesotheliomas (AKA peritoneal inclusion cyst). Slides were reviewed using appropriate positive and negative controls, and were evaluated for percentage of nuclear staining and the intensity of staining, the latter using a two tier system: 1+ = weak nuclear staining, and 2+ = intense nuclear staining. Results: See Table 1   Table 1 Diagnosis Total number of PAX-8 positive lesions Conclusions: This monoclonal PAX-8 antibody is expressed in a signifi cant number of peritoneal lesions: 35% of malignant mesotheliomas, 11% of well differentiated peritoneal mesotheliomas, and 68% of peritoneal inclusion cysts. In many of these cases the percentage of positive cells and the intensity was striking. Thus PAX-8 is not reliable in discriminating ovarian carcinomas from peritoneal mesothelioma.
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Validation of a Novel Subclassification of Endocervical
Adenocarcinoma: Pitfalls of Inter-Observer Variability C Paquette, SK Jeffus, CM Quick, MH Stoler, KA Atkins. University of Virginia, Charlottesville, VA; University of Arkansas, Little Rock, AR.
Background:
The newly proposed subclassifi cation system by EG Silva and colleagues for endocervical adenocarcinoma (EAC) identifies patients who need regional lymphadenectomy (LA), and potentially spares LA (and morbidity) in patients at low risk for metastases. As EAC is rare (1.76 cases/100,000 woman-years), accumulating cases to assess these assertions is diffi cult. The objective of this multi-institutional study is to determine whether gynecologic pathologists confi rm the utility of this classifi cation. Design: 66 cases were identifi ed from the past 10 years of two academic hospitals. The cases were independently classifi ed by two gynecologic pathologists per institution into: Pattern A: well demarcated glands, no lymphovascular invasion (LVI) Pattern B: early stromal invasion arising from well-demarcated glands Pattern C: diffuse, destructive invasion Follow-up for nodal metastases was via pathology reports and chart review. Results: Of the 66 cases, 16 were excluded upon review (missing, misclassifi ed, etc). Age ranged from 27-78 years (mean 43.8). Weighted kappa () statistics comparing the two pathologists was determined for each institution: for one (35 cases, 71-77% pattern C) the  was 0.909, and the other (15 cases, 20-27% pattern C) had a  of 0.524. The patterns were A (12%), A vs. B (4%), B (22%), B vs. C (8%), and C (54%). All 5 cases of unanimous A had negative LA. Of 11 cases of unanimous B, eight had negative LA, one had no nodal disease by imaging, while two presented at Stage II and did not receive LA. One of the negative LA patients had LVI. Of the 26 cases of unanimous C, 18 (69%) had negative LA, while four (15%) had positive nodes, and four did not receive LA. Conclusions: Our review adds data to confi rm that pattern A EAC is low risk for nodal disease. For pattern B patients, while metastatic disease was present at diagnosis for two, those with EAC limited to the cervix did not have nodal disease. Pattern C is clearly a signifi cant risk factor for nodal disease. The inter-observer agreement was robust at one institution with predominantly C, and moderate at the other with predominance of B. This may refl ect more agreement regarding 'diffuse destructive' invasion and more subjectivity for 'early' invasion. In both institutions there were calendar years with no EAC, suggesting skills may fall into disuse. Further investigation of inter-observer variability in application of this new classifi cation with a group enriched with A and B is needed to confi rm applicability in the real world setting. Background: Mucinous adenocarcinoma is the most common type of adenocarcinoma in the uterine cervix, comprised of three variants; endocervical, intestinal, and signet ring cell variants (SRCV) based on histopathological features. However, diagnostic value and clinical signifi cance to separate SRCV as an independent disease entity have not been clarifi ed. Design: During the histopathological review of adenocarcinomas of the uterine cervix from 150 patients treated at the Asan Medical Center, Seoul, Korea, during 11 yearperiod, 14 cases of SRCV were identifi ed. We attempted to defi ne the clinicopathological characteristics of SRCV by immunohistochemistries for MUC2, MUC5AC, MUC6, HIK1083, P16, P53, Ki67 and alcian blue pH2.5-DPAS mucin stain. We correlated various clinical parameters of the patients with SRCV including disease-free survival rate, metastatic and recurrence rates, and depth of invasion with those of the patients with endocervical and intestinal variants. Results: Histologically, SRCV formed well defi ned solid nests composed of mucin containing cells with signet ring cell like features. However, the cells maintained cohesiveness between the tumor cells, which are different from signet ring cell carcinoma of gastrointestinal tract. All 14 cases were admixed with endocervical variant within the same tumor in variable extent. Notably, SRCV were frequently associated with signifi cantly increased infi ltrations of neutrophils or lymphoplasma cells in the stroma. The tumor cells expressed MUC5 (13/14, 93%), MUC6 (10/14, 72%) MUC2 (6/14, 43%) and HIK1083 (3/14, 21%), but all (14/14, 100%) were stained blue in alcian blue pH2.5-DPAS stain, suggesting acid mucin secretion. All 14 cases showed immunopositivity for P16, while none of them showed P53 expression, which were similar to those of endocervical variant. Although Kaplan-Meier analysis showed lower disease free survival rate in cases of mixed SRCV compared to pure endocervical variant (p=0.003), metastatic and recurrence rates, depth of invasion, and lymphovascular involvement were not signifi cantly different. Conclusions: Although cytomorphologic features of individual tumor cells have some similarities to those of signet ring cell carcinoma of gastrointestinal tract and the secreted mucin has some properties of gastric and intestinal mucins, clinical signifi cance of segregating SRCV as an independent disease entity is not so high. Coexistence with endocervical variant in most cases, and similar immunoprofi les of P16 and P53 may suggest that SRCV is a histologic variant of endocervical type.
Clinicopathological Characteristics of Signet Ring Cell Variant of Endocervical Mucinous Adenocarcinoma
1240 Histological Characteristics of Gastric-Type Adenocarcinoma of the Uterine Cervix JY Park, CO Sung, K-R Kim. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Background: Gastric type adenocarcinoma (GAS) of uterine cervix has been proposed as a specifi c subtype of cervical adenocarcinoma (EC), characterized by secretion of gastric type mucin, and immunopositivities for MUC6 and/or HIK1083 and having a poor prognosis compared to other subtypes. However, histological characteristics or required ancillary techniques to confi rm the subtype has not been widely acknowledged. Design: We attempted to defi ne the histological characteristics of GAS determined by immunohistochemical features of MUC2, MUC5AC, MUC6, HIK1083, P16, P53, Ki67 and alcianblue-DPAS stains among 150 patients with EC treated at the Asan Medical Center, Seoul, Korea, during 11 year-period along with a validation of previously described clinicopathologic features of GAS. Results: Five cases (5/150, 3%) showing positivities for all three parameters, HIK1083 (+), MUC6(+), and gastric type mucin (+), were classifi ed as 'probable GAS' and the microscopic fi ndings showed common characteristic features ('gastric features'); 1) small tubular shape and rarely branching glands, 2) single layered epithelium with pale pink cytoplasm (with or without nuclear atypia), 3) often dilated lumen with occasional intraglandular micopapillary features. Seventeen cases (17/150, 11%) showing positivities for any two parameters, including HIK 1083  MUC6 (n=9), HIK1083  gastric mucin (n=2), MUC6  gastric mucin (n=4), were classifi ed as 'possible GAS', among which 'gastric features' were variably identifi ed ranging from 44%-100%. However, among 17 cases of 'possible GAS' defi ned by positivities for two parameters regardless of histologic fi ndings, intestinal subtype (n=3), signet ring cell subtype (n=2), and poorly differentiated adencarcinoma were also included, suggesting that these parameters are not specifi c for GAS. The patients with 'probable GAS' or 'probable and possible GAS' had signifi cantly shorter disease-free survival times in Kaplan-Meier survival analyses (P=0.021), signifi cantly larger tumor size, and deeper invasion of cervical wall than the patients with other subtypes. Conclusions: Subtyping of GAS appears to be clinically signifi cant due to a signifi cant prognostic difference, and the 'gastric features' may be helpful in the recognition of GAS, however, accurate subtyping should always be combined with ancillary techniques including HIK1083, MUC6, and alcian blue-DPAS. It is still diffi cult to subtype the cases showing positivities for only one or two parameters since MUC6 and HIK1083 were occasionally positive for intestinal and signet ring cell subtype.
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Diagnosis of Endometrial Versus Endocervical Adenocarcinoma: Quantitative Image Analysis Is a Useful Diagnostic Tool
CE Parra-Herran, B Djordjevic. University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. Background: Distinction between endometrial and endocervical adenocarcinoma on biopsy is a common diagnostic issue. While immunohistochemistry is often helpful, up to 50% of endocervical and 70% of endometrial tumors do not fully adhere to expected patterns. Digital image analysis is a novel ancillary tool in surgical pathology, and to date its role in the above differential has not been explored. The aim of this project is to use digital image analysis to uncover distinctive morphologic features between endometrial and endocervical adenocarcinoma. Design: 24 cases of FIGO grade 1 and 2 endometrial adenocarcinoma and 26 cases of endocervical adenocarcinoma were retrieved from our fi les. The HE slides were digitally scanned (Aperio). Two representative tumor areas were selected, and a TIFF image fi le of each was obtained at 20X magnifi cation. The images were analyzed using digital software (Zen 2011, Carl Zeiss Microscopy, Germany). The following nuclear features were measured: diameter, area, perimeter, area fi lled, circularity, convexity, ellipse angle, feret ratio, fi bre length, form circle, roundness, grey, blue, red and green levels. Collected data was analyzed using statistical software (SPSS v 17). Results: Of 15 nuclear features analyzed, diameter and feret ratio (a measure of nuclear membrane irregularity) were signifi cantly different between endometrial and endocervical adenocarcinomas by independent samples comparison of means test, while ellipse angle (a measure of relative nuclear alignment) approached signifi cance (Table 1) . A classifi cation tree algorithm combining these variables classifi ed 79.2% of endometrial and 88.5% of endocervical adenocarcinomas correctly (Figure 1) . Conclusions: For the fi rst time, we demonstrate that digital image analysis can detect signifi cant differences in nuclear morphology of endometrial and endocervical adenocarcinomas, which are imperceptible to the human eye. As such, it has a potential value as a future ancillary diagnostic tool, and may perform more reliably than immunohistochemistry. Background: High Grade Serous Carcinoma (HGSC) originates in the hormonally sensitive fallopian tube epithelium. Most HGSC cases express estrogen receptor (ER). Anti-estrogen therapy is often used to treat recurrent disease, but associations between ER expression and tumor response are not well documented. We hypothesize that i) reproductive hormone signaling is altered in HGSC, that ii) reproductive hormone receptor status (ER/PR) may be an important indicator of clinical outcome and that iii) ER target gene expression will provide further insight into the use of anti-hormone therapy in ovarian cancer. Design: FFPE tissues (n=334) and snap-frozen tissues (N=43) from HGSC naïve to chemotherapy were obtained from the UHN Pathology Department. Clinical outcome data inclusive of both recurrence-free (RFS) and overall survival (OS) was available on 165 cases. Using tissue microarrays and standard immunohistochemistry, ER and PR expression was analyzed using automated image analysis. A candidate list of ER target genes was generated by comparing tumor gene expression profi les of the sub-groups based on ER/PR expression. Candidate genes were validated by qPCR and immunohistochemistry on tissue microarrays. Statistical analysis was performed using ANOVA (p<0.05) and Fisher's Exact Test (p<0.05). Results: High PR expression cases (31%) had a signifi cant increase in both RFS (p<0.05) and OS (p<0.005) compared to the PR-low samples. ER expression, positive in 88% of cases, did not predict for survival. Combining expression of PR with ER created four subgroups, with ER-high/ PR-low being the most frequent expression pattern (57%), followed by ER-high/ PR-high (25%), ER-high/ PR-low (12%) and ER-low/PR-high (5%). Overall survival was prolonged in the ER-low/PR-high cases with the shortest OS seen in the ER-high/PR-low patients (p=0.002). Gene expression analysis revealed 202 ER target genes with more than a 2 fold-change in expression (p<0.05). Five genes (DKK3, SOX11, IGF2, TKTL1, NY-ESO-1) were selected for validation by qPCR and IHC, based on gene ontology and cancer pathway associations. Conclusions: HGSC is predominantly an ER-high/PR-low cancer, but other patterns of hormone receptor expression exist which predict for an increased overall survival. ER-high differ transcriptionally from ER-low HGSC although some known ER target genes are still transcriptionally activated in the absence of PR. This information should provide further insight into the use of hormone receptors as indicators of anti-hormone therapy response in ovarian cancer. 
Results: CAIX was expressed in 44/61(64%) of the EOC TMA cohort and in 34/35(98%) of the ovarian full-face sections. Breast cancers were less likely to show tumour hypoxia with 24/89(28%) expressing CAIX. Loss of membranous CTNNA3 was identifi ed in 5/14 breast tumours staining positive for CAIX. In the remaining 9 tumours, which, on the whole, retained membranous CTNNA3, focal loss was seen specifi cally in CAIX positive regions in 6/9. Adjacent normal breast tissue showed crisp membranous CTNNA3 in all cases.Loss of membranous CTNNA3 was seen in 20/35(57%)EOCs with hypoxia. Strong expression was seen in 3/35(8%), with weak expression in 12/35(34%). All of the 3 tumours displaying strong membranous CTNNA3 staining, showed focal loss specifi cally in areas of strong CAIX expression. Conclusions: CAIX can be more commonly demonstrated in EOC than in breast cancer. Loss of membranous expression of the cell adhesion molecule CTNNA3 is frequent in breast and ovarian cancer. In those tumours retaining membranous localisation of CTNNA3, there was focal loss specifi cally in CAIX positive regions suggesting a relationship between loss of membranous CTNNA3 and the presence of tissue hypoxia. This is further supported by the in vitro fi nding of loss of membranous CTNNA3 in a chronic hypoxic cell line.
1244
CK17 as an Adjunctive Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia MB Podoll, M Moghadamfalahi, MA Sanders. University of Louisville, Louisville, KY. Background: Vulvar intraepithelial neoplasia (VIN) is a premalignant lesion of vulvar squamous cell carcinoma (SCC). Two subtypes exist in the current ISVVD classifi cation. Usual type VIN (uVIN) is more common, occurring in younger patients, and is associated with human papillomavirus. Differentiated type VIN (dVIN) typically occurs in postmenopausal women, is associated with chronic infl ammatory dermatoses, commonly lichen sclerosis, and has a higher risk of SCC. Pathologic diagnosis of dVIN is challenging due to the subtle histologic fi ndings, including parabasal cell atypia and eosinophilia that distinguish dVIN from benign lesions. Cytokeratin 17 (CK17) immunohistochemistry has been used as a marker of dysplasia in the cervix. The aim of this study was to determine the utility of CK17 as an adjunctive marker in the diagnosis of dVIN. Design: The pathology archives at our institution were searched for cases of dVIN from 2010 to 2013. Histologic slides were reviewed to confi rm the diagnosis and select the paraffi n embedded blocks for CK17 immunohistochemistry. CK17 antibody (1:50, Dako, Denmark) was used according to the manufacturer's instructions. The staining intensity (weak, intermediate, strong) and location (basal, parabasal, middle or superfi cial layers) were evaluated. Results: Fifteen cases of dVIN were identifi ed, 4 biopsies and 11 surgical specimens. Eleven cases included normal mucosa and 2 cases included lichen sclerosis. All cases showed staining with CK17. Thirteen of 15 (87%) dVIN cases showed intermediate to strong staining predominantly in the suprabasal, middle and superfi cial mucosal layers. Of the remaining 2 cases, one was equivocal with patchy strong staining in the middle and superfi cial layers, and the 2nd was considered negative with focal weak staining. A sharp contrast between CK17 staining of dVIN and normal mucosa was observed. Normal mucosa demonstrated at most weak staining of the basal layer, although strong staining was noted in normal skin appendages. Two cases with both dVIN and lichen sclerosis demonstrated positive staining of dVIN and negative staining of lichen sclerosis. Conclusions: Of the premalignant lesions in the vulva, dVIN is more commonly associated with SCC and can be missed on pathologic diagnosis due to subtle histologic fi ndings of atypia. Recognizing dVIN is important for appropriate management and cancer prevention. While current ancillary studies that support a diagnosis of dVIN include p53 and Ki-67, we fi nd CK17 to be a useful marker to add to the immunohistochemical panel.
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Primary Endometrial Yolk Sac Tumor (YST): Clinicopathologic and Immunohistochemical Characterization of a Diagnostically Problematic Entity CG Przybycin, B Yang, R Soslow. Cleveland Clinic, Cleveland, OH; Memorial SloanKettering Cancer Center, New York, NY. Background: Primary endometrial YST is rare, with only 4 cases reported to date. Given its overlapping morphologic features with usual endometrial carcinoma, it can be easily misdiagnosed. We report the morphologic features of a series of cases and assess a panel of immunohistochemical stains for differentiating endometrial YST from Müllerian-type adenocarcinomas. Design: Database searches for endometrial YST were conducted at two large institutions. HE slides were reviewed and clinical and morphologic features recorded. Immunohistochemical analysis with antibodies against SALL4, Pax-8, ER, PR, AFP, p53 and Hepatocyte antigen was performed. Immunostaining results were analyzed. Results: Four cases were identifi ed (3 hysterectomy specimens and 1 endometrial curettage) from 4 patients (age range=35 to 67 y, mean=57). All tumors were pure YST; none had components of Müllerian-type adenocarcinoma or carcinosarcoma. All 4 cases showed a glandular pattern, including 2 with endometrioid-like glandular pattern. Other admixed patterns included hepatoid in 2 cases, solid in 1 case and trabecular in 1 case. Moderate to focally high grade nuclear atypia was present in all cases. Hyaline globules were seen in 3 cases. Of the staged cases, 2 were stage IA and 1 was stage IB. Of the cases with follow-up, 2 patients are alive with no evidence of disease at 5 and 8 months. One patient had a perirenal and mesenteric recurrence and is alive with disease at 14 months. Immunohistochemical results are given in the Conclusions: Keratin-associated amyloid materials (CK5 and CK14) were found to be unique in localized vulvar amyloidosis. This is probably due to leakage of keratins from the basal layer of the epithelium into the superfi cial dermis and it appears to be associated with high grade and low grade VINs and rarely in lichen sclerosus and in benign vulvar skin. It has recently been shown to be a good marker for smooth muscle differentiation. Distinguishing endometrial stromal neoplasms and smooth muscle tumors of the uterus can be challenging. Immunohistochemistry is often not helpful. Many tumors have been shown to express muscle actins and desmin. Others have failed to express markers such as h-Caldesmon and/or CD10. The goal of this study was to determine whether transgelin, a smooth muscle-specifi c marker, could accurately distinguish endometrial stromal tumors from uterine smooth muscle tumors. Design: The immunohistochemical expression of transgelin, CD10, Smooth muscle actin (SMA), Desmin, h-Caldesmon and Ki-67 was studied in 11 endometrial stromal tumors (4 low grade endometrial sarcomas, 4 undifferentiated endometrial sarcomas and 3 metastatic endometrial sarcomas) and 10 myometrial tumors (2 leiomyomas and 8 leiomyosaromas). The diagnostic performance of Transgelin was assessed in comparison to other smooth muscle markers in terms of sensitivity, specifi city and accuracy. Results: Upon assessment of the diagnostic performance, Transgelin showed diffuse and strong positivity in all myometria, leiomyomata, and leiomyosarcomas. Of interest, none of the smooth muscle tumors expressed 100% positivity with the other three smooth muscle markers at any given time, as was the case with Transgelin. In contrast, Transgelin expression was totally absent in all endometria and endometrial stromal neoplasms except within blood vessels. However, focal smooth muscle actin positivity was noticed in 2 of the 11 endometrial sarcomas, and 3 of them were negative for CD10.
Conclusions:
Transgelin has shown to be a specific marker of smooth muscle differentiation in the uterus, with 100% sensitivity and specifi city. The novel marker is useful for distinguishing myometrial from endometrial stromal neoplasms. It could be used as an additional marker for decision making, especially in those tumors with questionable histology and immunophenotypes. Background: Although clear cell renal cell carcinomas (CCRCC) are known to have an expansive group of potential metastatic sites, they only rarely involve the gynecologic (Gyn) tract. In this study, a multi-institutional dataset was analyzed to provide insights into the clinical, morphologic, and immunophenotypic features of this phenomenon. Design: 17 metastatic CCRCC (met-CCRCC) involving the Gyn tract (9 ovary/ fallopian tube, 2 vulva, 3 endometrium, 2 cervix, 1 uterine serosa) were assessed for a variety of clinicopathologic features. Their immunophenotypes were compared with 102 mullerian clear cell carcinomas (Gyn-CCC: 49 endometrial, 53 ovarian) using a panel of 9 potentially discriminatory markers. Results: The average patient age was 62.3 years (range 45-79 months). In only 1 of 17 cases -a cervical metastasis -was the gyn tract lesion the initial presentation of the renal tumor. Rather, most cases (15/17) presented as a recurrence an average of 19 months (range 6 -60) after nephrectomy. In 8 (53%) of these 15 recurrences, the Gyn lesion was the fi rst known recurrence. In 10 cases, metastases to other locations (most frequently bone and lungs) were identifi ed concurrent with, or shortly subsequent to the discovery of the Gyn tract lesion. Of the 9 adnexal metastases, only 2 were bilateral, and the average size was 3.7cm. The 2 vulvar metastases presented as ulcerative masses, whereas 5 of the 6 uterine lesions were identifi ed in samples obtained to work up abnormal bleeding. Although met-CCRCC and Gyn-CCC displayed extensive morphologic overlap, 4 statistically signifi cant morphologic differences were identifi ed: i) a diffuse nested/alveolar pattern (14/17 vs 6/102, p<0.0001), ii) mitotic index (6.3 vs 2.9, p=0.04), iii) diffuse hobnail cells (0/17 vs 67/102, p<0.0001) and iv) tubulocystic pattern (0/17 vs 55/102, p<0.0001). Seven of the 9 markers listed below signifi cantly distinguished between the 2 groups, PAX8 and HNF1 being the only exceptions. and the Glu298Asp variant (rs1799983) using real-time PCR-based Taqman allelic discrimination. Placental sections were reviewed to confi rm the absence of acute chorioamnionitis. Data were analyzed by X 2 and odds ratios were reported with 95% confi dence intervals. Results: The AGT Thr235 allele was signifi cantly more common in PTL (q=0.83) compared with negative controls (q=0.70) (OR: 2.7 [1.2-5.7], p-value=0.01). The eNOS Asp298 variant associated with preeclampsia tended be more common in the PTL group (OR=1.5 [0.6-3.7], p=0.2). The uncommon combined TT/AA haplotype (12% of cases) provided an odds ratio of 2.9 [1.0-8.3] (p=0.05) and it was more predictive of reduced placental weight and birthweight than the AGT genotype alone.
The AGT variant associated with preeclampsia is also associated with idiopathic preterm labor, consistent with our working hypothesis that these two common and serious pregnancy complications may share an underlying pathophysiology. The eNOS variant was not as predictive as AGT Thr235, but the combined AGT/eNOS haplotype appears to be more closely associated with fetoplacental growth. 
Background:
We describe the clinicopathologic features of a group of endometrial polyps that exhibited large areas of infarction, as well as scattered glands within the necrotic zones whose level of atypia prompted some consideration of the possibility of serous endometrial intraepithelial carcinoma (S-EIC). Design: 13 cases of infarcted polyps with glandular atypia (IPGA) were retrieved from our routine (4), referral (7) and consultation (2) fi les. A variety of descriptive clinicopathologic features were documented. To comparatively assess their immunophenotypic features, we performed immunohistochemical studies for p53 and MIB1 on all cases, as well as on a 27-case control group comprised of 13 consecutive endometrial polyps without infarction, 10 cases of papillary syncytial metaplasia associated with breakdown (PSM), and 4 endometrial polyps with foci of S-EIC. Results: The 13 patients with IPGA ranged in age from 41-77 years (mean 62.4). All polyps were diagnosed in biopsies or curettages. The average size of the biopsied sample was 1.9 cm (0.7-4.3). The polyps showed a distinctive pattern of isolated glands within its immunohistochemical expression in uterine mesonephric lesions as compared to endocervical and endometrial adenocarcinomas. Design: A cohort of 57 cases was selected from the archives including 31 uterine mesonephric lesions, 16 endocervical adenocarcinomas and 10 endometrial adenocarcinomas. Hematoxylin-eosin slides were reviewed and immunohistochemical staining for GATA3 was performed on the most representative section. The immunostaining pattern was recorded as: positive (nuclear staining) or negative with distribution of staining as diffuse or focal (< 20% cells) and intensity as weak, moderate or strong. Results: Thirty-one mesonephric lesions included 16 remnants, 12 hyperplasias, 1 carcinoma and 2 carcinosarcomas. All but one of them (96.7%) were diffusely positive (>95% of cells, strong, nuclear) for GATA3. One carcinosarcoma case showed focal staining (30% carcinoma cells, 5% sarcoma cells, moderate to strong, nuclear). All the endocervical adenocarcinomas were of the usual type. Of these, 75% (12 cases) were negative and remaining 25% showed focal (<20% tumor cells, weak, nuclear and focal cytoplasmic) staining. The endometrial adenocarcinoma cases included 8 endometrioid and 2 high-grade mixed carcinomas with serous component. Of these, 80% (8 cases) including 6 endometrioid and 2 high-grade mixed carcinomas were negative and remaining 20% showed focal (<10% tumor cells, weak to moderate, nuclear) staining. Conclusions: Our study demonstrates that GATA3 protein is overexpressed in mesonephric lesions, regardless of their nature (benign or malignant). Loss of GATA3 expression was seen in the majority of endometrial adenocarcinomas (both endometrioid and serous types) as well as in the majority of endocervical adenocarcinomas. Only 20% of endometrial adenocarcinomas and 25% of endocervical adenocarcinomas revealed focal staining. This pattern is very distinct from the diffuse nuclear staining pattern seen in mesonephric lesions. These results support that GATA3 immunostain can be a useful tool in differentiating mesonephric lesions from endocervical and endometrial adenocarcinomas. 
Folate Receptor Alpha Expression in Gynecologic Tumors
Results:
The most frequently positive tumor was ovarian serous carcinoma followed by ovarian clear cell carcinoma. The endocervical and endometrial carcinomas were less frequently positive compared to ovarian non-mucinous carcinomas (p <0.0001). However; of the 72 positive ovarian carcinomas, only 6 had H-score >200 and 16 had H-scores >150. The predominant pattern of staining in serous tumors was apical, with membranous present to a lesser degree. A typical apical reactivity was seen in the majority of FT. Conclusions: FRA expression is more frequent in ovarian carcinomas compared to other gynecological tumors. However, diffuse strong reactivity is uncommon, and was seen only in 8% of positive ovarian carcinoma cases. As folate receptor antibody is tested in clinical trials, we suggest that biomarker assessment with H-scoring be performed to accurately assess response and aid in optimal patient selection for targeted therapy in the future. The preferential expression of FRA for the serous subtype and fallopian tube in combination with the apical staining pattern also provides further evidence supporting FT origin of high grade ovarian serous carcinomas. Results: Pt ages ranged from 30-74yo (median 53). Clinical presentation was known in 12 pts: abnormal vaginal bleeding (8 pts); urinary symptoms (3 pts); uterine mass (3 pts); abdominal distention (2 pts). Tumor size, known in 10 pts, ranged from 7 to 22.5 cm (median 13) with stage known in 13 pts: 3 Stage I; 0 Stage II; 4 Stage III; 6 Stage IV. 11 pts had documented metastases (mts): 4 lung, 4 abdomen, 2 pelvis, 1 liver. Biopsy of a lung mt in 1 pt showed mt of the HE. Follow up from 2 to 55 months was available for 12 pts: 10 dead of disease; 2 alive with disease. Tumor characteristics for each pt are summarized in Table 1 Conclusions: All HE in SMT occurred in the background of conventional leiomyosarcoma. Clinical presentation and course are similar to conventional LMS. Most HE are malignant, but rarely may be benign. Bone HE were most frequent in this series followed by rhabdomyosarcoma. Recognition of HE in SMT is important to avoid mischaracterization of tumor type and origin given the HE may be the sole or dominant element in subsequent metastases. (25) were subjected to IHC for several proteins, found to be differentially expressed between EEC and NEEC by cDNA and protein analysis: p53, p16, ER, cytoplasmic and nuclear PTEN, IMP2, IMP3, HER2, Cyclin B2 and E1, HMGA2, FolR1, MSLN, Claudin 3 and 4, NRF2. IHC values ranged from 0 to 300, according to intensity and percentage of positive cells. First, differential expression was assessed with a Mann-Whitney test. Second, for each signifi cant protein, a conditional threshold in the IHC value scale was determined to discriminate between EEC and SC, using the Gini index, assessing its signifi cance with a logistic regression model. Third, signifi cant proteins in the models were selected to defi ne a signature based in the number of satisfi ed conditions. A convenient minimum number of conditions was established to predict the sample type. The usefulness of this classifi er was checked in two TMAs composed of EEC grade 3 (33 cases), and mixed EEC-SC (both components) (9 cases). Results: Nine biomarkers showed signifi cant differences between EEC 1-2 and SC, defi ning for each one a conditional threshold in the IHC value for predicting SC against EEC 1-2 (p53>35, IMP2>110, IMP3>0, Cyclin E1>215, HMGA2>15, FolR1>50, p16>150, nuclear PTEN>0 and ER<50) (p-values<0.005). All 9 conditions were then combined, specifi cally considering those cases satisfying 0 to 5 conditions (predicted as EEC) respect to those satisfying 6 to 9 conditions (predicted as SC). This discriminating rule correctly predicted all EEC 1-2 cases and 22 SC cases, but 3 SC cases were wrongly predicted as EEC. Sensitivity was 100% (CI: 89%-100%) and specifi city was 88% (CI: 69%-97%). This prediction rule also identifi ed all 33 EEC 3 cases, as EEC, but only identifi ed correctly the EEC and SC components in 4 out of 9 mixed EEC-SCs. Conclusions: Several proteins are differentially expressed between EEC 1-2 and SC, as single markers. Combination of these markers correctly identifi ed all 46 EEC 1-2, most SC (22 of 25), and all 33 EEC 3 cases. However, expression in mixed EEC-SC was complex, suggesting that they have ambiguous IHC features, regardless of the morphological appearance of the different components. INK4 IHC was performed. Distribution of expression was interpreted as negative, focal/sporadic, diffuse lower half of epithelium, or diffuse upper half to full thickness of epithelium. Follow-up cervical pathology data (1-7 years) was collected through the electronic pathology database. Current disease status was documented as: follow up diagnosis higher grade than primary ("progression"); follow up diagnosis equal grade as primary ("persistence"); and follow up lower grade than primary ("regression"). Treatment with LEEP excision within 1 year of primary diagnoses was also documented. Cases without follow up were excluded. Statistical analysis included Chai-squared tests.
p16INK4 expression in primary pre-neoplastic cervical biopsies and subsequent long term follow up.
All Lesions (n=134)
Progression (n=7; 5%)
Persistence (n=8; 6%) Regression (n=119; 89%) INK4 IHC is not predictive of long-term disease progression. As several previous studies have found, the majority of HG lesions ultimately regressed in long-term follow up. many putative MERT may represent instead ES of proximal type (PT-ES). However, as compared to ES, MERT is less often keratin or CD34-positive, and shows SMARCB1 mutations as compared to homozygous deletions in ES. We studied 5 vulvar tumors classified as ES or MERT for SMARCB1 abnormalities with the goal of better understanding the proper classifi cation of these lesions. Design: Five cases previously coded as "ES" (2 PT-ES, 2 classical ES (CT-ES)) or "MERT" (1) involving the vulva were retrieved from our archives. Cases classifi ed as ES showed pleomorphic epithelioid morphology and strong keratin and CD34 expression. The case classifi ed as MERT showed small cell/rhabdoid morphology and weaker expression of keratin and CD34. Cases were tested for SMARCB1 abnormalities by multiplex ligation-dependent probe amplifi cation (MLPA). Tumors with heterozygous deletions were analyzed by Sanger DNA sequencing to identify SMARCB1 coding region mutations. Results: Follow up was available for 4 of 5 patients (range 4-40 months, mean 14). 3 patients were alive with disease and 1 was without evidence of disease at last follow up. Immunohistochemical fi ndings are summarized in Table 1 . MLPA and sequencing results are summarized in Table 2 . In women who wish to preserve fertility, or who are not candidates for hysterectomy, myomectomy is an alternative and increasingly common method of treatment. Classifi cation of most uterine SMTs is straightforward though a minority present a signifi cant diagnostic dilemma. Surgical myomectomy, or recent hormone therapy, may aggravate these diffi culties. The behavior of atypical leiomyomata treated by myomectomy has been investigated, but reports are few. Outcomes of other problematic uterine SMTs after myomectomy are also unclear. Design: We searched our institutional archives for uterine SMTs removed via myomectomy between the years 1980 and 2013. We included cases diagnosed as atypical leiomyoma (AL; either of low risk of recurrence, symplastic, or of limited experience), smooth muscle tumor of uncertain malignant potential (STUMP), leiomyosarcoma (LMS), and uterine SMTs shared intra-departamentally as documented in the diagnostic report. All HE-stained sections were re-examined. Relevant clinicopathological data were recorded. Special attention was given to necrosis which was assigned into 4 categories: none, ischemic/hyaline necrosis, coagulative tumor cell necrosis (CTCN), or uncertain. Results: Our search yielded 1161 cases, 26 of which constituted our fi nal study group with a mean follow-up of 150 weeks (range 4-642) and mean age of 37 years (range 24-62). There were 15 AL (58%), 8 STUMP (31%), 2 LMS (8%), and 1 apoplectic leiomyoma (4%). Recent hormone therapy existed in 13 (50%). Cases of AL showed few mitoses/10hpf (mean 2, range 1-6), focal/multifocal severe atypia (13, 87%), but no CTCN, while LMS patients had numerous mitoses (mean 18), diffuse atypia (100%), and CTCN (100%). Uncertainty in type/extent of necrosis often resulted in a STUMP designation (5 patients, 63%), which may have been complicated by prior hormone use. Of the 26 cases, 1 patient died of disease (LMS), 1 is followed for atypical but likely benign liver lesions (AL), and 24 are alive with no evidence of progression. Conclusions: Uncertainty in the type/extent of necrosis was over-represented in cases diagnosed as STUMP, and was likely complicated by recent hormone therapy rather than sampling. Nevertheless, existing classifi cation schemes accurately predicted tumor behavior. Appreciation for changes associated with prior hormone therapy, particularly those related to necrosis, may be of help in challenging cases. -3) , mitoses/10 high power fi elds (MI), coagulative tu cell necrosis (CTCN), tu/myometrial interface, lymphovascular invasion (LVSI), % clear-cell component, hyalinization and follow-up (f/u). Results: Pts' ages ranged from 27 to 88 yrs (median 44) with 3.5 to 171 months f/u (median 64) for 28 patients. Six had a diagnosis of epithelioid leiomyoma (eLM), 13 of ESMTs of uncertain malignant potential (eSTUMP), and 16 of epithelioid leiomyosarcoma (eLMS). Tu stage was known for 34 pts: I, 25; II, 0; III, 5; IV, 4. Tu size ranged from 1.3-21 cm (median 8 cm) with a median EC of 90%. Thirteen (37%) ESMTs had grade 3 nuclear atypia. Median MI for eLMS was 12/10hpf. 10 tu (29%) had CTCN and 9 (26%) had an infi ltrative tu borders/myometrial interface. LVSI was present in 7 (20%) ESMTs. 20 (57%) ESMTs had hyalinization which was prominent in 6 tu. 19 (54%) ESMTs had clear cells (<10% to 75% of the tu). Of the eLMS patients: 7 died of disease (DOD); 8 were alive, disease status unknown (ADU); 3 were alive with disease (AWD), 10 had no evidence of disease (NED Conclusions: LAST recommends p16 to improve the detection of HSIL and thus high SN and PPV are required. 16P04 and JC8 clones perform as well or better than E6H4. However, the prevalence of HSIL was lower in the CINtec group (34%) than the 16P04 (58%) and JC8 (45%) groups (p<0.0002) which could affect PPV and NPV. Limitations of this analysis include variation in sampling, processing, defi nition of p16+ and threshold for HSIL diagnosis. Further studies should be undertaken to directly compare the widely used E6H4 clone with 16P04 and JC8. The precursor lesion of HPV-negative vulvar squamous cell carcinoma, differentiated VIN (dVIN), frequently shows aberrant p53 immunostaining. In 30% of cases it manifests as a complete loss or p53-null pattern. This allows clear demarcation between neoplastic p53-null and non-neoplastic squamous epithelium, with the latter exhibiting wild type (patchy basal) p53 expression. Design: 14 cases, from 10 patients, were identifi ed from pathology archives of two teaching hospitals based on: 1. presence of dVIN, with or without invasive carcinoma, and 2. p53-null immunostaining pattern. 10 cases had associated invasive carcinoma. All sections from each case were stained for p53 and reviewed together with all HE sections. The status of the resection margins based on the original pathological assessment was compared to that assessed with p53 IHC. Results: One case showed p53 loss in the invasive carcinoma but patchy basal positivity in the region diagnosed as dVIN, supporting interpretation as a benign hyperplastic focus, rather than dVIN. In the remaining 13 cases, the areas originally diagnosed as dVIN, as well as associated invasive carcinoma (if present) were p53-null. In 7 of these cases, dVIN was more extensive than originally recognized, based on p53-null immunostaining pattern and subtle morphological abnormalities. In the remaining 6 cases, the regions diagnosed as dVIN correlated well with the extent of p53 loss. The spectrum of morphological changes in p53-null regions that were in continuity with areas originally recognized as dVIN were subtle and typically consisted of an abrupt change in maturation of the squamous epithelium (loss of keratohyaline granules and parakeratosis), tinctorial alterations in the keratinocytes, with cells containing more abundant eosinophilic cytoplasm, and minimal basal nuclear atypia. Margin status changed from negative to positive in 4 of 13 cases, and from focally to more extensively positive in an additional 3 cases. Conclusions: The clonal in situ component of non-HPV vulvar squamous cell carcinoma can show very subtle morphological abnormalities that are under-recognized based on current diagnostic criteria. As a result, resection margin involvement by dVIN is signifi cantly underestimated. Better tools for diagnosis of dVIN are needed; until such tools are developed the limitations in the current diagnosis of dVIN should be recognized. Background: There is increasing evidence that different ovarian carcinoma histotypes show different responses to treatment, and this has lead to histotype-specifi c treatment algorithms. As a result, there is a premium on accurate ovarian carcinoma histotype diagnosis. Although the gold-standard for ovarian carcinoma diagnosis is examination of the resection specimen, in some clinical settings patients may start on treatment or be enrolled in a clinical trial based on a core biopsy or cytology specimen, however the accuracy of diagnosis based on these more limited samplings is not known. Design: We prospectively collected 30 cases of adnexal mass identifi ed by the surgeon as highly being suspicious for carcinoma. We performed aspiration and prepared Thinprep smears, took core biopsies, and prepared frozen sections. The 3 study pathologists were asked to place each ovarian tumor into one of six categories (high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, mucinous carcinoma, clear cell carcinoma, or other) based on each of these samples. For the core biopsy specimens, the reviewing pathologists permited to order immunostains. These diagnoses were compared to the diagnosis made on the resection specimen. Results: Diagnoses were most accurately made based on the core biopsy specimens, with the three pathologists making correct diagnoses in 25/29, 26/29 and 26/29 cases. Immunostains were requested in 7, 9 and 9 cases, respectively. Based on frozen sections, the pathologists were able to correctly classify 24/30, 25/30 and 25/30 cases. None of the study pathologists were able to consistently subclassify tumors based on the liquid-based cytology slides. Five cases accounted for a large majority of the diagnostic errors: 2 high-grade serous carcinomas, one with exclusively glandular architecture, and another with prominent fi bromatous stromal reaction (misdiagnosed as carcinosarcoma), an endometrioid carcinoma with higher grade nuclear features, a metastasis from a primary endocervical adenocarcinoma, and a poorly differentiated adenocarcinoma lacking features of specifi c histotype differentiation. Conclusions: Accurate diagnosis of ovarian carcinoma histotype is possible in most cases, based on either core biopsy or frozen section. There is potential for improved diagnostic accuracy based on awareness of problematic areas in differential diagnosis identifi ed through this case series. Background: Uterine smooth muscle tumors of uncertain malignant potential (STUMP) have variable pathological features and recurrence rates, which results in considerable treatment uncertainty. New prognostic markers are required. Alternative lengthening of telomeres (ALT) maintenance is associated with poor survival in some soft tissue leiomyosarcomas (LMS). ALT maintenance is related to mutations in ATRX (-thalassemia/mental retardation syndrome X-linked) and DAXX (death-domainassociated protein) genes and their respective proteins are involved in remodelling of chromatin structure. ALT maintenance also produces extremely long protein structures ALT-associated PML bodies (APB). Design: 40 LMS, 17 STUMPs, and 10 leiomyomas (LM) were studied and follow-up data obtained. They were screened for APBs by immunofl uorescent study (anti-PML, H-238, Santa Cruz). Telomere DNA was detected using a Cy3-labelled PNA probe (Life Technologies, Carlsbad). APB positive occur when when both PML protein and telomeric DNA are seen in the nucleus in≥ 0·5% of cells. Immunohistochemistry was done with ATRX and DAXX antibodies (respectively HPA001906  HPA008736 Sigma-Aldrich, St Louis). Staining in <10% of nuclei were considered loss of expression. p53 (DO-7, Cell Marque) was also done. Results: Mean patient ages and tumor sizes for LMS, STUMP and LM were respectively 49.5, 44.1 and 50.4 years, and 10, 8.5, and 3.5 cm. Recurrence/death was seen in 35% (6/17) STUMPs and 60% (24/40) LMS. No LMs recurred. For STUMPs, 24% (4/17) were APB+ve and 30% (5/17) overexpressed p53. Loss of staining for ATRX and DAXX was seen in 30% (5/17) and 12% (2/17), respectively. For LMS, 40% (16/40) were APB+ve and 42% (17/40) overexpressed p53. Loss of staining for ATRX and DAXX was seen in 58% (23/40) and 15% (6/40), respectively. All 6 STUMPs and 92% (22/24) LMS followed by recurrence/death showed loss of ATRX or DAXX expression. 60% (17/28) of these cases with adverse outcome were also APB positive. Overexpression of p53 (p=0.001) and loss of ATRX and/or DAXX expression (p<0.05) were associated with a poor outcome. Conclusions: Loss of ATRX or DAXX expression in uterine smooth muscle tumors identifi ed a clinically aggressive molecular subtype. Background: Vulvar dermatofi brosarcoma protuberans (DFSP) is a rare malignancy of fi broblastic lineage. Its occurrence in the vulva is poorly defi ned with fewer than 30 cases described in the literature. DFSP is known to undergo sarcomatous transformation and to harbor a characteristic COL1A1/PDGFB fusion. However, both events are limited to single case reports in vulvar tumors. Our study aimed to expand the clinical, morphologic and molecular genetic description of vulvar DFSP by compiling the largest series to date of genetically analyzed tumors. Design: Eight cases were retrieved from the institutional archive. Each was reviewed for its clinical history and histologic features. All cases were immunohistochemically stained with antibodies to CD34, p53, desmin and SMA. FISH was performed on formalin-fi xed paraffi n-embedded sections utilizing a laboratory developed break apart probe for PDGFB (at 22q12.3-13.1). Performance and interpretation of interphase FISH was done according to a validated protocol. Results: Patient age ranged 29-75 years (median 49). Six tumors showed classic DFSP, 1 tumor exhibited complete fi brosarcomatous transformation and 1 case comprised classic DFSP transitioning to undifferentiated pleomorphic sarcoma (UPS). All cases of classic DFSP exhibited diffuse positivity for CD34 and patchy, weak positivity for p53 and were entirely negative for desmin. SMA showed patchy positivity in 2 cases of classic DFSP with focal myoid differentiation. In contrast, 2 cases containing sarcomatous transformation showed weak or negative CD34 and strong p53. Six cases including the fi brosarcomatous case were positive for PDGFB rearrangement and two were negative. The case of classic DFSP transitioning to UPS contained additional intact PDGFB fusion signals, possibly indicating additional copies of chromosome 22 or duplication of the gene region. Follow up was available for 6 patients and ranged 1-108 months (median 20). All patients were free of disease at last follow up. Conclusions: DFSP of the vulva is a rare sarcoma of intermediate malignancy similar to its cutaneous counterpart. Fibrosarcomatous transformation may occur in a subset of cases and demonstrates a distinct morphologic and immunohistochemical profi le. COL1A1/PDGFB fusion is detectable in a majority of tumors including those with sarcomatous overgrowth. Copy number gain of PDGFB has been proposed as a marker of progression to fi brosarcomatous transformation in DFSP of other sites. To our knowledge, this is the fi rst description of this fi nding in the vulva.
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Silencing HPV16 E6 Oncogene in a Cervical Cancer Cell Model IS Soyingbe, CD Spillane, CM Martin, JJ O'Leary. Trinity College Dublin, Dublin, Ireland; The Coombe Women  Infants University Hospital, Dublin, Ireland. Background: Human papillomavirus (HPV) infection is the major risk factor for development of cervical cancer. HPV16 and 18 are two leading high-risk types that account for about 70% of cervical cancers. Genomic integration with host is a characteristic event in high risk types as it defi nes the basis for cervical cancer pathogenesis via overexpression of oncogenic E6 and E7. High risk HPV E6 is transcribed as spliced polycistronic transcripts E6, E6*I, E6*II. E6 and E7 subvert normal cellular functions via interactions with tumour suppressor genes p53 and Rb respectively. In this work, short interfering RNAs (siRNAs) were utilized to ablate E6 activity in a HPV 16 infected cell line to acquire a better understanding of the role and mechanism of action of E6. Design: SiHa cells containing 1-2 copies of HPV16 per cell was the in-vitro cervical cancer cell model system of choice. Five siRNAs targeting varying regions and isoforms of HPV16 E6 were utilized. Cells were forward transfected using Lipofectamine RNAiMax in 6 well plates for 72hours and knockdown levels were assessed. Results: Over 70% reductions in E6 and E7mRNA levels were achieved in 4 out of the 5 siRNAs. A 2-10 fold increase in p21-downstream biomarker levels in all of the siRNAs compared to the controls. Knockdowns were validated at protein level by evaluating p21, p53 and pRb protein levels via western blot analysis. Other analyses used in examining the effect of E6 silencing in all knockdowns included senescence activation, morphology, apoptosis induction and cell cycle using fl ow cytometry. Conclusions: This work illustrates the usefulness of siRNAs as molecular tools to silence effects of oncogenic HPVs in cervical cancer. This approach revealed that the targeting of varying regions in full length E6 and its isoforms yields different responses. The uncoupling of such responses will assist in elucidating the molecular mechanism involved in oncogenic subversion in cervical cancer and facilitate the development of novel therapies for cervical cancer. 
Background:
The SEE-FIM protocol for detailed evaluation of the fallopian tubes is routinely employed in cases of risk-reduction salpingo-oophorectomy specimen for identifi cation of precursor lesions of ovarian high grade serous carcinomas. The aim of this study was to evaluate this protocol in sporadic pelvic serous carcinomas in comparison to borderline and benign surface epithelial neoplasms and normal controls. Design: The SEE-FIM protocol was employed prospectively to evaluate 37 cases of high grade pelvic serous carcinoma, seen between January 2012 to March 2013; 56.25% cases had received neoadjuvant chemotherapy. Other groups included normal age-matched controls (10), benign (10) and borderline (6) surface epithelial tumors. Putative precursor lesions including Secretory Cell OUT growths (SCOUTs), p53 signatures and Serous tubal Intraepithelial Carcinoma (STIC) were evaluated by immunohistochemistry for Bcl-2, p53 and Ki-67. The SCOUT index was derived from the SCOUT counts. Results: A total of 668 sections from the proximal and distal fi mbrial fallopian tubes were evaluated morphologically. Precursor lesions: The SCOUT count and index was higher in serous carcinomas as compared to the other groups. It was higher in the fi mbrial end as compared to the proximal tube irrespective of the group. In serous carcinomas, SCOUT index in proximal tube was 0.8 and ratio of SCOUTs in the fi mbrial/ cross section was 2.12:1. p53 signatures were always seen in the tubal fi mbrial end. p53 signatures were observed in 21/32 (65.6%) cases of serous carcinoma as compared to 3/10 (30%) controls; it was not observed in benign and borderline surface epithelial tumors. STICs were seen only in the fi mbrial end of serous carcinomas and not in any other groups and were more common in the ipsilateral tubes of the serous carcinomas with ovarian origin as compared to tumors with peritoneal origin. STIC lesion was present with an invasive carcinoma component in 25% cases in the fi mbrial end and without an invasive component in 6.25% cases of pelvic serous carcinomas.
Conclusions:
The distal fallopian tubal fi mbrial epithelium shows invasive serous carcinoma as well as its precursor lesions highlighting the importance of its detailed evaluation by the SEE-FIM protocol in cases of non-familial pelvic serous carcinoma.
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Villoglandular Endometrioid Carcinoma with Squamous and Mucinous Differentiation and MELF-Type Invasion: Association with Lymph Node Metastasis, and with Microsatellite Instability P Stephenson, V Samouelian, K Rahimi. Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Université de Montréal, Montréal, QC, Canada. Background: Low-grade, stage IA endometrioid carcinoma is considered to have a low risk of lymph node metastasis. In our institution, we noted an association between a peculiar morphologic type of low-grade endometrioid carcinoma (with villoglandular architecture, focal mucinous and squamous differentiation, intra-tumoral infl ammation and microcystic elongated fragmented (MELF) type invasion) and lymph node metastases, sometimes with isolated tumour cells. We hypothesized that the variegated features of these tumors may be related to genetic instability due to microsatellite instability (MSI). Design: Cases of low-grade endometrioid carcinoma with the features described above were identifi ed. Clinical information was obtained from medical records, and pathologic data were obtained from the gross descriptions and review of HPS-stained slides. Immunohistochemical staining was performed for MLH1, PMS2, MSH2 and MSH6 expression; if expression of any of these was lost, molecular analysis was performed to confi rm microsatellite instability. In cases with loss of MLH1 and PMS2 staining, molecular testing for MLH1 promoter hypermethylation was performed. Results: Thirteen cases were identifi ed in one year. In all but one case with lymph node sampling (11/12), lymph node metastases were observed, in one of two patterns: isolated histiocytoid tumor cells; or scattered metastases, with innumerable isolated tumor cells, as well as discrete glands. In over of half of the cases (7/13), loss of staining for one or more mismatch repair proteins was found, and microsatellite instability confi rmed. Six were due to MLH1 promoter hypermethylation, and one was due to inactivating mutation of MSH6. Conclusions: Cases of endometrioid carcinoma with villoglandular architecture, focal mucinous and squamous differentiation, intra-tumoral infl ammation and MELF-type invasion were associated with lymph node metastases, even when only superfi cially infi ltrative. Moreover, these cases show a high proportion of MSI. Background: HLRCC syndrome is an autosomal dominant disorder resulting from mutations in the fumarate hydratase gene which predisposes patients to cutaneous and uterine smooth muscle tumors as well as renal cell carcinoma. The latter is often aggressive and can present in young patients. Uterine leiomyomas (ULs) are more common, and their recognition may offer an opportunity to identify patients with HLRCC. Recently, the histological features of HLRCC ULs have been described, however, the specifi city and sensitivity of these features is not known. The aim of this project was to compare the frequency of previously described HLRCC features in ULs of patients with known HLRCC syndrome to those in patients with sporadic ULs. Design: 4 patients with known HLRCC and ULs, and 100 patients under the age of 41 with no personal or family history of HLRCC syndrome and ULs (multiple with at least one≥ 3 cm or solitary≥10 cm) were identifi ed. The following tumor pathological features were assessed: tumor number and size, cellularity, mitotic activity, nuclear enlargement, and presence of prominent nucleoli and perinucleolar clearing. Results: The clinical and pathological features of 4 HLRCC ULs and 100 presumed sporadic ULs are summarized in Table 1 . Increased cellularity (8%) and focal cells with prominent nucleoli and perinucleolar clearing (67%) were commonly found in sporadic ULs The most distinguishing characteristic of HRLCC ULs compared to sporadic ULs was the presence of diffusely distributed cells (5-10%) with a combination of both enlarged (3x) nuclei with irregular contours and eosinophilic nucleoli with perinucleolar clearing. These features were identifi ed in 100% of HRLCC and 3% of presumed sporadic ULs. Conclusions: Recognition of specifi c morphologic features in ULs may identify patients who can benefi t from genetic testing for HLRCC syndrome. If subsequently diagnosed, these patients and their family members can be followed by renal cancer surveillance programs. 
Background:
The MET receptor is a specifi c tyrosine kinase receptor for hepatocyte growth factor ligand and has been identifi ed as a target for molecular therapy. However, there are only a few recent papers that report MET expression in endometrial carcinomas, and it has not yet been well examined in uterine carcinosarcoma(CS). The aim of this study was to investigate MET protein overexpression and alterations in its gene copy number in the carcinomatous component(CAC) and sarcomatous component(SAC) of CS, acquire insights on the genesis and clonal divergence of both these components and contribute information that could lead to potential molecular therapies for treating CS. Design: Representative paraffin-embedded tissue blocks were collected from 52 surgically -resected consecutive cases of uterine CS, (30 homologous and 22 heterologous). Tissue microarrays including CAC and SAC and adjacent endometrium were constructed for each case. MET protein overexpression was examined using immunohistochemistry and defi ned as moderate to strong circumferential membrane staining in≥ 10% of the constituent cells. MET gene copy number alterations were examined using brightfi eld double in situ hybridization (DISH) and classifi ed into high-level polysomy and MET gene amplifi cation. Results: MET protein overexpression was detected in 34 cases (65%): CAC only in 25, SAC only in 1, both in 8. High-level MET polysomy was present in 11 cases (21%): CAC only in 3, SAC only in 5, both in 1. True MET gene amplifi cation was detected in 5 (9.6%) and was always detected in SAC in heterologous type. MET protein overexpression and MET gene amplifi cation were double positive in 6 (12%) and 3 (5.8%) of CAC and SAC, respectively. In the adjacent endometrial tissue, MET gene alterations were not detected. Conclusions: MET protein overexpression and MET gene amplifi cation were frequently observed in uterine CSs, but their status was frequently discordant between the CAC and SAC. A large part of MET protein overexpression appeared to occur through a mechanism other than MET gene copy alteration. In heterologous CS, it was speculated that the SAC frequently occur through clonal divergence in accompanied with MET gene amplifi cation. Molecular target therapy for the MET receptor may become a viable treatment option for patients with CS with MET protein overexpression and/or MET gene amplifi cation. Background: Uterine sarcomas are aggressive neoplasms classifi ed in three groups according to their origin: endometrial stromal tumors, smooth muscle tumors and miscellaneous mesenchymal tumors. The only recognized prognostic factor so far is the pathological staging. The purpose of this study is to determine whether there are any alteration of the cell signaling pathways and some of the factors associated with invasion such as YB that may be related with outcome. Design: 75 cases between 1998 and 2013 were selected from our archive: 11 smooth muscle tumors of uncertain malignant potential (STUMPS), 22 endometrial stromal sarcomas (ESS), 15 undifferentiated sarcomas (UES) and 17 leiomyosarcomas (LMS). 10 leiomyomas (LS) were used as control. Clinical follow-up data was obtained by review of hospital records, obtaining a mean follow-up of 152.47 months. Immunohistochemical stains were performed using tissue microarrays. Biomarkers studied comprise: eIF4E, peIF4E, 4E-BP, p4E-BP, 4E-T, pMapK, YB1, pYB1, HER3, mTOR, pS6, GLUT1. In addition, Ki67, CD10, p16 and hormonal receptors immunostains were also performed as routine. Results: High grade uterine sarcomas overexpress eIF4E, peIF4E, 4E-BP, p4E-BP, 4E-T, pMapK, YB1, pYB1, pS6 and GLUT1 when compared to low grade neoplasms (p<0.05). p4EBP expression was the only marker studied which differed amongst LMS and UES (p<0.05). Smooth muscle tumors (LS, STUMPS, LMS) expression of cell signaling markers is different between groups (p<0.05), with GLUT1, peIF4E, 4E-BP and YB1 being overexpressed comparing LS to STUMPS (p<0.05), whereas eIF4E, pMapK, pYB1 and pS6 are also overexpressed comparing LS to LMS. UES had a higher expression of eIF4E, 4E-T, 4E-BP, p4E-BP, YB1, pYB1, GLUT1 and pS6 compared to ESS (p<0.05). Among all cell signaling markers, YB1 overexpression in high grade sarcomas is related to lower survival times (Log rank p<0.05). Conclusions: High grade uterine sarcomas overexpress most signaling markers, regardless of their nature. Interestingly, among them YB1 overexpression has been associated with lower survival times. In the smooth muscle uterine tumors we have observed a gradual increasing expression of those markers along with malignant potential. Moreover, STUMPS are closer to LMS according to their expression. Given the aggressive nature of these tumors, and the overexpression found in those cell signaling pathways, which can be druggable, further studies are required to assess its possible therapeutic value. Background: Based on the current WHO classifi cation and Stanford scheme, uterine smooth muscle tumors (USMT) can be classified as usual leiomyoma (ULM), mitotically-active leiomyoma (MALM), cellular leiomyoma (CLM), atypical leiomyoma (ALM), uncertain malignant potential (STUMP) and leiomyosarcoma (LMS). Aside from ULM and LMS, the nature of the other variants is largely unknown and remains a challenge for diagnosis and management. In this study, we evaluated the histologic correlation and clinical follow-up in those problematic USMT. Design: We reviewed the pathology database over the last 20 years at two institutions to retrieve 127 patients with a diagnosis of LMS or one of the USMT variants. Each case was reviewed by two pathologists to confi rm the diagnosis based on Stanford scheme and histologic criteria were documented. Each patient's chart was also reviewed up to June 2013 to document the original treatment, additional follow-up, current disease status and survival. The histologic and clinical outcomes were then compared. Results: Among the original diagnoses of 127 problematic USMT, 18% (23/127) of cases were reclassifi ed, indicating a common problem in rendering a defi nite diagnosis. Five ALM and 7 STUMP were misclassifi ed due to subjective mitotic counts. Eight CLM were initially diagnosed as ALM due to mild cytologic atypia and 6 MALM were called ALM due to frequent mitoses. (Table 1 ) Among the 127 cases, 84 cases were reviewed clinically via chart review and included 38 LMS, 30 ALM, 12 CLM, 1 MALM, and 3 STUMP. Clinical data for the remaining cases from the other institute is still under review. Patients' follow-up ranged from 12 months to 230 months. Of 38 LMS, 18 died with metastatic disease, 1 died without LMS, 4 were alive with LMS, and 13 were alive without LMS. Two patients were lost to follow-up. Of the other USMT variants, no deaths were attributed to USMT, but 1 STUMP and 2 ALM had recurrence. (Table 1 Background: Uterine smooth muscle tumors (USMT) consist of a group of histologically heterogeneous tumors. While benign leiomyoma (ULM) and malignant leiomyosarcoma (LMS) are well-defi ned, the relationship to other histologic USMT variants, including mitotically-active leiomyoma (MALM), cellular leiomyoma (CLM), atypical leiomyoma (ALM), and borderline tumors (STUMP), is largely unknown. Thus diagnosis often remains a challenge. In this study, we selected relevant IHC markers and investigated their value in the diagnosis of USMT variants. Design: We collected 111 cases with a diagnosis of either LMS or another USMT variant. The cases included 38 LMS, 13 STUMP, 27 ALM, 18 CLM, 7 MALM, and 8 ULM. Tissue microarrays with 2 mm cores were prepared and immunohistochemical (IHC) stains for 17 markers were performed, including Bcl-2, CD24, C-Kit, EGFR, ER, Fascin, HMGA2, Ki-67, PR, p16, p21, p53, pAKT, PTEN Rb, PS6, and RBL2. The IHC stains were analyzed blindly using a two-tiered scoring system and the results for each IHC and USMT subtype were statistically analyzed.
Results:
The immunoprofi le of all 17 markers revealed that LMS clustered together. The markers that were signifi cantly different between LMS and other variants included ER, PR, Bcl-2, p16, p21, p53, and Ki-67. When we removed PR, 70% of ALM aggregated with LMS. Interestingly, ALM shared several oncogenic markers with LMS, including p16, p53, Bcl-2, and Fascin (Figure 1 ). However, ER and PR clearly separated LMS from ALM. In contrast, STUMP had wide range of immunoreactivity for these markers. PR had 0% staining for 1/27 ALM and 32/38 LMS. ER had a similar pattern to PR, but not as dramatic. P16 had a high percent and intensity staining for 15/27 ALM and 30/38 LMS. The other USMT subtypes were mostly negative, including STUMP. P53 had a similar pattern with 2 diffusely positive ALM and 9 LMS.
Conclusions: LMS showed a characteristic immunoprofi le different than other USMT variants. ALM shared several oncogenic IHC markers with LMS, including Bcl-2, Fascin, p16 and p53. However, LMS could be clearly separated from ALM by ER, PR and Ki-67. All other USMT variants could not be easily distinguished from each other using the selected IHC markers. Results: Out of 73 cases, 48 were diagnosed as benign, 18 as borderline and 7 as primary malignant or metastatic at the time of FS evaluation. Of 48 cases interpreted as benign at FS, 9 were borderline and one was malignant. Of 18 cases diagnosed as borderline in FS, 5 showed invasion on additional sections and were signed out as malignant. All of ovarian primary or metastatic mucinous neoplasms were accurately diagnosed. Overall, the agreement between FS interpretation and fi nal diagnosis was observed in 58 out of 73 cases (79%). Average sizes for the accurately diagnosed benign, borderline and malignant tumors were 12.0 cm, 19.0 cm, and 17.0 cm retrospectively. In the accurately diagnosed MBTs, 3 frozen sections were submitted for evaluation in 11 out of 13 cases (85%). Underdiagnosed MBTs (9 cases) were 24.0 cm in average size with complex multiloculations and solid components. In 7/9 (78%) cases, only 2 frozen sections were submitted for evaluation.
Frozen Section Guidelines for the Evaluation of Mucinous
Conclusions:
Multiple prior studies have shown that inaccurate FS diagnosis occurs more commonly with MT, specifi cally MBT. This discrepancy is likely due to the larger diameter and heterogeneity of these tumors. Moreover, multiple sections of the most complex appearing foci of tumor can possibility decrease the discrepancy. Also, consultation with a gyn pathologist at the time of frozen section is helpful. We suggest that 3 sections of the MTs that are 20 cm or larger should be examined at the time of FS. These sections should be taken from the solid and most complex foci of the tumor. Based on our fi ndings, this approach can decrease the possibility of sampling errors and rates of false negative FS diagnosis. Occasionally, LEEP specimens are negative for dysplasia or show low grade squamous intraepithelial lesion. Our goal is to compare 2-year follow-up results of patients with negative or positive LEEP and to determine which factors predict the likelihood of a negative LEEP. Design: Total 697 LEEP specimens at our institution between 2009 and 2012 along with detailed patient demographics, high risk HPV status, prior cytologies and biopsies, colposcopic fi ndings, and follow-up cytology results within two years were studied. Results: HGSIL was identifi ed in 525 specimens (75%, Positive LEEP) but not in the remaining 172 cases (25%, Negative LEEP). HRHPV for patients with negative LEEP was positive in 38%, equivocal in 6%, negative in 9%, and unknown in 47% of cases. For patients with positive LEEP, HRHPV was positive in 49%, equivocal in 3%, negative in 7% and unknown in 41% of cases. Prior biopsy and cytology results are shown in table 1. Colposcopic fi ndings at the time of LEEP are shown in table 2. Most of these patients were followed by cytology for two years. Among 154 patients with negative LEEP, 6 (4%) had recurrent HGSIL, 15 (10%) had ASCUS/LGSIL, and 133 (86%) had negative cytology. Among 420 patients with positive LEEP, 58 (14%) had recurrent HGSIL, 73 (17%) had ASCUS/LGSIL, and 289 (69%) had negative cytology.
Target HGSIL is present in 75% but absent in 25% of LEEP specimens. We have shown that negative LEEP is commonly associated with equivocal HRHPV, prior negative or low grade biopsy, and no lesion or LGSIL on colposcopic examination. Compared to patients with positive LEEP, negative LEEP patients do not show higher risk of persistence/recurrence (4% vs 14%). Therefore patients with positive or negative LEEP could be managed similarly and followed with regular cytology. Background: The L1 cell adhesion molecule (L1CAM) is a 200-220kDa membrane glycoprotein of the immunoglobulin superfamily whose expression has been shown to be related to epithelial-mesenchymal transition (EMT). Recent studies have found that activation of EMT pathways eventuate in increased cellular plasticity, 'stem cellness' and tumorigenicity. The purpose of this study is to evaluate the role of L1CAM expression and related EMT and stem cell phenotypes in the pathogenesis of endometrial clear cell carcinoma (CCC). Design: 54 CCC, 17 endometrial serous carcinoma (ESC), and 49 endometrioid carcinomas (EEC; 18 G1, 19 G2, 12 G3) in a TMA were immunohistochemically assessed for their expression of the EMT-related markers L1CAM, Snail, Slug, E-Cadherin, BMI1, as well as the putative cancer stem cell markers NANOG, NAC1 and Musashi. In addition to conventional microscopic assessment, objective staining scores were also assigned by an automated image capture system that incorporated staining intensity and extent on tumor cells. Results: L1CAM expression was present in 81%, 69%, 58%, 26%, and 0% of CCC, ESC, G3 EEC, G2 EEC, and G1 EEC respectively. Analysis of the automaticallygenerated staining scores showed that statistically signifi cant higher levels of L1CAM were present in CCC as compared with EEC of all grades, G3 EEC, and G1/G2 EEC (p <0.0001 to 0.0226). No differences were found between CCC and ESC, ESC and G1/G2 EEC, and between ESC and G3 EEC (p 0.33-0.88). In all the high grade cancers (CCC, ESC, G3 EEC), there were signifi cant positive correlations between L1CAM and at least 2 of the other EMT (BMI, Slug, Snail) markers. However, CCC, unlike G3 EEC and ESC, did not show any positive L1CAM correlations with stem cell (NANOG, NAC1, Musashi) markers. Additionally, in ESC and G3 EEC, there was an inverse correlation between with L1CAM and e-cadherin, consistent with activation of an EMT-like program. However in CCC, as well as in G1/G2 EEC, there was no signifi cant correlation between the 2 markers. In univariate (but not multivariate) Cox regression analyses, increased L1CAM expression showed a near-signifi cant association with reduced overall (p=0.0698) and relapse-free (p=0.0688) survival in CCC. Conclusions: L1CAM expression patterns highlight a distinct novelty in the pathogenesis of CCC, whereby a "mesenchymal" phenotype is activated in a manner similar to the other high grade carcinomas (G3 EEC and ESC). However, unlike the latter tumors, and similar to G1 and 2 EEC, there is no concurrent downregulation of e-cadherin. The mammalian target of rapamycin (mTOR) pathway plays an important role in tumor pathogenesis, and is a promising target for directed therapies. The mTOR pathway often begins through inactivation of the PTEN tumor suppressor gene and eventuates in increased protein translation through the phosphorylated S6 ribosomal protein (among others), and cell cycle progression through p27 kip1 (p27) depletion. This study evaluated dysregulation of the mTOR pathway, as inferred from their protein expression patterns, in endometrial clear cell carcinoma (CCC) relative to endometrial endometrioid carcinoma (EEC) and non-neoplastic endometrium (NNE). Design: 100 endometrial carcinomas (51 clear cell, 49 endometrioid [18 grade 1, 19 grade 2, 12 grade 3], and 24 NNE (9 proliferative, 10 secretory and 5 atrophic) were evaluated by immunohistochemistry for expression of 4 proteins associated with the mTOR pathway (PTEN, Phospho-S6 ribosomal protein [PSRP], p27 and phosphorylated-mTOR [p-mTOR]). Results were scored on a 0-12+ scale for staining intensity and extent, which were then correlated with clinicopathologic parameters. Results: Decreased p-mTOR (scores 4+) were more characteristic of CCC than other tissues, with 61% of CCCs showing decreased p-mTOR, as compared to 0% of EEC (p<0.01), and 0% of NNE (p<0.01). PTEN was depleted (scores 2+) in 33% of CCC, as compared with 61% of EEC (75% of grade 3 EEC [EEC3], p<0.02; 57% for EEC grades 1 and 2, p<0.05]) and 9% of NNE (p<0.01). 44% of CCC showed high (scores≥5+) p27 expression, as compared with 100% of EEC3 (p<0.01) and 14% of grdes 1 and 2 EEC (p<0.01). 73% of CCC showed high PSRP expression, as compared with 49% of grades 1 and 2 EEC (p<0.03), and 50% of EEC3 (p=0.2). PTEN, PSRP and p27 were not associated with patient outcomes. Low p-mTOR was associated with poor outcome in the CCC cohort (5-year disease-free survival 0%, p<0.03) on univariate, but not multivariate analysis. Conclusions: This study provides new evidence of dysregulation of the mTOR pathway in CCC, and highlights the potential utility of mTOR inhibitors in treating this rare histotype. Both CCC and EEC showed evidence of pathway dysregulation, albeit at different levels. Grade 3 EEC had increased mTOR signally with high p-mTOR, low PSRP, high p27, and frequently depleted PTEN. CCC displayed less pathway activation, as evidenced by lower p-mTOR, high PSRP, low p27, and less frequent PTEN depletion. Understanding histotype-related differences in mTOR pathway dysregulation is critical in assessing variations in responsiveness to associated directed therapies. Background: For more than a decade, proteomic techniques have been deployed in trying to understand various aspects of endometrial carcinoma, but very limited work has been done on clear cell carcinoma (CCC). Matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS) utilizes a matrix assisted laser desorption/ ionization technique that allows the relative abundance and spatial distribution of proteins and peptides within a tissue sample to be visualised with an extremely high resolution, and to be defi ned with the molecular specifi city of mass spectometry. The purpose of this study is to determine whether mass spectral profi les can be correlated with clinicopathologic features in endometrial clear cell carcinoma (CCC). Design: MALDI IMS was performed on slides from tissue microarrays comprised of 47 CCC, with spectral information obtained from every 0.05 mm 2 area of tissue. We then assessed whether clinicopathologic variables were signifi cantly correlated with any spectral peaks at the p <0.05 threshold for signifi cance, using a regression analysis. The assessed variables included: patient age, FIGO stage, pT classifi cation (AJCC), lymphovascular invasion (LVSI), mitotic index, tumor architectural pattern, the presence of isolated infi ltrating tumor cells (in≥10% of tumor), tumor necrosis, and≥10% solid component, depth of myometrial invasion, and presence/absence of lymph node metastases (lymph node status).
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